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Background of multiple sclerosis
Multiple Sclerosis (MS) is a devastating neurological disease that strikes 
young people in the prime of their life. Over 2 million people worldwide are 
affected.(1) It is estimated that approximately 17,000 people are affected in 
the Netherlands, and this figure may be an underestimate.(2) The disease 
most commonly impacts individuals between the ages of 20 and 40 year, and 
there is a female preponderance.(3) Despite its relative low prevalence, MS 
has a great impact on a social and economic level, since it strikes at young 
working age, treatment costs are high and rise with increasing disability.(4)
The exact aetiology is unknown, although it involves interactions between 
environmental, genetic and epigenetic factors, all of which contribute to 
the development of MS.(5) The pathophysiology of MS is characterized 
by the development of focal inflammatory lesions in the central nervous 
system (i.e. brain and spinal cord) that leads to neuronal demyelination and 
axonal damage.(6) A central hallmark of the disease is that the neuronal 
inflammation occurs with dissemination in space and time. This essentially 
means that inflammation develops in different locations of the central 
nervous system, and at different moments in time, respectively. In addition, 
neurodegenerative damage appears as a consequence of the accumulated 
inflammatory lesion burden, as well as an independent pathophysiological 
process.(7) Inflammatory and neurodegenerative pathology are found in the 
white and grey matter as well.(6)
Clinical course and diagnosis
The clinical course of MS is highly heterogeneous. In accordance with 
dissemination in space and time that characterizes pathophysiology, clinical 
symptomatology presents as episodes of signs in different neurological 
systems. Typically, symptoms develop within days to weeks, before reaching 
a certain peak of severity, and subsequently resolves during weeks with or 
without residual deficits. Such an episode of symptoms is referred to as a 
clinical relapse (referred to as “schub” in Dutch). The number and severity of 
the episode, extent of the recovery, and which neurological system is affected 
differs widely between and within individuals with MS.
The clinical course of MS can be categorized into different phenotypes 
(schematic representation in figure 1).(8) The first clinical relapse, which is 
suggestive of MS but does not (yet) fulfil the diagnostic criteria, is defined 
as a clinically isolated syndrome (CIS). If a second relapse occurs, involving 
another neurological system, the clinical course is regarded as relapsing-
remitting MS (RRMS). In approximately 30 – 60% of patients, the clinical 
course eventually shifts to a more slowly progressive symptomatology. This 
phase is referred to as secondary-progressive MS (SPMS). During this phase 




occur. A minority of patients (approximately 15%) presents with progressive 
symptoms since the onset of the disease. This phenotype is referred to as 
primary-progressive MS (PPMS). Patients with this phenotype are generally 
older than RRMS patients, and this phenotype is more common in males.
Figure 1, clinical phenotypes Multiple Sclerosis (reproduced from Stys et al. with permission 
from Springer Nature.(7)
The formal diagnosis of MS is based on a combination of clinical symptoms, 
coupled with fi ndings from ancillary investigations, of which magnetic 
resonance imaging (MRI) and cerebrospinal fl uid (CSF) are most relevant. 
Demyelinated lesions can be typically visualized using MRI. These lesions 
commonly occur in specifi c locations in the brain (i.e. periventricular, (juxta)
cortical and infratentorial) and spinal cord. Supportive CSF fi ndings include 
CSF-specifi c oligoclonal bands, an increased IgG index and no more than 
50x106 leucocytes per litre. Clinical symptoms, MRI and CSF fi ndings are 
incorporated into the McDonald criteria that aids in the eff orts to diagnose 
MS.(9) These criteria are summarized in fi gure 2, which also illustrates the 
importance of demonstrating dissemination in space and time in diagnosing 
MS.(10) The 2017 revision of the criteria allows an earlier diagnosis while 
preserving good specifi city. Importantly, the McDonald criteria are principally 
categorizing criteria that primarily facilitates the phenotyping of the clinical 
course, rather than being true diagnostic criteria. This implies that the criteria 
must be used for the right patient in the right context; specifi cally a clinical 
syndrome suspect for MS. As such, other diseases with similar symptoms 
must therefore be ruled out suffi  ciently. A recent study illustrates that the 
clinical and radiological aspects of the criteria can be misunderstood and 




Figure 2, 2017 revised McDonald criteria (reproduced from de Angelis et al. with permission 




Clinical assessment in multiple sclerosis
One of the biggest challenges facing MS care and research is the assessment 
of its clinical presentation. Before we point out some of these challenges and 
set the stage for this thesis, we will elaborate on the relevance of good clinical 
assessment.
Relevance
Good clinical assessment is relevant throughout all stages of patient care and 
research. In the diagnostic process, making the diagnosis of MS begins with 
good clinical assessment. This means that MS can only be diagnosed with a 
clinical syndrome suspect for MS. Ancillary investigations, such as MRI, are 
very valuable, but cannot be used in isolation to make the diagnosis. In fact, 
one could get into difficult situations when an MRI has been performed and 
typical MS lesion are found, while no symptoms are present (e.g. in the case 
of a “preventive” total body MRI) or symptoms are not specific for MS (such 
as headache or fatigue). A situation like this is referred to as a radiologically 
isolated syndrome (RIS). The exact therapeutic consequences of a RIS are 
largely unknown.(12)
The assessment of the clinical course of MS, irrespective of whether or 
not the patients is on disease modifying therapy (DMT), is based on two 
main pillars: disease activity and progression. Neuroinflammation and 
neurodegeneration respectively are the main underlying pathophysiological 
processes.(13) Disease activity is reflected clinically in the occurrence of 
relapses, and radiologically in the increase of lesion load or formation of 
gadolinium enhancing lesion. Disease progression is defined as a slow accrual 
of disability independent from clinical relapses. These pillars are used to 
categorize patients into different phenotypes, which are displayed in figure 
3.(14) Adequate assessment of these pillars is crucial for effective treatment 
decision making.
Accurate and early diagnosis is increasingly important because of major 
advantages in terms of treatment possibilities. The development of DMT in 
MS in the past three decades is depicted in figure 4.(15) Treatment goals in 
the early 1990’s were restricted to moderate suppression of disease activity 
and possibly delay of disability progression. Thanks to increasing DMT 
efficacy, present treatment goals are much more ambitious. Using the novel 
high efficacy DMT, the complete absence of disease activity and progression 
is achieved in 23 – 48% of patients.(16) This outcome is referred to as ‘no 
evidence of disease activity’ (NEDA). Notably, in order to achieve this result, it 
is important that the appropriate treatment is either initiated early on in the 
disease course, or treatment is switched swiftly to another (more effective) 
DMT when disease activity persists. Early and accurate diagnosis has also 
become more important for the progressive forms of MS (SPMS and PPMS), 
since DMTs have recently become available for these phenotypes.
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*Activity determined by clinical relapses and/or MRI activity (contrast-enhancing lesions; new or unequivocally enlarging T2 
lesions assessed at least annually); if assessments are not available, activity is “indeterminate.” **CIS, if subsequently clinically 
active and fulfilling current multiple sclerosis (MS) diagnostic criteria, becomes relapsing-remitting MS (RRMS).
*Activity determined by clinical relapses assessed at least annually and/or MRI activity (contrast-enhancing lesions; new and un-
equivocally enlarging T2 lesions). **Progression measured by clinical evaluation, assessed at least annually. If assess-ments are 
not available, activity and progression are “indeterminate.” MS 5 multiple sclerosis; PP 5 primary progressive; PR 5 progressive 
relapsing; SP 5 secondary progressive.
 
Figure 3, clinical phenotypes according to disease activity and progression, compared with con-





Figure 4, historical overview of disease modifying treatment (adapted from Thompson et al. 
with permission from Elsevier.(15)
Several other arguments are also relevant in emphasizing the importance 
of accurate clinical assessment. Firstly, clinical symptomatology does not 
necessarily correlate with radiological pathology (i.e. the clinic-radiological 
paradox).(17) This implies that not all disease activity is captured by MRI 
in isolation (and vice versa). Secondly, accrual of disability is currently the 
only meaningful measure to assess neurodegeneration in clinical practice. 
Although various other measures are used in research as surrogate 
markers for neurodegeneration (e.g. brain atrophy,(18) optical coherence 
tomography(19) and neurofilament light chain(20)), they are not yet sufficient 
to use in individual cases. Lastly, clinical assessment can be done quickly, 
regularly and cost-effectively (relative to performing an MRI for example).
Challenges
Several challenges exist in the clinical assessment of MS patients in daily 
practice and clinical trials. The most important challenge is the high variability 
of disease expression and course. Patients exhibit a wide symptomatologic 
variation in terms of relapse frequency and severity, as well as accrual of 
disability. Furthermore, relapses present with essentially all neurological 
symptoms in which there also is an age-dependent distribution.(21) The 
extent to which the clinical syndrome of a relapse contributes to disability 
is also variable. The heterogeneity of clinical presentation also hampers 
defining (uniform) outcome measures of disability for clinical trials.
Another challenge is the overall slow accumulation of disability. In clinical 
practice, this may cause difficulties to assess whether a patient is stable (on 
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DMT) or exhibits progressive symptoms. This is particularly important in order 
to establish an indication to start, or to evaluate the efficacy of treatment in 
the progressive phenotypes. In clinical trials, the slow accumulation dictates 
long-term follow-up to assess treatment effects.
Lastly, there are several confounding factors exist that influence the 
assessment of disability, which may not directly be related to disease activity. 
Examples include co-existing fatigue, mood disturbances, deconditioning, 
spasticity and side effects of medication. These factors will have to be 
accounted for to achieve an individualized treatment approach in clinical 
practice.
Aims and outline of this thesis
Good clinical assessment is essential in MS care and research, yet this remains 
challenging. As such, this thesis aims to improve the clinical assessment of 
MS patients. To create the framework for the studies presented here, an 
overview of clinical and paraclinical outcome measures is given in chapter 2.
Part II, describes the assessment of upper extremity functioning (UEF) and 
mobility. In chapter 3, UEF is assessed using several measures in subgroups 
of MS patients with different levels of ambulatory impairment. In chapter 4, 
various aspects of existing clinical measures for UEF and mobility are assessed, 
and their relative value is determined. Chapter 5 sets out to determine a 
minimal clinically important difference of improvement of a patient-reported 
outcome measure for UEF. In chapter 6, the responsiveness of various 
measures for UEF and mobility are assessed in several subgroups of MS 
patients.
In part III, three studies are presented in which several aspects of video-
assisted assessment of motor functioning are evaluated. Chapter 7 presents 
the added value of reference videos in the assessment of motor functioning. In 
chapter 8, combinations of video-assisted assessment were compared with 
classical performance measures of UEF and mobility. In chapter 9, a proof 
of concept study is presented that describes the use of auto-encoders to 
ensure data privacy when sharing videos of patients performing movements.
Part IV – chapter 10, summarises the conclusions of this thesis and 
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Due to the heterogeneous nature of the disease it is a challenge to capture 
disease activity of multiple sclerosis (MS) in a reliable and valid way. Therefore, 
it can be difficult to assess the true efficacy of interventions in clinical trials. In 
phase 3 trials in MS, the traditionally used primary clinical outcome measures 
in MS trials are the expanded disability status scale and the relapse rate. 
Secondary outcome measures in these trials are the number or volume of 
T2-hyperintense lesions and Gadolinium enhancing T1-lesions on Magnetic 
Resonance Imaging (MRI) of the brain. These secondary outcome measures 
are often primary outcome measures in phase 2 trials in MS. Despite several 
limitations, the traditional clinical measures are still the mainstay for assessing 
treatment efficacy. Newer and potentially valuable outcome measures 
increasingly used or explored in MS trials are clinically the MS functional 
composite and patient-reported outcome measures, and on MRI brain atrophy 
and the formation of persisting black-holes. Several limitations of these 
measures have been addressed and further improvements will probably be 
proposed. Major improvements are the coverage of additional functional 
domains, such as cognitive functioning and assessment of the ability to carry 
out activities of daily living. The development of multidimensional measures 
is promising because these measures have the potential to cover the full 
extent of MS activity and progression. In this review, we provide an overview 
of the historical background and recent developments of outcome measures 
in MS trials. We discuss the advantages and limitations of various measures, 
including newer assessments such as optical coherence tomography, 
biomarkers in body fluids and the concept of no evidence of disease activity.




Multiple sclerosis (MS) has a female predominance and typically develops 
at young age with a peak incidence between 20 and 40 years.(1) Clinically, 
it is characterized by a large variability of symptoms arising from focal 
inflammation of the central nervous system which may occur at various points 
in time. Symptoms generally last for several days to weeks, but occasionally 
persist for many months, with subsequent full or partial recovery. These 
periods are being referred to as relapses. Radiologically, MS is characterized 
by typical white matter lesions that are best visualized with magnetic 
resonance imaging (MRI). The occurrence of clinical relapses or new white 
matter lesions on MRI are used to estimate disease activity. Demonstrating 
dissemination in time and place, clinical or radiological, is the core feature in 
the diagnostic criteria.(2) 
The occurrence of relapses is the dominant clinical picture in the vast majority 
of patients during the earlier disease stages and is defined as relapsing-
remitting MS (RRMS). If a patient only experienced a single episode with clinical 
symptoms, it is referred to as a clinically isolated syndrome (CIS). Relapses 
eventually subside and the disease course often evolves to a slow worsening 
of symptoms, leading to disability accrual (i.e. disease progression). When there 
is a disease progression independent from relapses, this is referred to as 
secondary-progressive MS (SPMS). Approximately 15% of patients have slowly 
progressive disease from onset without evident relapses and are categorized 
as primary-progressive MS (PPMS).The first effective immunomodulatory 
treatments were the injectables interferon-β and glatiramer acetate that 
were introduced in the 1990s.(3) After a decade the more potent natalizumab 
(in 2004) and the first oral drug fingolimod (in 2010) were introduced. More 
recently approved treatments include teriflunomide, dimethylfumurate, 
alemtuzumab and daclizumab. Ocrelizumab and cladribine are expected to 
be approved in the near future. In the phase 3 trials of these treatments, 
the outcome measures used to evaluate efficacy were relapse rate, disability 
worsening and MRI (formation of new T2-hyperintense lesions (T2HL) or 
Gadolinium enhancing T1-lesions (GdT1L)). These measures have been 
generally accepted as measures of (short-term) treatment effects.
Clearly, treatment options in MS are rapidly expending and are applied in 
patients with different clinical phenotypes. It is therefore important to have 
clear, comprehensive and universally accepted outcome measures. For this 
purpose, an outcome measure has to be valid, reliable and responsive. In 
practical terms this means it must measure what it intends to measure, it 
should be free of measurement errors and able to detect true change of 
performance (due to disease activity or progression).(4) Furthermore, it 
needs to capture clinically relevant changes and ideally has predictive value. 
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Unfortunately, standardized definitions of outcome measures in MS research 
are lacking for which there are several explanations. First, the clinical disease 
expression and course are highly variable which hampers defining a uniform 
concept of disability in MS.(5-7) There is wide variation between patients 
concerning relapse frequency (including seasonal variation(8)) and accrual 
of (relapse-related) disability. Also, patients may present with virtually all 
neurological symptoms that exhibit an age-dependent distribution (table 
1).(7) Moreover, the extent in which symptoms contribute to overall disability 
is variable. This may be more dependent on the location of the lesion than 
on the size or activity. For example, a severe persisting hemiparesis may 
have a greater impact on disability than a mild sensory deficit, while both 
may result from pathologically comparable lesions. In fact, lesions may occur 
subclinically without causing disability worsening.(9) Another difficulty is that 
disability often accumulates slowly. Consequently, long term follow-up is 
needed to assess treatment effect, which makes trials time-consuming and 
expensive. Lastly, disability is influenced by confounding factors that may 
not be directly related to disease activity (e.g. fatigue, mood disturbances, 
deconditioning, spasticity and side effects of medication).(10)
Table 1, distribution of patients (%) by presenting clinical symptoms to age of onset.(7)
age at on-

















<20 23 18 6 4 14 46
20-29 23 12 7 6 11 52
30-39 13 11 7 14 15 44
40-49 9 17 3 31 13 33
≥50 6 13 4 47 11 32
With all these difficulties in mind, we aim to provide a non-systematical 
comprehensive overview of clinical and paraclinical outcome measures that 
are used in clinical research of MS (summarized in table 2). We elaborate on 
traditional and newer measures such as brain atrophy, optical coherence 
tomography (OCT), biomarkers in body fluids and the concept of no evidence 
of disease activity (NEDA). We highlight the most important advantages, 
limitations and caveats of these measures.
Outcome measures in MS
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Table 2, primary, secondary and exploratory outcome measures in phase 3 trials for MS.
Primary outcome measures
Clinical:
- expanded disability status scale (EDSS): 3- or 6 months confirmed disability worsening or 
improvement




- MS functional composite (MSFC): timed 25-foot walk test, nine-hole peg test, paced auditory 
serial addition task or symbol digit modalities test
Paraclinical:
- T2-hyperintense lesions
- Gadolinium enhancing T1-lesions
- whole brain atrophy
Exploratory outcome measures
Clinical:
- as candidate component of MSFC: low-contrast letter acuity test
- patient-reported outcome measures: e.g. quality of life, depression and anxiety, fatigue, 
specific functional domains
Paraclinical – imaging:
- volumetric measures of specific structures (e.g. thalamus, upper cervical cord area)
- persisting black-holes
- functional MRI for analysis of functional connectivity
- diffusion tensor imaging to examine brain tissue integrity
- magnetization transfer ratio MRI as a marker for brain myelin content
- optical coherence tomography
Paraclinical – biomarkers:
- biomarkers in body fluids: in CSF or blood
Composite:
- no evidence of disease activity (NEDA): typically covering (confirmed) EDSS progression, 
relapse rate and formation of MRI lesions; whole brain volume increasingly included (i.e. 
“NEDA-4”)
Electronical devices:
- e.g. Assess MS system, Glove analyzer, accelerometers
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2 CLINICAL OUTCOME MEASURES
Outcome measures can be generic or disease-specific, physician- or patient-
based, direct or indirect, and may cover all or specific aspects of MS. 
Various clinical outcome measures are available, assessing different disease 
characteristics. Which characteristics are important largely depends on the 
aim of the study. Here, we first describe the traditional measures expanded 
disability status scale (EDSS) and relapses. Subsequently, the more recently 
developed MS functional composite (MSFC) will be discussed. Finally, we 
elaborate on patient-reported outcome measure (PROM)s as these patient-
based measures are increasingly being used in MS trials.
2.1 The expanded disability status scale
The EDSS intends to capture disability of MS patients based on neurological 
examination by describing symptoms and signs in eight functional systems 
(FS). Furthermore, it encompasses ambulatory function and the ability to 
carry out activities of daily living (ADL). An overall score can be given on an 
ordinal scale ranging from 0 (normal neurological examination) to 10 (death 
due to MS). Scores from 0 to 4.0 are determined by FS scores, which means 
that in this range the EDSS is essentially a measure of impairment. Scores 
from 4.0 and higher basically address disability. Ambulatory function and the 
use of walking aids heavily determine the range of 4.0 to 7.0, and scores 
between 7.0 and 9.5 are largely determined by the ability to carry out ADL. A 
schematic representation of the EDSS is given in figure 1.
In clinical trials of MS, the EDSS is the most widely used outcome measure 
to determine disability worsening and define relapse-related change in 
neurological function. Furthermore, it is used as an inclusion criterion and 
to characterize study populations. The value of the EDSS as a surrogate 
outcome measure for future disability is limited.(11-15)
2.1.1 Limitations and caveats
Despite general acceptance of the EDSS, there are many limitations and 
caveats (summarized in table 3).(16) First of all, EDSS holds high intra- and 
interrater variability.(10, 11, 17-19) This can be explained by the subjective 
nature of the neurological examination itself on which the EDSS is largely 
based, particularly in the lower EDSS range. Also, complex and ambiguous 
scoring rules for the FS probably explain some of the variability.
Non-linearity of the EDSS is another limitation (visualized in figure 1). The 
staying time in the middle scores is shortest and this results in a bimodal 
distribution with peaks at 1.0 to 3.0 and 6.0 to 7.0.(7, 20) It means that the
Outcome measures in MS
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Figure 1, schematic representation of expanded disability status scale depicting the factors 
that determine overall score; the graph shows the distribution of patients over the expanded 
disability status scale (EDSS)(7)
rate of progression as assessed by the EDSS varies depending on baseline 
score. Furthermore, responsiveness of the EDSS is limited.(21, 16) Scores 
higher than 4.0 are less influenced by changes in FS scores. For example, 
development of a paresis in a patient with an EDSS of 6.0 will not result in a 
higher EDSS. Reversely, EDSS would have changed with a baseline EDSS of 
4.0.
The non-linearity and limited responsiveness should both be accounted 
for when interpreting changes over time.(22) Nevertheless, EDSS change is 
often presented without accounting the baseline score. As a result, statistical 
significant change may erroneously be presented as clinically relevant and 
vice versa. An increasingly used clinically meaningful change is a change of 
1.0 or more if EDSS at baseline was 0 to 5.5, and 0.5 or more for higher 
baseline EDSS scores. This is more driven by reproducibility data than by 
clinical relevance data. 
Because the EDSS is an ordinal scale, non-parametric statistics should be 
used in statistical analysis. This implies that significant differences between 
groups can be calculated, but the magnitude of differences cannot. In line with 
this, results should not be presented with means and standard deviation, but 
with median values and interquartile ranges. Also, a caveat of numeric values 
is that they might give the false impression of being precise.
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Table 3, limitations, caveats and improvements for clinical outcome measures. PASAT = paced 
auditory serial addition task.
Expanded disability status scale (EDSS)
Limitations and caveats Improvements
- High intra- and interobserver variability
- Non-linearity (bimodal distribution)
- Limited responsiveness
- Necessity to use non-parametric statistics (ordinal scale)
- Uneven distribution of relapsing-remitting and progressive 
patients
-Several functional domains not assessed
- Accounting for baseline 
score when determining 
change (e.g. change ³1.0 
with baseline score 0 to 5.5, 
and ³0.5 for higher baseline 
scores)
- Determining disability wors-
ening with confirmation of 
the EDSS progression after at 
least six months
- Using standardized scripts 
for questioning patients 
(improving reliability and de-
creasing risk of unblinding)
- Simplification of scoring 
rules (decreasing variability)
- Streamlining by stripping 
components of the func-
tional systems that are less 
informative
- Modification to improve lin-
earity and facilitate statistical 
analysis
Relapses
Limitations and caveats Improvements
- Strong subjectivity
- Recovery of signs or symptoms before confirmation of   
relapse
- Recall bias of patient and observer bias of examiner
- Newly reported symptoms not always clearly depicted in 
change of the EDSS
- Identification largely depended on patient reporting it
- Higher relapse rate prior to inclusion: over-reporting to 
fulfill inclusion criteria, high relapse rate inclusion criterion 
leading to decrease of relapse rate because of regression to 
the mean, placebo effect, decrease of relapse due to natural 
course of MS
- Confirming a relapse by 
another examiner
- Increasing number of visits 
to identify more relapses
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Multiple sclerosis functional composite (MSFC)
Limitations and caveats Improvements
- moderate reliability, sensitivity and responsiveness of the 
PASAT
- the PASAT often disliked by patients, requirement of mathe-
matical ability and ceiling effect
- Several important functional domains are not assessed
- lack of a clear dimension of the overall score (resulting in 
difficult interpretability)
- Z-scores are influenced by results of the reference popula-
tion and obscure the meaning of crude scores
- Replacing the PASAT with 
the symbol digit modalities 
test
- Adding the low-contrast let-
ter acuity test (covering visual 
domain)
- Adding other functional 
domains
- Determining minimal 
clinically relevant changes of 
the Z-scores and confirming 
change after six months
- Determining clinical rele-
vance
- keeping elements separated 
instead of combining them 
into a single score
Patient-reported outcome measures (PROM)
Limitations and caveats Improvements
- Unblinding nature
- Potential expectance bias
- Assessment of quality of life may be influenced by multiple 
factors
- Possible response shift over time
- Weighing of individual ques-
tions appropriately
- Using (computer) adaptive 
testing to reduce test length 
and improve tolerability
Another limitation is that clinical phenotypes are unevenly distributed across 
the EDSS. Because ambulatory dysfunction is one of the main characteristic 
in patients with progressive disease (SPMS and PPMS), these patients 
represent a larger proportion in the range of 4.0 to 7.5.(23, 24)
Lastly, several domains are not (sufficiently) assessed. Examples are cognitive 
function, mood, energy level and quality of life. Symptoms in these domains 
are frequently observed in MS patients and they may influence FS scores, 
ambulation and ADL function.
2.1.2 Suggested improvements
During an international conference on disability outcomes in MS (ICDOMS), that 
was held in 2011, several refinements for the EDSS were suggested to improve 
performance.(25) Firstly, standardized script for questioning patients (which 
is necessary for some FS scores) might improve reliability and decrease the 
risk of unblinding in clinical trials (an example of the Neurostatus form may 
be found on http://www.neurostatus.net/). Secondly, simplification of scoring 
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rules might reduce intra- and interrater variability. Thirdly, long term disability 
worsening should be assessed with confirmation of EDSS worsening at six 
rather than three months. The main reason for this is that relapses may 
improve beyond three months, and thus EDSS worsening may be temporary.
(26) Fourthly, streamlining of the EDSS might be achieved by finding the 
components of FS that contribute most to confirmed worsening of disability 
and omitting the other less informative components. Lastly, modification of 
the EDSS to improve linearity of measurement will facilitate statistical analysis 
and clinical understanding.
Whatever its limitations, the EDSS probably continues to be the main disability 
measure in the near future because of the vast experience with it and the 
possibility to make historical comparisons. Until we have better alternatives, 
clinical assessment can be improved by using the EDSS in conjunction with 
other measures.
2.2 Relapses
The other traditional outcome measure is assessment of relapses. By 
consensus, a relapse has been defined as new or worsening neurological 
symptoms that are objectified on neurological examination in the absence 
of fever and last for more than 24 hours, and have been preceded by a 
period of clinical stability of at least 30 days, without another explanation 
than MS.(27, 28) The relation of number of relapses with disability worsening 
is not completely clear, although conclusions may be drawn from natural 
history studies. Various of these studies showed that relapses early in the 
course of MS were associated with long term disability and increased risk of 
conversion to SPMS, which probably relates to faster disability worsening.
(29-32) However, superimposed relapses in the progressive phase did not 
lead to faster disability worsening.(33) Treatment effects on relapses is 
confined in the change of annualized relapse rate or time to second relapse 
(i.e. conversion to clinically definite MS).(34) Treatment effect on relapses 
gives a fair reflection of short-term efficacy.
2.2.1 Limitations and caveats
There are several caveats when using relapses as an outcome measure 
(summarized in table 3). First of all, identification of a relapse is subjective. 
Ensuring perfect blinding for treatment is therefore essential. To limit 
subjectivity, a second assessment can be performed to objectify the relapse. 
The problem with this approach is that symptoms or signs may already have 
recovered, and recall bias of the patient and observer bias from the examiner 
may influence the second assessment.(35)
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Another caveat is that identification of a relapse largely dependents on a 
patient reporting new symptoms. When a patient only reports new symptoms 
on scheduled visits and not spontaneously, the established relapse rate will 
be lower than in reality. In fact, increasing the number of visits in a trial period 
may increase the relapse rate.(36)
An interesting phenomenon is that relapse rate is often remarkably high 
prior to inclusion into trials. Various explanations may be given for this.
(37, 38) First of all, relapses in the preceding period of a trial are usually 
determined retrospectively and patients may over report the exact number 
to qualify for inclusion. Secondly, the inclusion criterion of relapse rate is 
often high, meaning that only patients with very active disease are included. 
As a consequence, it can be expected that relapse rate of these patients 
will decrease towards a disease average during the trial (i.e. regression to the 
mean). Thirdly, patients participating in a trial may do better merely because 
of a placebo effect or better comprehensive care during the trial. Lastly, 
during the natural course of MS the relapse rate will eventually decrease, 
independent of treatment.(39) These factors may obscure the interpretation 
of absolute relapse rate reduction in treatment trials.
2.3 The multiple sclerosis functional composite
Because of the limitations of the EDSS and assessment of relapses, the MSFC 
was developed to improve clinical assessment.(40, 41) It was introduced in 
the early 1990s, a time when the first effective treatments were introduced. 
In contrast with the EDSS, the MSFC covers three functional domains: 
ambulatory, hand and cognitive function (a schematic summary is given in 
figure 2). The results of the tests that assess these domains are depicted 
in an interval scale (seconds or number of correct responses) and can be 
converted to a Z-score that is based on values of a reference population.(42) 
An overall score can be calculated by averaging the Z-score of the subtests.
The MSFC has been extensively evaluated. The overall score of MSFC 
correlated strongly with EDSS (43) and subtest scores did moderately.(40) 
Also, change of MSFC correlated with EDSS change and relapse rate.(40, 44, 
45) Furthermore, it was predictive of conversion from RRMS to SPMS.(44) 
Concerning the relation with MRI abnormalities, MSFC correlated with white 
matter lesion load and various atrophy measures.(46-48) Lastly, correlations 




Figure 2, schematic representation of the multiple sclerosis functional composite (MSFC) with 
candidate components.
2.3.1 The original components
Ambulatory function is tested with the timed 25-foot walk test (T25W, explained 
in table 4). The T25W is a reliable test for patients with more severe gait 
impairment, because it primarily assesses walking speed. Assessing walking 
speed seems clinically relevant, because it relates to the capacity to perform 
outdoor activities important in daily life.(54) For patients with mild gait 
impairment the T25W may not be sensitive enough to detect abnormalities 
and because of that has a floor ceiling effect.(55) For these patients it may be 
more appropriate to assess walking endurance with longer walking distances, 
for example with a 6 minutes walking test.(56)
2.3.2 Candidate components
A candidate cognitive test that may replace the criticized PASAT is the 
symbol digit modalities test (SDMT, explained in table 4).(62, 63) It measures 
information processing speed. The advantages of the SDMT are that it is 
easily administrated, better tolerated by patients (probably because there 
is no time pressure),(64) and more robust and reliable than the PASAT.
(65, 66) Moreover, the SDMT correlated more strongly with white matter 
abnormalities than PASAT.(67, 68) It also correlated with worsening of 
cognitive impairment(69, 70) and MRI abnormalities (atrophy measures in
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Table 4, description of components of the multiple sclerosis functional composite (MSFC).
Original components
Timed 25-foot walk test 
(T25W) 
The patient is directed to one end of a clearly marked 25-foot 
course and is instructed to walk 25 feet as quickly as possible, 
but safely. The task is immediately administered again by 
having the patient walk back the same distance. Patients may 
use assistive devices when doing this task. In clinical trials, it is 
recommended that the treating neurologist select the appro-
priate assistive device for each patient.[42]
Nine-hole peg test (9HPT) The patient is asked to take nine small pegs one-by-one from 
a small shallow container, place them into nine holes and 
then remove them and place them back into the container. 
Results are depicted in seconds to complete the task of both 
the dominant and non-dominant hand; two trials for each 
side.[42]
Paced auditory serial addition 
task (PASAT)
The PASAT is presented on audiocassette tape or compact 
disc to control the rate of stimulus presentation. Single digits 
are presented either every 3’’ (or every 2” for the optional 2” 
PASAT) and the patient must add each new digit to the one 
immediately prior to it. The test score is the number of correct 
sums given (out of 60 possible) in each trial. To minimize 
familiarity with stimulus items in clinical trials and other serial 
studies, two alternate forms have been developed; the order 
of these should be counterbalanced across testing sessions. 
The PASAT is the last measure of the MSFC that is adminis-
tered at each visit.[42]
Candidate components
Symbol digit modalities test 
(SDMT)
Patients are presented with a key that includes nine numbers, 
each paired with a different symbol. Below this key is an array 
of these same symbols in pseudorandom order paired with 
empty spaces. Patients must then provide the correct num-
bers that accompany the symbols as indicated in the key.[64]
Low-contrast letter acuity test 
(LCLA)
Seven charts with different levels of contrast (0.6 – 100%) 
are presented to the patient. On each chart multiple rows 
are depicted with gray letters with decreasing size on a white 
background. The letter scores indicate the number of letters 
identified correctly. Each chart is scored separately.
particular).(71, 72) A limitation is that a patient has to have an intact visual 
system, which may be impaired in MS patients. Although there is a ceiling 
effect, it is less pronounced than for the PASAT. Taken all points together, the 
SDMT probably is a good replacement for the PASAT.
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When the MSFC was developed, no data on suitable tests to assess visual 
function were available.  The past decade, various visual outcome measures 
for MS research have been studied.(73) Of these the low-contrast letter 
acuity test (LCLA, explained in table 4) may be a good candidate to add to 
the MSFC.(74) Results correlated with clinical phenotypes, MRI abnormalities 
and PROMs for visual impairment and quality of life (which supports clinical 
relevance).(75, 76) Moreover, some clinical trials showed treatment effect on 
the LCLA in the active group compared with placebo.(77)
2.3.3 Limitations and caveats
There are several limitation and caveats of the MSFC (summarized in table 3). 
A frequently postulated objection to the MSFC is that the overall score lacks 
a clear dimension, which hinders interpretability and therefore appears to 
be difficult for the interpreter to get familiar with the score. In other words, it 
is difficult to form a mental picture of it.(78) This difficulty may be addressed 
by keeping the elements of the MSFC score separated instead of combining 
them into a single score. Nonetheless, comparison of subtest results between 
studies will remain impossible due to the Z-scores that obscure the meaning 
of crude scores.
Another problem is that results of the reference group strongly influences the 
Z-scores of patients.(79) With that, assessing changes in time is problematic, 
because the overall score is influenced by variability between time-points 
of both the reference and patient group. Consequently, it is impossible to 
determine if change is a result of statistical variance or true progression of 
disability.(38) 
A potential solution to some of the statistical caveats of Z-scores might be 
to determine the minimal clinically relevant change.(21, 80) This means that 
change should be confirmed on a subsequent time point, preferably at six 
months (because of possible disability improvement after a relapse). This 
approach has been tested in a clinical trial dataset.(45) Sensitivity of worsening 
was found to be similar between MSFC and EDSS, and it correlated with other 
clinical and MRI outcome measures. However, the downside of this approach 
is that it will hamper sensitivity to change, which is of particular importance in 
patients with severe disability.
Despite its disadvantages, the MSFC is an appealing alternative for the EDSS. 
It can be performed within 20 minutes, covers three domains, has good 
intra- and interrater reliability and it results in a score on a continuous scale. 
The MSFC has once been used as primary outcome in a treatment trial in 
SPMS.(49) While MSFC progression was slowed, treatment effects were not 
observed with the EDSS. When applying its components in a sensible way, it 
may be used as a primary endpoint in future clinical trials.
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2.4 Patient-reported outcome measures
A PROM is defined as “any report of a patient’s health condition that comes 
directly from the patient, without interpretation of the patient’s response by a 
clinician or anyone else”.(81) A PROM may provide valuable insight into the 
patient-perspective of a treatment or matter of interest. For example, 
treatment success for a patient might be more influenced by adverse events 
than a physician perceives or deducts from other outcome measures. 
Furthermore, it may detect clinically meaningful changes and leave out 
changes with no clinical relevance. A PROM can assess perceived efficacy, 
side-effect, depression and anxiety, fatigue, mobility, quality of life, ability to 
carry out ADL, sexual dysfunction and symptoms specific for MS. A list of 
PROMs that are being used in MS research is presented in table 5.(82-105)
Patient-reported outcome measures that assess the ability to carry out ADL 
may be of particular value. They are able to demonstrate clinical relevance of 
MS-specific outcome measures. For example, one study found a correlation 
between the EDSS and a 42 items ADL scale which was mostly driven by 
impairment of mobility.(106) Another advantage is that measuring ADL 
activity allows comparison between studies of MS as well as other diseases. 
Currently, no MS-specific ADL measures are available. Nevertheless, PROMs 
that were developed for stroke patients (Ranking scale(107, 108) and Bartel 
index(109)) were used in some MS trials.(110, 111)
There are several limitations of PROMs (summarized in table 3). Among these, 
are the unblinding nature and potential expectance bias. Also, questionnaires 
assessing quality of life are prone to be influenced by more than only 
disability. Other factors that are commonly seen in MS patient contribute as 
well (e.g. fatigue, depression, anxiety and physical comorbidities).(112) Also, 
the individual questions should be weighted appropriately. Summing up all 
the subscores assumes equal importance which is generally not the case. 
Lastly, PROMs are prone to response shift over time.(113) Response shift 
occurs when a patient answers an item differently than previously done due 
to change of internal standards, values or conceptualization of the purposed 
domain (e.g. quality of life).
Typically, PROMs are fixed in length and all patients have to fill in the complete 
questionnaire. The number of questions that have to be answered can be 
reduced with computer adaptive testing.(114) It leads the patient through 
an iterative process in which the answer to a question determines what 
question is presented next. For example, if a patient is fully dependent on a 
wheelchair, a question about climbing stairs is irrelevant. With these methods 
patients’ tolerability for a questionnaire may be improved.
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Table 5, patient-reported outcome measures that are used in MS research.
Measure
Quality of life
MS quality of life-54[103]
MS quality of life inventory[86]
European quality of life-5D[87]
Health utilities index mark 3[87]
World health organization quality of life brief form[100]
Sickness impact profile[83]
Life satisfaction questionnaire[96]
Hamburg quality of life questionnaire in MS[91]
Quality of life index[85]
Leeds MS quality of life scale[90]
Disability and impact profile[101]
The MS international quality of life questionnaire[102]




Hospital anxiety and depression Scale[94]
Fatigue
Modified fatigue impact scale[89]
Fatigue impact scale for daily use[88]
Single functional domain
MS walking scale-12[93]





Guy’s neurological disability scale[97]
MS impact profile[105]
3 PARACLINICAL OUTCOME MEASURES
Numerous paraclinical outcome measures are available and could be used 
as adjunct to clinical measures to obtain information on treatment efficacy. 
Some are potentially valuable (e.g. cerebrospinal fluid (CSF), visual evoked 
potentials) while others are less suitable (e.g. brainstem auditory evoked 
potentials).(115) Here, we shortly discuss the value of white matter pathology 
as detected on MRI. Subsequently, we will elaborate on newer outcome 
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measures, such as brain atrophy, persisting black-holes (PBH), OCT and 
biomarkers in body fluids.
3.1 Magnetic resonance imaging
3.1.1 White matter pathology
Magnetic resonance imaging is sensitive to detect, characterize and quantify 
lesions in the white matter. It plays a fundamental role in the McDonald 
diagnostic criteria for MS to demonstrate dissemination in time and space 
in addition to clinical signs.(2) Radiological dissemination in space is defined 
as having at least one lesion in at least two for MS typical areas in the central 
nervous system. Dissemination in time is determined when at least one 
new lesion is demonstrated on a follow-up MRI, or if one asymptomatic 
Gadolinium-enhancing and one non-enhancing lesion is demonstrated on 
the initial MRI.
The MAGNIMS workgroup recently proposed a revision of these criteria allowing 
even earlier diagnosis with MRI.(116) The value of MRI as a diagnostic tool is 
principally the high sensitivity to detect (past) disease activity. Formation of 
new T2HL and GdT1L may occur subclinical and are thus more frequently 
seen than clinical relapses.(9, 117) The moderate correlation of T2HL load 
with relapse rate(118, 26) and disability(119, 120) is possibly related with this 
phenomenon. Nevertheless, white matter pathology has predictive value for 
the clinical disease course. For example, patients with a CIS and a high T2HL 
load at baseline had an increased risk to reach an EDSS of 3.0.(121) Also, 
the presence of two or more GdT1L in patients treated with interferon-β 
predicted EDSS worsening at 15 years.(122)
Because of the high sensitivity for detecting disease activity, MRI has 
been widely accepted as a secondary endpoint in clinical trials. Moreover, 
demonstrating efficacy on MRI lesions is crucial in the development of 
immunomodulatory treatments. Treatment effects on MRI could also act as 
a surrogate endpoint for clinical disease activity. A study supported this by 
showing that treatment effect on MRI activity explained more than 80% of the 
variance of treatment effect on relapse rate.(123) Other studies confirmed 
this by showing the related MRI effects on relapse rate and accumulation of 
disability worsening (up to 16 years).(124-126)
These classical MRI parameters largely depicts (past) neuro-inflammation 
in MS. However, the neurodegenerative aspect of MS is being increasingly 
studied with MRI. One reason for this is that with the current therapy we 
are now able to suppress neuro-inflammation effectively, but the ultimate 
goal of therapy is prevention of neuronal tissue loss or, in the long run, to 
stimulate neuronal repair. Another reason is that neuropathological and 
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MRI techniques have improved our insight in underlying neurodegenerative 
processes of MS.(127) Consequently, measures that reflect these processes 
are more frequently used as secondary outcome measures. The most widely 
used neurodegenerative MRI measures are atrophy and PBH.
3.1.2 Atrophy
Brain volume loss in MS patients occurs considerable faster than in healthy 
people: 0.5 to 1.0% versus 0.1 to 0.3% brain volume loss per year.(128, 
129) Atrophy may be found throughout the disease course, even in the 
early phases.(130) Remarkably, the atrophy rate of gray matter structures 
accelerates in patients with SPMS to a 14-fold of that of healthy persons.(131) 
Virtually all gray matter structures are affected, although variation exists 
between clinical phenotypes.(132)
Brain volume can be visualized in various ways. The somewhat older 
measures assess loss of brain volume indirectly by measuring corpus 
callosum size,(133) bicaudate ratio(72) and ventricular volumes(133, 72). 
Also, whole brain volume can be measured directly with conventional MRI.
(72, 128) Nowadays, segmentation of the brain into white and gray matter 
compartments or specific gray matter structures is possible and several 
automated methods reduced processing time.(134-136) 
The relation of atrophy measures with clinical signs has been extensively 
investigated. Whole brain and gray matter atrophy correlated strongly with 
disability and cognitive impairment, both cross-sectional and longitudinal.
(132) These correlations existed throughout the disease course and clinical 
phenotypes. Atrophy of gray matter structures may even be more closely 
related to clinical signs than white matter lesion or whole brain atrophy.
(137) Atrophy of several structures correlated remarkably strong with certain 
clinical symptoms. For example, cerebellar gray matter atrophy correlated 
strongly with cerebellar symptoms and hand function,(138) upper cervical 
cord area with ambulatory dysfunction,(139) and hippocampal atrophy with 
memory deficits.(140) Thalamic volume showed a remarkably firm correlation 
with cognitive impairment.(141) Also, various atrophy measures showed 
predictive value for future disability and cognitive impairment.(142, 137, 143, 
144)
Furthermore, spinal cord volumes can be assessed for which the upper 
cervical cord area is often used. Several studies showed a correlation with 
spinal cord volume loss and clinical disability. (145, 146, 144) It has also been 
correlated with long term disability.(147)
An extensive summary of clinical trials that used brain atrophy as a secondary 
endpoint may be found elsewhere.(148, 149) Noteworthy is a recent meta-
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analysis that showed that 75% of the variance of treatment effect on disability 
was explained by whole brain atrophy and T2HL.(150) Another meta-
analysis found evidence that whole brain atrophy in patients that received 
immunomodulatory treatment was lower than placebo group.(151)
Although volumetric measurements are appealing outcome measures, 
there are some caveats and limitations. Firstly, atrophy accumulates very 
slowly, what in generally means that longer follow-up is needed to detect 
significant changes. Clearly, this accounts particularly for treatment effects 
on smaller structures, such as thalamic volume. Secondly, the short-term 
effect of immunosuppression on brain tissue may cause decrease of brain 
volume due to resolution of inflammation. This volume loss is not a sign 
of neurodegeneration, because there is no loss of neuronal tissue. This is 
often referred to as pseudo-atrophy. Importantly, this effect may last up to 
one year after initiation of treatment.(152, 153) Thirdly, various physiological 
variations in the content of the intra- and extracellular compartments affect 
volumetric measurements.(154) Lastly, factors that are not MS-specific (such 
as dehydration, alcohol use, smoking, genetic variation, comorbidities and 
age) may influence brain volume.(154)
3.1.3 Persisting black-holes
Another MRI marker for neurodegeneration is formation of PBH. These 
lesions are often defined as non-enhancing T2HL with persisting signal 
intensity between that of the gray matter and the CSF on T1-weighted scans.
(155) Approximately 30 to 40% of active T2HL will eventually evolve into PBH 
within six to 12 months.(156) The underlying neuropathology of PBH is severe 
and irreversible tissue damage.(156) Accumulation of PBH is associated with 
accrual of disability.(157, 158) Furthermore, the PBH load correlated with 
disability worsening over 10 years.(159) Some clinical trials found significant 
effects of treatment on the formation of PBH.(160-163)
Several more advanced MRI techniques are potentially valuable outcome 
measures, although they need further research to clarify the exact relevance. 
Examples are functional MRI for analysis of functional connectivity,(164) 
diffusion tensor imaging to examine brain tissue integrity(165) and 
magnetization transfer ratio MRI as a marker for brain myelin content.(166, 
167)
3.2 Optical Coherence Tomography
The retina can be visualized non-invasively, safely and fast with OCT. This 
technique uses the reflection of near infra-red light on the retina. Different 
layers of the retina can be distinguished on high-resolution images. It has 
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been proven to be valuable in quantifying pathology in these layers, although 
the exact underlying pathophysiological processes of these findings are 
largely unclear.(168, 169) 
Most findings of the research with OCT in MS point to neurodegenerative 
changes such as axonal loss and neuronal soma shrinkage.(170) Therefore, 
OCT is a good candidate outcome measure to assess treatment effect on 
neurodegeneration, which makes it an attractive tool in progressive MS trials. 
For this purpose, the retinal nerve fiber layer (RNFL) is of particular interest. 
The thickness of this layer may be decreased following optic neuritis,(171, 
172) but also decreases more slowly in patients without prior optic neuritis.
(171, 173) The latter may indicate ongoing neurodegeneration. Furthermore, 
RNFL thickness correlated with cerebral atrophy measures(174, 175) and 
with axonal loss in the anterior visual pathway.(176, 177)
Clinically, thinning of the RNFL correlated with worse performance on the 
LCLA (explained in table 4),(171, 178) and a reduced visual quality of life.(179) 
Correlations of RNFL thickness with EDSS were less consistent.(180, 181) 
In a recent large multicenter study of patients without prior optic neuritis, 
persons with a RNFL thickness in the lowest tertile at baseline had double 
the risk of disability worsening in two years compared with the other tertiles.
(182) The risk further increased with a longer follow-up. The clinical relevance 
of other layers, such as macular volume(183) and retinal ganglion-cell/ inner 
plexiform layer thickness,(184, 185) is less clear.
The advantage of OCT over MRI that it is technically easier and widely 
accessible. When using a predefined scanning protocol it has a good 
reliability.(186) Nevertheless, further research is needed before OCT can 
be implemented as an outcome measure. This is particularly the case for 
longitudinal data of the various layers.
3.3 Biomarkers in body fluids
Both MRI and OCT allow detection of neuro-inflammation and -degeneration 
at various time-points, but have limited sensitivity to detect ongoing processes. 
Biomarkers in body fluids, such as CSF and blood, might be more useful for 
this purpose. Although it is beyond the scope of this review to discuss this 
topic thoroughly (recently reviewed elsewhere(187)), a few biomarkers are 
worth mentioning.
There are several potential valuable CSF biomarkers that might give a real-
time reflection of ongoing neurodegeneration. A biomarker that reflects 
axonal injury is neurofilament. This protein is a major component of the axonal 
cytoskeleton and is released following neuronal damage.(188) Neurofilament 
levels in CSF are generally raised in MS patients, particularly during an acute 
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relapse.(189, 190) Furthermore, increased levels were associated with 
worse EDSS,(190) faster disability worsening in 15 years, (191) Gd-enhancing 
lesion load,(192) and atrophy (of the brain and spinal cord) in 15 years.(193) 
Neurofilament levels were also responsive to treatment with fingolimod(194) 
and natalizumab,(195) and therefore might be biomarkers for treatment 
effect.
Other proteins of the axonal cytoskeleton that can be measured in CSF are 
actin(196, 197) and tubulin.(198, 197) Proteins that indicate ongoing disease 
activity are sphingolipids (component of the myelin sheet),(199) glial fibrillary 
acidic protein (GFAP),(200) S100B(200) and Chitinase 3-like proteins.(201)
Compared to CSF, blood is generally less well studied for biomarkers, but 
clearly has the advantage that it is much easier to obtain. Similarly like in CSF, 
neurofilament in the blood might act as a biomarker for neurodegeneration. 
Neurofilament levels predicted recovery of spinal cord lesions,(202) and 
higher concentrations were associated with faster conversion to definite MS 
and more cerebral lesions.(203) Another biomarker that is used to determine 
bioactivity of interferon-β is myxovirus-resistance protein A (MxA). It also 
seems to be indicative for recent and future disease activity.(204, 205) Lastly, 
various small noncoding microRNAs are potentially valuable for predicting 
disease course and treatment response.(187)
The exact value of these biomarkers as outcome measures will have to be 
determined. If clinically meaningful, they will probably be used in combination 
with other measures. They may be particularly useful to assess treatment 
effects in trials with progressive MS, because identification of progression or 
neurodegenerative changes remains very challenging.
4 NO EVIDENCE OF DISEASE ACTIVITY
The concept of a disease activity free status as the ultimate treatment goal has 
been used in other medical conditions, including cancer and inflammatory 
diseases such as rheumatoid arthritis. It implies the absence of measurable 
disease activity. This concept has been translated to NEDA and is used in 
more recent MS trials as a secondary outcome measure.(206, 207) It is 
essentially a multidimensional measure that typically covers (confirmed) 
EDSS progression, relapse rate and formation of MRI lesions (T2HL or GdT1L). 
However, any parameter related with disease activity may be added.
A recent study in a cohort of RRMS patients found that NEDA at two years 
had a positive predictive value for absence of disability progression at seven 
years of 78%.(207) Furthermore, the predictive value of NEDA was greater 
than each of the individual components. Other studies also showed that 
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combinations of clinical and MRI parameters had better predictive value for 
disability progression than individual measures.(125, 208, 150, 209, 210) 
For example, a recent meta-analysis found that treatment effect on T2HL 
and brain volume combined explained 75% of the variance of disability 
progression in two years, and this was significantly higher than predictive 
values of the MRI measures individually.(150)
In clinical practice, NEDA-like models are used to identify responders and 
non-responders to treatment. Examples are the Modified Rio Score(211) and 
the Canadian treatment optimization recommendation model.(35) Such tools 
need to have good long-term predictive power for disability, before treatment 
decision can be based on it.
When using NEDA as an outcome measure to assess treatment efficacy it is 
important to consider the timing of assessment. The reason for this is that 
a treatment needs to have had enough time to become effective. This can 
be illustrated by the finding that 70% of patients had NEDA two years after 
initiating treatment with natalizumab with baseline assessment after one 
year, compared with 51% NEDA with a baseline at initiation of therapy.(212) 
For alemtuzumab timing is different, because the true treatment effect starts 
after the second infusion cycle, one year after the initial course.(213) This 
issue has implications when determining if NEDA can be a valid outcome 
measure for disability at the long run.
Although NEDA seems an appealing outcome measure in some ways, it is 
not yet clear which (functional) domains are important to include and when 
or how frequently these should be assessed. It should, for example, reflect 
what is important in daily life for patients. Therefore, including a PROM seems 
indispensable. Also, markers for neurodegeneration should be involved when 
tissue loss is considered to be the ultimate treatment goal. Therefore, brain 
volume is increasingly added to NEDA (referred to as NEDA-4).(214) However, 
adding more assessments likely reduces the number of patients fulfilling 
NEDA, and may raise the bar to a too high level resulting in the rejection of 
highly active, but not perfect, interventions.
Taken together, NEDA will continue to evolve while evidence accumulates 
about what are valuable outcome measures. Standardization of timing and 
functional subdomains are imperative for comparison between studies.




The number and quality of outcome measures is increasing, and with that 
the assessment of treatment efficacy will improve over the coming years. 
Until new measures are validated and generally accepted, the traditional 
outcome measures EDSS and relapse rate will remain primary endpoints in 
clinical trials. However, it is very unlikely that these measures are sufficient 
to fully assess treatment efficacy. Eventually, measures that more explicitly 
capture multiple dimensions (e.g. MSFC and NEDA), will probably become the 
new standard. They are particularly useful to detect infrequent events (e.g. 
relapses) or small changes (e.g. brain atrophy and disability worsening) under 
treatment, which is increasingly important with highly effective therapy. The 
same accounts for treatment of progressive disease (SPMS and PPMS), 
in which small and gradual treatment effects can be expected. Moreover, 
multidimensional measures might decrease duration and size of clinical 
trials. The caveats of multidimensional measures that have to be taking into 
account are summarized in table 6.(25)
In addition to improvement of existing outcome measures, innovative 
techniques such as electronic devices and mobile device applications 
are potentially valuable. They allow, for instance, multiple or continuous 
assessment which might give a more adequate picture of a patients’ ability or 
disability and the impact of the disease on daily living. 
Table 6, limitations and caveats of multidimensional measure.
- Interpretation may not be straightforward, particularly if clinical relevance of (some) compo-
nents are not immediately obvious
- An overall score lacks a clear dimension, which complicates the interpretability of the score
- Components should be normalized or weighted without obscuring the clinical meaning
- Components may shift in opposite directions (improvement vs harm) which might obscure 
interpretation of treatment efficacy
- Components should capture the expected (biological) effects of the intervention under 
investigation
- Increasing the number of components not necessarily increases sensitivity
- Redundant components might cause a large change of the composite score in patients that 
have symptoms in that domain, while the change may be smaller or absent in patients with 
symptoms in other domains
- Increasing sensitivity to change does not necessarily lead to higher sensitivity for treatment 
effects




Several electronic devices are under development to assess disability. An 
example of this is the Assess MS system that uses an infra-red camera to 
register movements of upper and lower limbs, trunk and ambulation for 
automatic quantification of these movements. Results from a pilot study in 
MS are promising and these preliminary results are currently being validated 
with a new high-resolution camera.(215) Another device that has been 
developed is the Glove analyzer system that is able to record data from finger 
movements to assess hand and arm function.(216) Also, accelerometers are 
potentially useful tools to measure mobility automatically.(217) Apart from 
other attractive aspect, electronic devices are free of intrarater variability.
Mobile device applications are increasingly being used in the medical field 
and are also potentially useful in assessing outcome in MS trials. Applications 
can be easily distributed and accessible for everyone with a smart phone. 
They can be used in several ways, for example, for assessing a PROM 
on regular basis up to several times per day. Also, applications may be 
connected online with investigators to get real-time access to or feedback 
from a patient status. This may decrease the number of visits needed or 
could help to decide whether or not a face to face contact with a patient is 
needed. In the past years, healthcare hackathons (i.e. an acronym of HACKers 
marATHONS) were organized to stimulate development and integration of 
medical devices and mobile device applications.(218, 219) However, many 
of these applications need rigorous scientific validation before they may be 
considered as outcome measures in clinical trials.
6 CONCLUSIONS
To conclude, assessing outcome in clinical trials in MS is not straightforward 
and therefore a challenging field. Although much has been achieved the past 
decades, “old habits die hard” and traditional measures probably remain the 
standard in the near future. When more advanced measures have proven 
their value, they need to earn general acceptance by health care providers 
and especially regulatory agencies. In the end, only multidimensional 
measures will allow full coverage of disease activity and progression of MS 
and are thus best suited to assess treatment efficacy in MS trials.
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Upper extremity function (UEF) is often compromised in multiple sclerosis 
(MS), although its importance is commonly under-recognized relative to 
ambulation. We explored the concurrent presence of UEF and ambulatory 
impairment in MS, by examining various aspects of UEF across different 
levels of ambulation.
Methods  
247 patients were included with clinically definite MS or clinically isolated 
syndrome according to the revised 2010 McDonald’s criteria. The Nine-Hole-
Peg test (9HPT) and Expanded Disability Status Scale were used to stratify 
patients into clinically different UEF and ambulation subgroups. Multiple 
aspects of UEF were examined with various clinical tests and the patient-
reported outcome measure ‘Arm Function in MS Questionnaire’ (AMSQ).
Results   
Patients with worse ambulatory impairment displayed worse performance 
on the 9HPT, clinical UEF tests and the AMSQ. Although most patients had no 
obvious ambulatory restrictions, more than 80% exhibited some level of UEF 
impairment. Most patients had mild UEF impairment (n=174), accounting for 
the largest proportion in all ambulation groups (52 – 78%).
Conclusion  
UEF and ambulation showed distinct patterns of impairment in MS, affecting 
multiple aspects of UEF. Better assessment of multiple facets of disability 
may be helpful in treatment decisions, and support the development of 
rehabilitations strategies specially targeted towards UEF impairment.




Walking impairment is a common consequence of multiple sclerosis (MS),(1) 
which is routinely assessed as an indicator of disability progression and to 
monitor the efficacy of treatment.(2) Although upper extremity function (UEF) 
is often compromised as well, its importance is under-recognized relative 
to ambulation.(3) UEF impairment can impact the ability to use walking aids 
and is important to maintain the capacity to perform activities of daily living 
(ADL). Additionally, the magnitude of upper extremity (UE) dysfunction was 
shown to negatively impact quality of life,(4) and was a significant predictor of 
direct disease related costs in MS.(5) Therefore, identifying UEF impairment 
and characterizing its magnitude and impact is of importance for MS 
management.
The traditional endpoint to rate disability in MS therapeutic trials is the 
Expanded Disability Status Scale (EDSS), which is heavily weighted on 
walking ability, especially in the higher scale range.(6) The use of UEF-specific 
measures in clinical trials has increased since the introduction of the MS 
Functional Composite (MSFC), a composite of quantitative measures of UEF 
(Nine Hole Peg test (9HPT)), walking speed (Timed 25-foot Walk test (T25WT)) 
and cognitive function.(7) Although this improved the assessment of UEF, 
the instrument does not fully capture the broader aspects of function 
necessary to define the level of severity on more complex tasks, such as ADL. 
Furthermore, the incorporation of specific patient-reported outcome (PRO) 
measures would be valuable for enhancing information on the functional 
impact of UEF impairment, which is increasingly being recommended as 
integral component in clinical trials.(8)
Recent developments in the assessment and management of UEF 
restrictions, and in the spectrum of interventions available, brings renewed 
hope. A large phase 3 trial (ASCEND) explored the effect of natalizumab on 
disease progression in secondary progressive MS (SPMS) patients. Although 
treatment did not have an effect on ambulation, it reduced progression of 
UEF impairment as measured with the 9HPT.(9) Similar data were presented 
recently from the ORATORIO trial, demonstrating that ocrelizumab reduced 
the risk of UEF impairment progression in primary progressive MS patients.
(10) The positive effect on UEF of several therapies thus indicates that 
patients with a more advanced stage of MS may benefit from disease 
modification. Furthermore, UE rehabilitation studies revealed that different 
types of training programmes, such as multidisciplinary and robot-based 
rehabilitation, specially targeted toward the upper limbs can improve UE 
capacity and performance in MS.(11)
Ideally, clinicians can identify subgroups of patients who are likely to benefit 
from disease modifying therapies and select patients that may benefit from 
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rehabilitation strategies, according to the level of function on UEF as well as 
ambulation. Therefore, the aim of this study was to explore the concurrent 
presence of UEF and ambulatory impairment in patients with MS, by 
examining various aspects of UEF across different levels of ambulation. 
2 METHODS
The data reported here are part of a larger study to develop the Assess MS 
system, which is a multinational project performed by large European MS 
centres.(12-16) Assess MS is being designed to automatically quantify motor 
dysfunction in MS, with the goal of providing a consistent and fine-grained 
measure of motor ability. Movements of MS patients were recorded non-
invasively with a 3D depth sensing and colour camera (Microsoft Kinect®) 
and analysed using machine learning algorithms. Written informed consent 
was obtained from all subjects prior to study participation and the study was 
approved by the respective ethics committees.
Subjects
In total 247 patients were included (165 females; mean age 47.3±13.0 years; 
median disease duration 13 (range 0–57) years; median EDSS 3.5 (range 
0.0–7.0)) with clinically definite MS (181 relapsing-remitting, 42 SPMS, 14 
primary progressive MS) or clinically isolated syndrome (n = 10), according to 
the revised 2010 McDonald’s criteria.(17) Further inclusion criteria required 
patients to have a Neurostatus-EDSS between 0.0 to 7.0,(18) aged above 18, 
without additional diseases that contribute to disability. Exclusion criteria 
were patients that were unable to follow procedures or read the consent due 
to psychological disorders, dementia or understand either the local language 
or English. 
Ambulation and upper extremity function measures 
All patients received a standardized EDSS assessment according to the 
Neurostatus definitions on the day of recording.(18) Furthermore, the 9HPT 
and T25WT were performed, as implemented in the MSFC.(7) For the T25WT, 
the performance of two trials was averaged for each patient. For the 9HPT, 
the averaged value of two trials were taken for the dominant and non-
dominant hand, which was determined through questioning the patient. For 
this study three UEF movements from Assess MS were chosen: the ‘finger-
to-nose test’ (FNT) to evaluate the level of ataxia (tremor/ dysmetria), the 
‘pronator drift test’ (PDT) to evaluate the level of pyramidal dysfunction, and 
the ‘drinking-from-cup’ test (CUP) to evaluate the level of motor dysfunction 
affecting ADL.(19) For CUP, patients were asked to take a sip of water from a 
standardized ¾ filled plastic cup on a table in front of them at arm’s length. 
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The Arm Function in Multiple Sclerosis Questionnaire (AMSQ)(20) and the 
Multiple Sclerosis Impact Scale 29 (MSIS-29)(21) were acquired to assess 
activity limitations due to impaired UEF in MS, and to examine the perceived 
physical and psychological impact of MS from the patients’ perspective, 
respectively.
Video rating of movements
A comprehensive description of the methodology used for video rating can 
be found elsewhere.(22, 23) In short, all colour videos of the movements 
of patients were rated by two neurologists with broad experience in MS. 
Predetermined rating scales were used for FNT and PDT based on the 
Neurostatus-EDSS functional system scoring definitions, which are rated 
on a five- (‘0=none’ to ‘4=severe limb ataxia’) and three-point Likert scale 
(‘0=none’ to ‘2=evident pronation and downward drift’), respectively.(18) 
For CUP a five-point Likert scale was created ranging from 0 (i.e. ‘normal 
performance’) through 4 (i.e. ‘impossible to perform). Using an algorithm 
that takes into account individual rater bias, the videos were subsequently 
assigned a consensus score.(24) This consensus score was used in the 
statistical analysis. Videos of insufficient quality or if not performed according 
to the protocol, were primarily excluded from the analysis.
Classification of ambulatory and upper extremity function 
impairment groups
The EDSS score was used to stratify patients into three clinically different 
ambulation groups based on the Neurostatus-EDSS scoring definitions: 
‘fully ambulatory’ (able to walk ≥500 meters; EDSS 0 – 3.5), ‘mild ambulatory 
impairment’ (unassisted walking distance of ≥100-300 meters, but <500 
meters; EDSS 4.0 – 5.5) and ‘severe ambulatory impairment’ (assistance 
required when walking, able to take a few steps; EDSS 6.0 – 7.0). The 9HPT 
of the dominant hand (despite disability due to MS) was used to stratify 
patients into clinically different UEF groups: ‘normal UEF’ (<18 seconds), 
‘mild UEF impairment’ (≥18 seconds and <33.3 seconds) and ‘severe UEF 
impairment’ (≥33.3 seconds). The lower benchmark was chosen based 
on previous work of Kierkegaard et al.(25) who provided evidence that 18 
seconds on the 9HPT differentiated MS patients with no impaired UEF from 
patients with minimally impaired UEF, who were at risk for activity limitations 
and participation restrictions.(25) The upper benchmark was derived from 
the proposed cut-off value of Lamers et al.(26) who used a median split of 
the 9HPT score of a large MS sample (n=105) , which differentiated between 
‘mild’ and ‘marked to severe’ UE dysfunction based on various measures 
of UEF (including assessment of strength, tremor, spasticity, pain) and 
participation level. Patients who were unable to perform the 9HPT due to MS-
related impairment were categorized in the ‘severely’ impaired groups. This 
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classification resulted in nine clinically different patient groups, according to 
the level of ambulatory and UEF impairment.
To identify different aspects of UEF at various levels of ambulation, the 
following variables were compared between the aforementioned patient 
groups: FNT, PDT, CUP, AMSQ and MSIS; along with demographical and 
disease specific characteristics (age, sex, disease type, disease duration, 
T25WT). Disease type (i.e. relapsing / progressive), PDT (i.e. 0 / ≥1), FNT and 
CUP (i.e. 0 / ≥1 / ≥2) were further categorized for ease of interpretation. 
To explore the relationship between the 9HPT, FNT, PDT and CUP, comparison 
Venn diagrams with multiple overlapping closed curves were created, each 
representing a set of patients performing abnormal [score of (≥1)] on either 
of the tests. Patients were included in the final analyses only if they completed 
all 4 tests. 
Statistical analysis
Statistical analysis was performed in SPSS version 24 (Chicago, IL). A p-value 
of less than 0.05 was considered statistically significant. The normality of each 
variable was assessed using histograms and normality plots. For variables 
with a normal distribution mean values with standard deviations (SD) were 
calculated, and median values with interquartile ranges (IQR) for non-normal 
distributions. Variables following a normal distribution were compared 
between groups using analysis of variance models, as appropriate, whereas 
categorical variables were compared using the Mann–Whitney and Chi-
square tests. The distribution of patients across the EDSS- and 9HPT-defined 
ambulation and UEF groups was compared using a Chi-square test.
3 RESULTS
Ambulation groups
The median EDSS of the total cohort was 3.5 (range 0 – 7.0). Based on the 
Neurostatus-EDSS, 147 patients were categorized as ‘fully ambulatory’, 
46 patients as ‘mild ambulatory impairment’, and 54 patients as ‘severe 
ambulatory impairment’ (table 1). All groups were similar in terms of sex 
(p=0.26). A direct comparison between groups revealed that patients with 
worse levels of ambulatory impairment displayed: a higher age, more 
progressive MS phenotypes, longer disease duration, and higher MSIS 
and T25FW scores, with significant differences between all groups (overall 
p<0.01). However, age, disease duration and MSIS did not differ between 
the  ‘mild’ and ‘severe ambulatory impairment’ groups (p=0.17, 0.21 and 0.27, 
respectively).





















































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































Figure 1, distribution of patients with abnor-
mal upper extremity test performance among 
the clinically diff erent ambulatory groups. 
Abbreviations: 9HPT= nine-hole peg test; 
FNT = fi nger-to-nose test; PDT = pronator drift 
test; CUP = drinking-from-a-cup. Shown are 
the percentages of patients that perform ab-
normal (score ≥1) on the 9HPT, FNT, PDT and 
CUP test among the clinically diff erent ambu-
latory groups.
Figure 2, distribution of Arm Function in Mul-
tiple Sclerosis Questionnaire (AMSQ) results 
among the clinically diff erent ambulatory 
groups. Shown are the median values with (in-
terquartile) range.
A similar trend was observed for all UEF measures, with a worse level of UEF 
performance along with a worse level of ambulatory impairment (all group 
diff erences overall p<0.01). This is illustrated by fi gure 1 and 2, which display 
the distribution of patients that performed abnormally on the 9HPT, FNT, PDT 
and CUP (percentages), and AMSQ (median with IQR) among the ambulation 
groups. This clearly illustrates that most patients were restricted on the 9HPT 
in each group, followed by FNT, CUP and PDT.
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Figure 3, distribution of patients among the clinically diff erent ambulatory and UEF impairment 
groups as defi ned by the EDSS- and 9HPT-benchmarks. Abbreviations: UEF = upper extremity 
function; EDSS = Expanded Disability Status Scale; 9HPT= nine-hole peg test. Fully ambulatory: 
EDSS 0 – 3.5; mild ambulatory impairment: EDSS 4.0 – 5.5; severe ambulatory impairment: EDSS 
6.0 – 7.0; normal UEF 9HPT <18 seconds, mild UEF impairment 9HPT  18 seconds and <33.3 
seconds; severe UEF impairment 9HPT ≥33.3 seconds
Distribution of upper extremity function groups
Figure 3 shows the results of the nine clinically diff erent ambulatory and UEF 
impairment groups, as defi ned by the EDSS- and 9HPT-benchmarks. Four 
patients were excluded from the analysis since the 9HPT was missing due to 
reasons not related to MS: three patients in the ‘fully ambulatory’ group and 
one patient in the ‘mild ambulatory impairment’ group. Overall, the cohort 
consisted of relatively few patients with ‘normal UEF’ (n = 30) and all of these 
patients, except one, were ‘fully ambulatory’. Most patients had mild UEF 
impairment (n=174) accounting for the largest proportion in all ambulation 
groups (77.8%, 75,6% and 51.9%, respectively). We observed a decline in 
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the proportion of patients with ‘normal UEF’ across the level of ambulatory 
impairment: 20.1% (fully ambulatory), 2.2% (mild ambulatory impairment) 
and 0% (severe ambulatory impairment); and a concurrent increase in the 
proportion of patients with ‘severe UEF impairment’; 2.1%, 22.2% and 48.1%, 
respectively.
EDSS = Expanded Disability Status Scale; 9HPT= nine-hole peg test. Fully 
ambulatory: EDSS 0 – 3.5; mild ambulatory impairment: EDSS 4.0 – 5.5; severe 
ambulatory impairment: EDSS 6.0 – 7.0; normal UEF 9HPT <18 seconds, 
mild UEF impairment 9HPT ≥18 seconds and <33.3 seconds; severe UEF 
impairment 9HPT ≥33.3 seconds.
Combination of upper extremity function tests
Figure 4 shows the Venn diagrams, revealing the proportion of area of 
overlap between patients who performed abnormally on the 9HPT, FNT, PDT 
and CUP.  Fifty-six patients were excluded from the analyses due to missing 
values on either one of the tests: 4 on the 9HPT, 23 on CUP, 30 on FNT and 
17 on PDT (74 missing tests in total).  Of the 191 remaining patients there 
were 165 (86.4%) who were restricted on the 9HPT, 105 (55.0%) patients 
performed abnormally on FNT, 49 (25.7%) on PDT and 91 (47.6%) on CUP. 
The vast majority of patients that were restricted on the 9HPT also performed 
abnormally on the other tests.
4 DISCUSSION
In this study, we aimed to explore the concurrent presence of UEF and 
ambulatory impairment in patients with MS, examining various aspects of 
UEF across different levels of ambulation. In a large representative cohort of 
MS patients with overall mild disability, UEF and ambulation showed distinct 
patterns of impairment. Although most patients exhibited only mild UEF 
deficits, this was already a prominent sign while ambulation was not obviously 
affected. Once ambulation was clearly impaired, deficits in UEF concurrently 
existed, affecting multiple aspects of function. Strikingly, in patients with 
markedly severe walking impairment (EDSS 6.0 – 7.0) there remained a 
large proportion of patients who displayed only mild UEF impairment. Our 
observations underscore the importance of the consideration of a patients’ 
UEF impairment with multiple measures, independent of ambulation. 
In the current study, more than 80% of patients exhibited some level of UEF 
impairment as measured with the 9HPT, which is in line with previous data 
on the magnitude of the problem.(27) To identify the relevant underlying 
constructs that comprised UE dysfunction, we examined  the relationship 
between the 9HPT and the FNT, PDT and CUP test using Venn diagrams. 
Although the 9HPT is often used as a performance-based measure of manual 
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Figure 4, Venn diagrams of the 9HPT, FNT, PDT and CUP tests. Abbreviations: 9HPT= nine-hole 
peg test; FNT = finger-to-nose test; PDT = pronator drift test; CUP = drinking-from-a-cup. Data of 
191 patients are included in the diagrams, excluding 56 patients because of missing values on 
either one of the tests (n= 74). Shown are schematic diagrams representing all possible relations 
between the patients that performed abnormally (score ≥1) on the 9HPT, FNT, PDT and CUP
dexterity, our results indicated that it may also be useful for identifying 
patients with pyramidal dysfunction, UE ataxia and the ability to perform 
ADL as the areas between patients performing abnormal on the 9HPT were 
largely overlapping with the clinical tests. This is in line with an earlier report 
on largely the same cohort of patients, which revealed that a large percentage 
of the variance of the 9HPT was explained by a combination of the UEF 
movements, of which CUP contributed most in all regression models.(19) 
However, additional studies are needed to determine the utility of the 9HPT 
as a performance-based measure of a variety of functional aspects in MS. 
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Previous studies already provided evidence that the 9HPT appeared to be 
a good outcome measure for differentiating the levels of severity of UE 
dysfunction.(25, 26, 28) Use has been recommended given its high test-retest 
reliability, sensitivity in discriminating MS patients from healthy subjects, and 
MS patients with different levels of UEF impairment. Furthermore, the test 
shows high convergent validity with other manual dexterity as well as more 
comprehensive UEF measures.(28) To date, it is still not clear which cut-off 
values on the 9HPT should be applied. For this current study, we used the 
proposed cut-off values published by Kierkegaard et al and Lamers et al for 
the lower and upper benchmark, because of their supposed relationship to 
real life anchors and functional independence.(29) Longitudinal and larger 
studies are needed to confirm the clinical utility and relevance of these 
proposed 9HPT benchmarks and to parse out whether there are additional 
benchmarks in the lower and higher ranges of performance. 
Previous papers have reported the relative patterns of UEF and ambulation 
impairment in patients with MS.(27, 30, 31) A cross-sectional study explored 
UEF and ambulation across different levels of disability.(27) The 9HPT and 
T25FW were used to stratify patients into different UEF and ambulation 
groups (>1 SD worse than age-/sex-related norms). Disability was defined 
as ‘mild’ (EDSS 1.0 – 3.5), ‘moderate’ (EDSS 4 – 5.5) or ‘severe’ (EDSS 6 – 9.5), 
which resulted in a distribution of 71%, 92% and 97% patients with UEF 
impairment; and 22%, 89% and 100% patients with walking impairment, 
respectively. The authors concluded that the majority of patients with MS 
experienced several concurrent disabilities, which were independently 
associated with the perceived physical and psychological impact from the 
patients’ perspective as measured with the MSIS-29. Although these findings 
are in line with our data, the authors did not provide a detailed insight into 
the broader aspects of UEF.
Another report provided a more detailed insight into the UEF of MS patients 
across different EDSS subgroups. In this cross-sectional study, various 
measures of UEF were included to assess strength, spasticity, sensation, and 
also the 9HPT and a PRO measure were incorporated. Findings indicated a 
concurrent deterioration of UEF on all aspects with disability accrual, which is 
in line with our data. However, a smaller proportion of patients was reported 
as being impaired on the 9HPT, which is probably due to the use of a different 
definition of “abnormal”.(30)
Another study investigated patterns of UEF and ambulation deterioration 
longitudinally.(31) The primary goal of the authors was to improve the 
assessment of disability accrual in patients with SPMS using the ‘EDSS-plus’, 
a composite endpoint adding the T25FW and 9HPT to the EDSS. They found 
that once the T25WT deteriorated with 20% change or more, UEF deteriorated 
more gradually than ambulation in the subsequent two years, especially in 
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the most severely disabled group (EDSS 6.0-6.5). Although our data might 
suggest a similar trend, no inferences on a longitudinal relationship can be 
made. 
Other studies confirm the presence of UEF impairment early in the disease 
course. Data from questionnaires of 35.000 patients collected in the North 
American Research Committee on Multiple Sclerosis registry revealed that 
in the first year after onset, 52% of patients reported minimal to mild UEF 
impairment, while 40% perceived no problems.(32) For ambulation, this 
was 35% and 50%, respectively. An important limitation of this study was 
that function was assessed with short 6- or 7-item questionnaires only, 
and additional physician- or performance-based measures were lacking. 
Two other studies on MS patients found subtle UEF impairments in the 
early disease course that were not detected with standard neurological 
examination.(33, 34) Abnormalities were found in movement smoothness, 
speed profile, and lifting tasks. These limitations were noticed by patients 
and had an impact on the ability to perform ADL.(33)
Several neurobiological explanations for different patterns of ambulatory 
and UE dysfunction can be given. One hypothesis is that changing functional 
networks that compensate for increasing structural damage are more robust 
in preserving UEF than in preserving ambulation. A similar phenomenon has 
been described in the preservation of cognition in patients with MS.(35) The 
“cognitive reserve hypothesis” postulates that genetic and environmental 
factors attenuate the negative effect of disease burden on cognitive decline.
(36) One might assume that ambulation is more brittle than UEF (i.e. neural 
degeneration has a larger impact on function), but has a larger capacity 
for compensation. Under this scenario, ambulation remains intact while 
structural damage has already affected UEF. However, once the buffer 
capacity is exhausted, the accumulation of walking impairment will outpace 
the worsening of UEF. Another hypothesis is that of a central length-
dependent axonopathy.(37) In this mechanism, longer neurons to the lower 
extremities are more vulnerable to accumulating focal damage, which causes 
secondary neurodegeneration. Clinically, this will lead to a faster deterioration 
of ambulation than UEF.
Study limitations
Our study also has some limitations. To define the level of ambulatory 
impairment, EDSS cut-off values were used. According to the Neurostatus-
EDSS definitions,(18) a patient with unrestricted ambulation (able to walk 
>500 meters) can have an EDSS score between 0 and 3.5, depending on 
impairment of other functional systems. As a result, we cannot rule out the 
possibility that other patterns of disability contributed to the classification 
of ambulatory function in our MS patients. Furthermore, in subjects with an 
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EDSS lower than 2.0, walking and balance can already be impaired compared 
to healthy controls, which should be considered when interpreting these 
findings. Another limitation was that MS patients included in our study were 
relatively mildly disabled (median EDSS 3.5), which limits the generalisation 
of our data to more severely disabled patients. However, our sample was 
representative for a general MS 
To conclude, this study emphasizes the importance of wider incorporation of 
performance-based and PRO measures that can be used for screening and 
assessment of UEF impairment in daily clinical practice and treatment studies. 
We have provided data on the relative patterns of UEF and ambulatory 
impairment and explored the concurrent presence of a variety of functional 
aspects of UEF. Further stratifying patients according to UEF, beyond 
ambulation, will enhance patient selection for future treatment and support 
the development of rehabilitation strategies specially targeted towards UEF 
impairment. Future studies are needed to explore the exact longitudinal 
relationship between accrual of ambulatory and UEF impairment, which will 
increase our understanding of the magnitude and impact of UEF impairment 
in MS patients and eventually improves patient care.
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CHAPTER 4
Tasks of activities of daily living 
(ADL) are moving more valuable 
than the classical neurological 
examination to assess upper 
extremity function and mobility 
in muliple sclerosis 
Caspar E.P. van Munster, Marcus d’Souza, Saskia Steinheimer, Christian P. 
Kamm, Jessica Burggraaf, Jonas Dorn, Jacques Boisvert, Manuela Diederich, 
Kristina Kravalis, Frank Dahlke, Ludwig Kappos, Bernard M.J. Uitdehaag. 





Accurate clinical assessment in multiple sclerosis (MS) is challenging. The 
Assess MS system is being developed to automatically quantify motor 
dysfunction in MS, including upper extremity function (UEF) and mobility.
Objective  
To determine to what extent combinations of standardized movements 
included in the Assess MS system explain accepted measures of UEF and 
mobility.
Methods  
MS patients were recruited at four European MS centres. Eight movements 
were selected, including tasks of activities of daily living (ADL) and classical 
neurological tests. Movements were recorded on video and rated by 
experienced neurologists (n=5). Subsequently, multivariate linear regression 
models were performed to explain the variance of the 9-Hole-Peg Test (9HPT), 
Arm Function in Multiple Sclerosis Questionnaire (AMSQ) and Timed-25 Foot 
Walk test (T25WT).
Results  
In total 257 patients were included. The movements explained 62.9 to 80.1% 
of the variance of the 9HPT models, 43.3 and 44.3% of the AMSQ models, 
and 70.8% of the T25WT. In all models, tasks of ADL contributed most to the 
variance.
Conclusion  
Combinations of movements are valuable to assess UEF and mobility. 
Incorporating ADL tasks into daily clinical practice and clinical trials may 
be more valuable than the classical neurological examination of UEF and 
mobility.




Assessment of disability in multiple sclerosis (MS) is traditionally performed 
with the Expanded Disability Status Scale (EDSS), which is a physician-based 
method. However, there are several limitations to the EDSS. Some of these 
are related to the heterogeneous nature of MS, others are inherently a 
consequence of methodological aspects of the scale itself, e.g. a high inter- and 
intrarater variability and a disproportional impact of ambulatory function on 
the total score.(1) To improve the clinical assessment of MS disability, various 
performance-based tests were introduced. Widely accepted performance-
based tests are the Nine-Hole Peg Test (9HPT),(2) the Timed 25-foot Walk Test 
(T25WT)(3) and the Symbol Digit Modalities Test.(4) Also, patient-reported 
outcome measures contribute to clinical assessment by giving insight into 
the patient-perspective of a certain aspect, such as upper extremity function 
(UEF) with the Arm Function in Multiple Sclerosis Questionnaire (AMSQ).(5)
A potential valuable improvement in clinical assessment would be the 
automatic quantification of disability with Machine Learning Algorithms (MLA). 
With this in mind, the Assess MS system is being developed to automatically 
quantify motor functioning by capturing standardized movements of patients 
recorded by the Microsoft Kinect® camera (Microsoft, Redmond, SA, USA)
(6). Several of these movements are used for the assessment of UEF and 
mobility, which are important functional domains in MS since the majority 
of patients experience UEF and mobility impairment at some point in the 
course of their disease.(7, 8) Furthermore, impaired UEF and mobility can 
impact the ability to perform ADL, on general health perception,(9, 10) and 
on quality of life and social participation.(11, 12)
The standardized movements used to develop the Assess MS include several 
classical neurological tests and tasks of activities of daily living (ADL), which 
can easily be administrated in daily practice. However, it is unclear to what 
extent these tests contribute to determining UEF and mobility. Presumably, 
not all tests are required to assess these functions, and it is unclear how 
much each test contributes to UEF and mobility.
In the current study, we investigate to what extent combinations of 
standardized movements explain accepted measures of UEF and mobility.
2 METHODS
Patients
Patients were recruited at four large European MS centres in Amsterdam, 
Basel, Bern and Lucerne. Inclusion criteria were: aged older than 18 years, 
diagnosis of MS or a clinically isolated syndrome suspicious for MS according 
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to the 2010 revised McDonald criteria, EDSS score between 0 and 7. Exclusion 
criteria were: inability to follow procedures or read the informed consent due 
to psychological disorders, dementia or insufficient ability to speak the local 
language or English. Each patient provided written informed consent prior to 
study entry and the study was approved by the respective ethics committees.
Procedure
An example of the experimental setup is illustrated in figure 1. All patients 
were recorded with the Kinect® camera that simultaneously captures depth 
and colour videos.
Figure 1, experimental setup. In this example, a patient sits on a chair and performs the finger-
to-nose test. The Assess MS machine is placed perpendicular to the patient and displays an au-
dio-guided instruction video of the movement on the large screen. A physician on the other side 
operates the machine with a tablet that in this example has been turned towards the patient for 
demonstration purposes. After showing the instruction video, the patient performs the move-
ment after a beep. This is recorded by the Kinect camera and stored locally on the machine. 
The people seen in this picture are members of the study group that gave their consent.
Eight standardized movements covering trunk, upper and lower extremities, 
which are partly based on the classical neurological examination, and 
movements typical of ADL were chosen. Three movements covering UEF were 
performed: finger-to-nose test (FNT), pronator drift test (PDT), as classical 
neurological tests, and drinking from a cup (CUP), as an ADL movement. For 
CUP, patients had to take a sip from a standardized plastic cup that was 
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at least half-full of water. To assess mobility the following five movements 
were performed: Romberg test (ROM), tight-rope-walking (TRW), as classical 
neurological tests, and sit-to-stand (STS), turning-on-the-spot (TOS) and 
walking a distance of 25-foot (GAT), as ADL movements. For STS, patients 
were instructed to get up from a standardized chair without touching it. 
Schematic representations of the movements can be found in figure 2.
Figure 2, schematic representations of the standardized movements.
All colour videos were rated by two independent neurologists with experience 
in MS. Each patient video was given a score based on a predetermined rating 
scale (see table 1). Some of these scales (FNT, PDT and ROM) were derived from 
the functional system subscores from the Neurostatus-EDSS.(13) For the ADL 
movements a 0 to 4 scale was created, in which 0 is a normal performance, 
1 mildly impaired (minor interference with function), 2 moderately impaired 
(clear interference with function), 3 severely impaired (severe interference 
with function) and 4 is impossible to perform. In addition, the videos were 
also presented as sets which the neurologists ordered from least affected 
to most affected. Using an algorithm similar to the one described by Sarkar 
et al(14) that takes into account individual rater bias, the videos were then 
assigned a consensus score. This consensus score was subsequently used in 
the statistical analysis. Videos of insufficient quality or videos that were not 
performed according to the protocol were excluded from further analysis. In
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Table 1, rating scales of movements.


















Tremor or clumsy movements easily 
seen, minor interference with function
Tremor or clumsy movements interfere 
with function in all spheres
Most functions are very difficult
Drinking 








































Discrete but clearly seen irregularities 
(problems grasping the cup, tremor, 
slow irregular movement, slowing in 
front of mouth, un-physiological posture 
of hand/arm (including holding the cup, 
cup gets impressed)). Minor interference 
with function (most of the movement is 
normal)
Clear irregularities (problems grasp-
ing the cup, tremor, slow irregular 
movement, slowing in front of mouth, 
un-physiological posture of hand/arm 
(including holding the cup, cup gets 
impressed)). Clear interference with 
function (whole movement is affected)
Severe irregularities (problems grasp-
ing the cup, tremor, slow irregular 
movement, slowing in front of mouth, 
un-physiological posture of hand/arm 
(including holding the cup, cup gets 
impressed)). Severe interference with 
function (drinking from cup is very diffi-











Tasks of ADL to assess UEF and mobility
4
89 




























Discrete but clearly seen irregularities. 
Minor interference with function, (most 
of the functions are normal)
Clear irregularities (needs to lean for-
ward, optimize sitting position, pushes 
with hands on thigh, instable). Clear 
interference with function (whole move-
ment is affected) 
Severe irregularities (needs to lean for-
ward, optimize sitting position, pushes 
with hand on thigh, instable, multiple 
tries). Severe interference with function 











Mild instability with eyes closed
Not stable with eyes closed































Discrete but clearly seen irregularities 
(ataxia, spasticity, limping, irregular/
slow movement, widened range). Minor 
interference with function (most of the 
functions are normal)
Clear irregularities (ataxia, spasticity, 
limping, irregular/slow movement, 
widened range). Clear interference with 
function (whole movement is affected)
Severe irregularities (ataxia, spasticity, 
limping, irregular/slow movement, wid-
ened range, tripping). Severe interfer-



































Discrete but clearly seen irregularities 
(ataxia, spasticity, limping, irregular/ 
slow movement, widened range). Minor 
interference with function (most of the 
movement is normal)
Clear irregularities (ataxia, spasticity, 
limping, irregular/ slow movement, 
widened range). Clear interference with 
function (whole movement is affected)
Severe irregularities (ataxia, spasticity, 
limping, irregular/ slow movement, 
widened range, tripping). Severe inter-
































Discrete but clearly seen irregularities 
(ataxia, spasticity, limping, irregular/ 
slow movement, widened range). Minor 
interference with function (most of the 
movement is normal)
Clear irregularities (ataxia, spasticity, 
limping, irregular/ slow movement, 
widened range). Clear interference with 
function (whole movement is affected)
Severe irregularities (ataxia, spasticity, 
limping, irregular/ slow movement, 
widened range, tripping). Severe inter-
ference with function (movement is very 
difficult)
the current study, only the video ratings of movements were analysed. 
The development of MLA is part of another study that is currently being 
performed. 
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All patients received a standardized Neurostatus-EDSS assessment(13) 
on the day of recording, performed by another examiner than the before 
mentioned neurologists that rated the videos. Furthermore, the 9HPT and 
T25WT were administrated, as performance-based measures of UEF and 
mobility. All patients were asked to complete the Arm Function in Multiple 
Sclerosis Questionnaire (AMSQ)(5), as a patient-reported outcome measure 
for UEF.
Data analysis
Statistical analyses were performed in IBM SPSS Statistics for Macintosh, 
Version 24. A p-value of <0.05 was considered statistically significant. The 
normality of each variable was assessed using histograms and normality plots. 
For variables with a normal distribution mean values with standard deviation 
(SD) were calculated, and median values with interquartile ranges (IQR) for 
non-parametric distributions. For the movements that were performed 
multiple consecutive times (FNT three times for both sides, and 9HPT and 
T25WT two times), the best performance was used for statistical analyses. 
Spearman’s rho correlation was used for assessing the relation between the 
9HPT and AMSQ.
After confirming the absence of strong collinearity with partial regression 
(collinearity present if r ≥0.9), combinations of the eight movements were 
used in stepwise multivariate linear regression models to determine how 
much the clinical ratings of the movements contribute to the variance of the 
9HPT and the AMSQ in UEF, and the T25WT for mobility. For UEF, different 
models were used for the left and right side, and for the dominant and non-
dominant hand. The rating scales were categorized into groups (i.e. dummy-
variables were created), because the relation between the outcome variables 
and the rating scales of the movements was not linear.
3 RESULTS
In total 257 patients were included in this study of which 171 (66.5%) were 
women and the mean age was 46.6 years (SD 12.8). The mean disease 
duration was 14.9 years (SD 11.7). Clinical phenotypes were distributed as 
follows: clinically isolated syndrome 11 (4.3%), relapsing-remitting MS 186 
(72.4%), secondary progressive MS 45 (17.5%) and primary progressive MS 
15 (5.8%) patients. Twenty-four (9.3%) patients experienced a relapse within 
three months prior to inclusion. The median EDSS score was 3.0 (IQR 2.0). 
Baseline characteristics and results of the 9HPT, T25WT, and questionnaires 
are shown in table 2.
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Table 2, baseline characteristics. SD = standard deviation; EDSS = Expanded Disability Status 
Scale; 9HPT = Nine-Hole Peg Test; T25WT = Timed 25-foot Walk Test; AMSQ = Arm Function in 
Multiple Sclerosis Questionnaire.
Total number of patients, N 257
Female, N (%) 171 (66.5)
Mean age, years (SD) 46.6 (12.8)
Mean duration, years (SD) 14.9 (11.7)




Relapse past 3 months, n (%) 24 (9.3)
Median EDSS (IQR) 3.0 (2)
Mean 9HPT right side, sec (SD) 24.2 (11.6)
Mean 9HPT left side, sec (SD) 24.8 (11.9)
Mean 9HPT dominant hand, sec (SD) 23.9 (11.0)
Mean 9HPT non-dominant hand, sec (SD) 25.2 (12.5)
Mean T25WT, sec (SD) 6.1 (3.8)
Mean AMSQ, sum (SD) 49 (24)
Correlation coefficients of the AMSQ, and 9HPT were 0.60 for the right side, 
0.46 for the left side, 0.61 for the dominant hand, and 0.44 for the non-
dominant hand. The video ratings of the eight movements are summarized 
in table 3.
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Table 3, assessments of movements. FNT = finger-to-nose test; PDT = pronator drift test; CUP 
= drinking from a cup; ROM = Romberg test; TRW = tight-rope-walking; STS = sit-to-stand; TOS 
= turning-on-the-spot; GAT = walking a distance of 25-foot; n.a. = not applicable; *: two ambi-
dextrous patients were defined as unrateable of which one CUP movements was unrateable.
Video rating score 0 1 2 3 4 Unrateable
Upper extremity function
FNT right side 101 74 51 4 0 27
FNT left side 88 91 48 3 0 27
FNT dominant hand* 99 77 48 2 0 31
FNT non-dominant hand* 90 86 50 5 0 26
PDT 178 51 9 n.a. n.a. 19
CUP right side 120 69 38 2 3 25
CUP left side 125 77 32 2 2 19
CUP dominant hand* 120 70 37 1 3 26
CUP non-dominant hand* 122 76 33 3 2 21
Mobility
ROM 77 92 32 15 n.a. 41
TRW 64 52 37 19 38 47
STS 149 39 27 9 7 26
TOS right 59 57 43 25 5 68
TOS left 64 59 46 25 5 58
GAT 111 49 29 17 21 30
Regression models for upper extremity function and mobility
No co-linearity was found between the video ratings of the movements. 
Results of the regression models are displayed in table 4. CUP, PDT and FNT 
explained 73.2% of the variance of the right sided-9HPT, and 78.2% of the 
left sided-9HPT. CUP, PDT and FNT explained 80.1 and 62.9% of the variance 
in the dominant and non-dominant hand models of 9HPT, respectively. In all 
models CUP contributed most to the variance of the 9HPT, with only a minor 







































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































In the AMSQ model in which CUP and FNT were stratified according to side 
(left and right side), 44.3% of the variance was explained by CUP and FNT of 
the right side. In the other AMSQ model in which CUP and FNT were stratified 
according to dexterity (dominant and non-dominant hand), 43.3% of the 
variance was explained with CUP from the dominant hand, and FNT of the 
non-dominant hand. In these models again, CUP contributed most to the 
variance of the AMSQ, and FNT contributed only to a minor proportion.
The six movements in the model for mobility, explained 70.8% of the variance 
of the T25WT. The STS contributed most to the variance in this model, and 
the other movements to a minor extent.
4 DISCUSSION
Combinations of standardized movements that are used in the Assess MS 
system explained UEF to a large extent as defined by the 9HPT as a measure 
of performance, and to a lesser extent as defined by the AMSQ as a measure 
of patient reported outcome. Mobility, as defined by the performance-based 
T25WT, was also explained to a large extent by a combination of movements. 
The ADL tasks CUP and STS contributed more to the variance of UEF and 
mobility, than classical neurological tests such as FNT and ROM.
The 9HPT was used as measure of UEF since it is the most widely used tool 
to assess UEF in MS studies so far.(15) It has good psychometric properties 
and clinical relevance concerning the ability to perform ADL tasks and quality 
of life.(2) Although the AMSQ has not yet been used as frequently as the 
9HPT, it has good psychometric properties to assess UEF as well,(5, 16) and 
additionally gives insight into the patients’ perspective of UEF. 
A large percentage of the variance of the 9HPT was explained by a 
combination of movements, of which CUP contributed most in all models. 
Various explanations may be given for this. Firstly, CUP is a typical ADL 
movement, and the 9HPT is known to correlate with the ability to perform 
ADL tasks.(2) Secondly, the 9HPT primarily quantifies hand function (i.e. distal 
arm function), which is relevant for the ability to hold a cup and drink from 
it.(2) Lastly, one study found that approximately 53% of the variance of the 
9HPT was explained by muscle strength, tactile sensitivity of the thumb and 
intention tremor,(17) which are all relevant in performing CUP. 
The variance of the AMSQ could only be explained for 43.3 and 44.3%. The 
AMSQ covers a variety of patient-perceived ADL tasks, ranging from gross 
(such as holding a plate) to fine movements (such as using a keyboard), and 
covering both proximal and distal arm function.(5) Therefore, the AMSQ 
score probably represents more than what is covered with CUP, FNT and 
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PDT. The strong contribution of CUP, being a typical ADL movement, in these 
models is in line with the focus of AMSQ on patient-perceived ADL tasks.
Although the FNT and PDT are valuable in the neurological examination for 
localisation purposes, our results indicate that these tests are less sensitive 
to assess UEF, as defined with the 9HPT or AMSQ.
In our study, we found a lower correlation between the 9HPT and AMSQ (r 
= 0.44 to 0.61) than in another study (r = 0.77).(16) This supports the idea 
that different constructs were tested with the 9HPT and AMSQ. This is in 
line with our finding that combinations of movements explained different 
proportions of the variances of the 9HPT and AMSQ. The difference of 
correlation coefficients between left vs. right and non-dominant vs. dominant 
hand may be explained with the AMSQ being a measure of perceived upper 
extremity ADL tasks. Objective impairment of the dominant hand, which is 
most frequently the right hand, probably influences perceived UEF more 
strongly.
With regard to the assessment of mobility, the T25WT was chosen, because 
it has good psychometric properties to assess ambulatory function.(3) It is 
primarily a measure of walking speed, which seems clinically relevant, because 
walking speed relates to the capacity to perform outdoor activities important 
in daily life(18) and employment status.(19) However, since walking speed is 
often preserved in less disabled patients, measures of walking distance or 
endurance can better used for these patients.
The movements used to assess mobility in in Assess MS explained 70.8% of 
the variance of the T25WT. In previous studies, the T25WT correlated with 
the ability to perform ADL tasks(18), which is in line with our finding that 
STS contributed most to the variance. Furthermore, there are similarities 
between STS and the Timed Up & Go test (in which a patient gets up from a 
chair), which correlated strongly with the T25WT.(3)
The GAT also contributed significantly to the variance of the T25WT. 
Although these tests are very similar, GAT is principally a qualitative measure 
of ambulation (i.e. “how well does a patient walk?”) and the T25WT only 
measures walking speed. However, the relation of walking speed with spatial 
and temporal gait parameters has been previously described.(12)
A strong point of our study is the use of a combination of simple movements to 
assess UEF and mobility that can be performed in a short time, that can easily 
be done in clinical setting. Our study has some limitations. Firstly, patients 
included in our cohort were relatively mildly disabled with a median EDSS of 
3.0, and this hampers generalisation to a more disabled population. This is 
also reflected in the distribution of assessments of the movements (table 3). 
Results of our models might have been different if more severely disabled 
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patients were included. This would particularly account for the T25WT, 
because of its limited sensitivity to detect abnormalities in patients with mild 
ambulatory impairment.(19) For these patients, it may be more appropriate 
to assess walking endurance with longer walking distances (e.g. with the 
6-minute walking test).(20) Secondly, our construct of mobility is probably not 
entirely covered with the T25WT. Our construct includes standing up from a 
chair, turning on a spot, walking a straight line and the Romberg test. With 
the T25WT, only the time that a patient walks straight for a distance of 25 foot 
is measured. This explains why TRW and TOS did not contribute significantly 
to the model. Using another measure than only the T25WT as surrogate for 
the construct of mobility, would have likely given different results. Lastly, the 
rating scales of the ADL tasks have not been validated yet. Future research 
should consider the assessment of psychometric properties of these tests, 
such as validity and reliability. Nevertheless, the neurologists who performed 
the video rating, experienced that the ADL scales were much easier to apply 
than the scales derived from the Neurostatus-EDSS.
We conclude that UEF and mobility can be assessed with a combination of 
standardized movements. ADL tasks contributed most to these assessments, 
which indicates that including ADL tasks (such as drinking from a cup and 
standing up from a chair) in daily clinical practice, may be more valuable 
than the classical neurological examination (such as placing a finger on one’s 
nose) to assess UEF and mobility. Also, incorporating ADL tasks in clinical 
trials may be valuable to assess motor functioning. Future research will have 
to determine whether these ADL movements have all the other psychometric 
properties that would make them valuable clinical assessments.




1. van Munster CE, Uitdehaag BM. Outcome Measures in Clinical Trials for Multiple Sclerosis. 
CNS Drugs. 2017;31(3):217-36.
2. Feys P, Lamers I, Francis G, Benedict R, Phillips G, LaRocca N, et al. The Nine-Hole Peg 
Test as a manual dexterity performance measure for multiple sclerosis. Mult Scler. 
2017;23(5):711-20.
3. Motl RW, Cohen JA, Benedict R, Phillips G, LaRocca N, Hudson LD, et al. Validity of the 
timed 25-foot walk as an ambulatory performance outcome measure for multiple 
sclerosis. Mult Scler. 2017;23(5):704-10.
4. Ontaneda D, LaRocca N, Coetzee T, Rudick R, Force NMT. Revisiting the multiple sclerosis 
functional composite: proceedings from the National Multiple Sclerosis Society (NMSS) 
Task Force on Clinical Disability Measures. Mult Scler. 2012;18(8):1074-80.
5. Mokkink LB, Knol DL, van der Linden FH, Sonder JM, D’Hooghe M, Uitdehaag BM. The Arm 
Function in Multiple Sclerosis Questionnaire (AMSQ): development and validation of a new 
tool using IRT methods. Disabil Rehabil. 2015:1-7.
6. Morrison C, D’Souza M, Huckvale K, Dorn JF, Burggraaff J, Kamm CP, et al. Usability and 
Acceptability of ASSESS MS: Assessment of Motor Dysfunction in Multiple Sclerosis Using 
Depth-Sensing Computer Vision. JMIR Hum Factors. 2015;2(1):e11.
7. Holper L, Coenen M, Weise A, Stucki G, Cieza A, Kesselring J. Characterization of 
functioning in multiple sclerosis using the ICF. J Neurol. 2010;257(1):103-13.
8. Johansson S, Ytterberg C, Claesson IM, Lindberg J, Hillert J, Andersson M, et al. High 
concurrent presence of disability in multiple sclerosis. Associations with perceived health. 
J Neurol. 2007;254(6):767-73.
9. Mansson E, Lexell J. Performance of activities of daily living in multiple sclerosis. Disabil 
Rehabil. 2004;26(10):576-85.
10. Yozbatiran N, Baskurt F, Baskurt Z, Ozakbas S, Idiman E. Motor assessment of upper 
extremity function and its relation with fatigue, cognitive function and quality of life in 
multiple sclerosis patients. J Neurol Sci. 2006;246(1-2):117-22.
11. Larocca NG. Impact of walking impairment in multiple sclerosis: perspectives of patients 
and care partners. Patient. 2011;4(3):189-201.
12. Motl RW. Ambulation and multiple sclerosis. Phys Med Rehabil Clin N Am. 2013;24(2):325-
36.
13. Kappos L, D’Souza M, Lechner-Scott J, Lienert C. On the origin of Neurostatus. Mult Scler 
Relat Disord. 2015;4(3):182-5.
14. Advait Sarkar CM, Jonas F. Dorn, Rishi Bedi, Saskia Steinheimer, Jacques Boisvert, Jessica 
Burggraaff, Marcus D’Souza, Peter Kontschieder, Samuel Rota Bulo, Lorcan Walsh, 
Christian P. Kamm, Yordan Zaykov, Abigail Sellen, Sian Lindley. Setwise Comparison: 
Consistent, Scalable, Continuum Labels for Computer Vision. Proceedings of the 2016 CHI 
Conference on Human Factors in Computing Systems Pages. 2016:261-71.
15. Lamers I, Kelchtermans S, Baert I, Feys P. Upper limb assessment in multiple sclerosis: a 




16. van Leeuwen LM, Mokkink LB, Kamm CP, de Groot V, van den Berg P, Ostelo R, et al. 
Measurement properties of the Arm Function in Multiple Sclerosis Questionnaire (AMSQ): 
a study based on Classical Test Theory. Disabil Rehabil. 2017;39(20):2097-104.
17. Lamers I, Cattaneo D, Chen CC, Bertoni R, Van Wijmeersch B, Feys P. Associations of 
upper limb disability measures on different levels of the International Classification 
of Functioning, Disability and Health in people with multiple sclerosis. Phys Ther. 
2015;95(1):65-75.
18. Kempen JC, de Groot V, Knol DL, Polman CH, Lankhorst GJ, Beckerman H. Community 
walking can be assessed using a 10-metre timed walk test. Mult Scler. 2011;17(8):980-90.
19. Goldman MD, Motl RW, Scagnelli J, Pula JH, Sosnoff JJ, Cadavid D. Clinically meaningful 
performance benchmarks in MS: timed 25-foot walk and the real world. Neurology. 
2013;81(21):1856-63.
20. Goldman MD, Marrie RA, Cohen JA. Evaluation of the six-minute walk in multiple sclerosis 
subjects and healthy controls. Mult Scler. 2008;14(3):383-90.





Minimal clinically important 
difference of improvement on 
the arm function in multiple 
sclerosis questionnaire (AMSQ)
Caspar E.P. van Munster, Levent Kaya, 
Morgan Obura, Nynke F. Kalkers, Bernard M.J Uitdehaag. 





The Arm function in Multiple Sclerosis Questionnaire (AMSQ) has been 
developed to assess upper extremity function of patients with multiple 
sclerosis (MS). A minimal clinically important difference (MCID) value has not 
been determined yet.
Objective  
To determine an MCID for AMSQ.
Methods  
We used the sensitivity- and specificity-based approach with dichotomized 
global perceived effect as an anchor.
Results  
The receiver operating characteristic curve yielded an optimal threshold 
value of 14.5 (sensitivity 0.68 and specificity 0.79). The area under the ROC 
curve value was 0.77. 
Conclusion  
We identified an MCID of 15 points for the AMSQ (range 31 – 186).




Traditionally, the focus of clinical assessment in multiple sclerosis (MS) has 
been on ambulation. However, other domains are being increasingly assessed 
in conjunction with ambulation. This includes the assessment of upper 
extremity function (UEF). Various measures are available of which the 9-hole 
peg test (9HPT) is considered as the gold standard for manual dexterity.(1) 
Nevertheless, a performance-based measure such as the 9HPT, does not 
provide any insight into the patient perspective of UEF. For this purpose, 
patient reported outcome measures (PROM) are valuable tools. To date, 
only one PROM is available that has been specifically developed to assess 
UEF in MS patients: the Arm function in Multiple Sclerosis Questionnaire 
(AMSQ).(2) The AMSQ is an unidimensional 31-item questionnaire with good 
psychometric properties.(3)
However, a minimal clinically important difference (MCID) has not been 
reported yet. An MCID defines the smallest amount of change on a scale that 
is important or meaningful to a patient.(4) Determining an MCID of a PROM is 
important, because a given change on the score generally does not have an 
obvious clinical importance to the clinician. The objective of this study is to 
determine an MCID of improvement on the AMSQ.
2 METHODS
Data were derived from patients that have been treated with fampridine. 
Fampridine increases axonal conduction velocity by selectively blocking 
potassium channels, which may lead to improvement of various motor 
functions, including UEF.(5) Effects generally occur within two weeks of 
treatment. Therefore, patients treated with fampridine are good subjects to 
assess change in AMSQ, and determine an MCID.
Patients
Patients were recruited in the VU Medical Centre in Amsterdam from an 
outpatient clinic that was specifically organised to assess eligibility for and 
efficacy of treatment with fampridine. All patients provided written informed 
consent prior to inclusion, and the study was approved by the local ethics 
committee. Patients were considered eligible if they complied to the official 
treatment label of fampridine.(6) Demographical data and MS characteristics, 




Arm function in Multiple Sclerosis Questionnaire (AMSQ)
Patients were asked to complete the AMSQ before treatment and during a 
follow up visit after a minimum of two weeks of treatment. The AMSQ consists 
of 31 items concerning activity limitations due to hand and arm functioning. 
A patient assigns a number to each item on a six-point Likert-scale ranging 
from “not at all” to “no longer able to”. The sum score ranges from 31 to 
186, with a higher score indicating more impairment. Change in the sum 
score was calculated by subtracting the AMSQ score of the follow up visit 
from the baseline value. Consequently, a positive change score indicates an 
improvement of UEF, and conversely a negative change score worsening of 
UEF. Questionnaires with more than two missing items were excluded from 
analysis. If one or two items were missing, the average of the other items was 
calculated and used as substitutes.
Determining the MCID
We used the sensitivity- and specificity anchor-based method to determine 
an MCID. In short, with an anchor-based approach the change in PROM score 
is being compared with change of another measure that is understandable 
and is considered as an anchor or external criterion.(7) As anchor, we used a 
global perceived effect (GPE) score that specifically addressed change in UEF 
and consisted of a five-point Likert-scale, including “much deteriorated” (1), 
“deteriorated” (2), “unchanged” (3), “improved” (4) and ‘‘much improved” (5). The 
GPE was determined by the treating physician on the follow-up visit by asking 
the patient how much the UEF was changed since the baseline visit. Because 
we used the sensitivity- and specificity approach, the GPE scores were 
dichotomized into “improved” or “unchanged”. Since we wanted to address 
improvement of UEF, we excluded scores 1, 2 and 5 to minimize the impact 
of these scores on the MCID value.(8) With this method the GPE is considered 
the gold standard, and the AMSQ as a diagnostic test for which the sensitivity 
and specificity to discriminate between “improved” and “unchanged”.(9) A 
receiver operating characteristics (ROC) curve was used to determine the 
MCID i.e. the AMSQ score that produces the greatest combined sensitivity 
and specificity (determined with the highest Youden’s index) . Additionally, 
the area under the ROC (AUROC) was determined. This value represents the 
probability that scores will correctly discriminate between “improved” and 
“unchanged” UEF.(7) A value of 0.7 to 0.8 was considered acceptable and 0.8 
to 0.9 excellent.(10) The correlation between AMSQ change and GPE was 
determined using Spearman’s rank-order correlation statistics. 
To investigate the statistical properties of the underlying distribution of 
change scores of the AMSQ, we calculated the Standard Error of Measurement 
(SEM).The SEM was calculated by multiplying the baseline standard deviation 
by the square root of one minus its reliability coefficient (i.e. the intraclass 
correlation coefficient).
MCID of improvement on the AMSQ
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Statistical analyses were performed in IBM SPSS Statistics for Macintosh, 
Version 24.
3 RESULTS
Data from 223 patients were analysed. The mean age was 51.3 years (standard 
deviation 10.5), with 57.4% females. Most patients had a progressive disease 
type (56.5%). The median (interquartile range) for disease duration was 11.4 
years (4.4 – 16.6), and for EDSS was 6.0 (4.0 - 6.5). The correlation coefficient 
between AMQ and GPE was 0.37 (p < 0.001). The AMSQ thresholds from 
the ROC curve with corresponding sensitivity and specificity are displayed in 
table 1. 
Table 1, threshold values from receiver operating characteristic curve with corresponding sen-
sitivity, specificity and Youden’s index. 
Threshold value Sensitivity 1 - Specificity Youden’s index
0.5 0.868 0.581 0.287
1.5 0.868 0.531 0.337
2.5 0.842 0.494 0.348
3.5 0.789 0.444 0.346
4.5 0.789 0.419 0.371
5.5 0.763 0.388 0.376
6.5 0.763 0.356 0.407
7.5 0.737 0.325 0.412
8.5 0.737 0.300 0.437
9.5 0.737 0.281 0.456
10.5 0.711 0.281 0.429
11.5 0.711 0.263 0.448
12.5 0.711 0.250 0.461
13.5 0.684 0.225 0.459
14.5 0.684 0.213 0.472
15.5 0.632 0.206 0.425
16.5 0.579 0.206 0.373
17.5 0.579 0.188 0.391
18.5 0.579 0.175 0.404
19.5 0.553 0.156 0.396
20.5 0.553 0.144 0.409
21.5 0.474 0.144 0.330
22.5 0.447 0.144 0.304
23.5 0.447 0.138 0.310
24.5 0.421 0.131 0.290
25.5 0.342 0.119 0.223
26.5 0.342 0.106 0.236
27.5 0.342 0.094 0.248
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Threshold value Sensitivity 1 - Specificity Youden’s index
29.5 0.316 0.081 0.235
32.0 0.289 0.081 0.208
34.0 0.289 0.075 0.214
35.5 0.289 0.069 0.221
37.0 0.289 0.063 0.227
38.5 0.289 0.056 0.233
39.5 0.289 0.050 0.239
40.5 0.263 0.050 0.213
43.0 0.237 0.044 0.193
48.0 0.211 0.044 0.167
51.5 0.211 0.038 0.173
54.5 0.184 0.031 0.153
60.0 0.158 0.031 0.127
63.5 0.158 0.025 0.133
66.0 0.132 0.025 0.107
69.0 0.132 0.019 0.113
71.5 0.105 0.019 0.087
75.0 0.053 0.019 0.034
79.5 0.053 0.013 0.040
82.5 0.026 0.013 0.014
84.5 0.026 0.006 0.020
A threshold value of 14.5 yielded the highest sensitivity (0.68) and specificity 
(0.79). The ROC curve is shown in figure 1. The AUROC value was 0.77. The 
SEM was 13.0.
Figure 1, receiver operating characteristics (ROC) curve.




We found an MCID value of 14.5 with a sensitivity of 0.68,a specificity of 
0.79, and an acceptable AUROC value. Since the AMSQ has no decimals, we 
rounded the threshold to 15 points. 
There is no consensus about the preferred threshold value that determines 
sensitivity and specificity. Mostly, the threshold is chosen that jointly maximizes 
sensitivity and specificity in order to have the lowest overall misclassification.
(11) We used this rational to determine the threshold.
There is a certain degree of uncertainty in our findings. This is reflected in a 
weak, albeit sufficient, (8) correlation between AMSQ and GPE, a moderate 
sensitivity and specificity and rather similar threshold values around the MCID 
value. Therefore, our findings will have to be confirmed in future studies.
This is the first study to determine an MCID value for the AMSQ. The strength 
of our study lies in the large sample size and the normal distribution of AMSQ 
results. However, our study also has some limitations. Firstly, we used only 
one method to determine an MCID while there are others available.(4, 7) 
Secondly, we used a subjective anchor that is prone to recall bias in which case 
a patient may have recalled answers given at baseline that have subsequently 
influenced completion of the questionnaire at follow-up. Therefore, an MCID 
should also be assessed with an objective anchor for UEF, such as the 9HPT. 
Lastly, a placebo effect might have influenced our findings. This accounts 
particularly for the GPE, since a patient may have experienced improvement 
of UEF, while no improvement has been noticed on the ability to perform a 
task of UEF (as assessed with AMSQ). Inclusion of other measures that assess 
capacity of UEF objectively, such as the 9HPT, allows more certainty and 
magnitude of true improvement of UEF. Furthermore, additional objective 
measures contribute to a more detailed description of UEF of a group of 
patients.
In conclusion, our MCID estimate for AMSQ is 15 points based on a sensitivity- 
and specificity anchor-based method. Future studies should investigate 
reproducibility of this finding with similar and other methods, in a cohort 
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Fampridine is an effective treatment to improve ambulation for some multiple 
sclerosis (MS) patients. Remarkable discrepancies exist between responder 
rates in clinical trials and the proportion of patients continuing treatment in 
clinical practice. This may be related to clinical phenotypes of MS patients, 
and the influence of patient reported outcome (PRO) on treatment decision 
making.
Objective  
To analyse responder rates to fampridine on ambulation and upper extremity 
function (UEF) and the influence on treatment decision making in different 
clinical subgroups in a real-world setting.
Methods  
MS patients with ambulatory impairment treated with fampridine were 
included. Patients were subdivided based on disease duration, clinical 
phenotype, Expanded Disability Status Scale (EDSS), baseline walking speed, 
and presence of UEF impairment. Ambulatory response was assessed with 
the Timed 25-Foot Walk (T25FW, responder defined as ≥20% improvement) 
and with the MS Walking Scale (MSWS, responder defined as ≥8 points 
improvement) as a PRO. For patients also reporting impaired UEF, the 
Arm Function in MS Questionnaire (AMSQ, responder defined as ≥15 
improvement) was the PRO of choice. Decision on treatment continuation 
was based on improvement of T25FW, MSWS and the clinicians’ overall 
impression for improvement.
Results  
In total 344 patients were included of which 75.3% continued treatment. 
More patients with a relapsing clinical phenotype continued treatment versus 
patients with a progressive phenotype (83.6 versus 68.6%, p <0.01). A positive 
linear trend was found between severity of walking disability, as determined 
by baseline walking speed, and T25FW response (p <0.01), while there was an 
inverse linear association between walking disability and MSWS response (p 
= 0.03). However, the proportion of patients continuing treatment was similar 
between subgroups of baseline walking speed. Impaired UEF was reported 
by 183 (66.5%) patients, of which 64 (39.3%) were AMSQ responders. 
Patients responding on AMSQ compared to non-responders, were also more 
frequently MSWS responders (82.8 vs 65.3%, p = 0.02), while response on 
T25FW was similar, and continued treatment more often (85.9 vs 70.7%, p = 
0.04). This suggests an influence of PRO on treatment decision making.




Responder rates and treatment continuation of fampridine differed between 
clinical subgroups of MS. PROs influenced treatment decision making of 
fampridine in clinical practice, particularly in patients with mild ambulatory 
impairment or those reporting UEF impairment. To some extent, these findings 
explain discrepancies found between clinical trials and clinical practice, and 
support the importance of subgroup analyses and incorporation of PROs in 
clinical trials. For clinical practice, using PROs to assess patients experience in 
conjunction with performance measures helps in treatment decision making.
1 INTRODUCTION
Many patients with multiple sclerosis (MS) experience some level of 
ambulatory impairment during the course of the disease, and this can 
already be a prominent factor leading to early disability. With progression 
of ambulatory impairment, preservation of upper extremity function (UEF) 
becomes more important to maintain mobility and the ability to perform 
activities of daily living (ADL). Also, UEF correlates with quality of life,(1, 2) and 
employment status.(3) Therefore, preservation of UEF is a clinically relevant 
treatment goal during all disease stages.
Fampridine improves motor functioning in MS by selectively blocking 
potassium channels which increases axonal conduction velocity.(4) In a pooled 
analysis of two phase 3 trials of fampridine, walking speed, as assessed with 
the Timed 25-Foot Walk test (T25FW), improved ≥20% in 37.6% of patients.
(5) Also, ambulation improved as reported by patients (assessed with the 
Multiple Sclerosis Walking Scale (MSWS)) compared with placebo. Treatment 
responses on UEF were less consistent, which may be due to heterogeneous 
study cohorts.(6-12)
Despite the approval by the European Medicines Agency (EMA) for treatment 
of ambulatory impairment in MS patients, in various European countries 
fampridine is not being reimbursed because the average group effects have 
been considered insufficient when balanced with the costs. In clinical practice 
however, patients may also report improvement in motor functions other 
than ambulation, such as UEF. In this way, clinicians are confronted with 
patients that benefit exceptionally, in which cases treatment might indeed 
be cost-effective.
Analyses of subgroups may facilitate identification of patients that benefit 
most from this treatment. In a pooled analysis of the phase 3 trials no 
differences were found in the proportion of responders (defined as an 
improvement of ≥20% on the T25FW) between subgroups of MS phenotype, 
Expanded Disability Status Scale (EDSS), disease duration, and baseline 
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T25FW performance.(5) However, patients treated in a real-world setting are 
always more heterogeneous than in trials with strict in- and exclusion criteria, 
which limits the external validity of these findings.(13)
We identified four studies with data of fampridine treatment from a real-
world setting.(12, 14-16) Findings in these studies generally suggested 
that fampridine response should be assessed with multiple measures for 
ambulation. The physician’s overall judgement of improvement was much 
larger (i.e. >70%) than was captured with a single ambulation test.(12, 14) 
Patient reported improvement was greater than improvement measured 
objectively, although we hypothesize this is partly related to a placebo-effect. 
Also, other MS-related symptoms improved, including UEF and fatigue. Only 
one of these studies stratified patients according to baseline walking speed 
(cut-off value T25FW of 8 seconds), and found better response on T25FW in 
the lower baseline walking speed.(12)
Although findings from these studies are valuable, the results offer insufficient 
insight into clinically relevant responses in subgroups of patients. A 
statistically significant difference does not necessarily mean that it is clinically 
relevant for a patient. For this, clinically relevant benchmarks and minimal 
clinically important differences have been determined.(17-21) These can be 
used as cut-off values to differentiate responders from non-responders to 
fampridine, and can subsequently be used to compare between subgroups. 
Furthermore, there is no data available of patient reported outcome (PRO) 
on UEF.
Therefore, in this study of patients from a real-world setting, we analysed 
fampridine response on ambulation according to clinically relevant responder 
definitions in various subgroups of MS patients, and PRO on UEF in patients 
also reporting problems in UEF. Furthermore, we aim to give insight into 
treatment decision making in clinical practice.
2 METHODS
Patients
Patients initiating fampridine treatment at VU University Medical Centre 
in Amsterdam were recruited. The study protocol was approved by the 
local ethics committee. All patients provided written informed consent 
prior to inclusion. Patients were enrolled between April 2016 and May 
2017. As standard practice in the Netherlands, patients were assessed for 
eligibility and efficacy for treatment with fampridine according to the EMA 
recommendations,(22) which is adopted in the official treatment label of 
fampridine. Inclusion criteria were consistent with the therapeutic indication 
Subgroup responder rates and PROM in fampridine treatment
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as stated in the label: diagnosis of MS, minimum age of 18 years, and 
ambulatory impairment defined as an EDSS score between 4.0 and 7.0. 
Contraindications were handled as exclusion criteria.(22) As is recommended 
by the EMA, patients were assessed during a baseline and follow-up visit, 
planned after a minimum of two weeks of treatment. Demographical and 
disease characteristics were recorded, including an estimated EDSS by the 
clinician at baseline. Treatment (dis)continuation was recorded, which was 
based on T25FW performance, MSWS score and clinicians’ best judgement 
of overall improvement of ambulation, as was instructed to the physician 
beforehand. Treatment was discontinued if benefit was not reported by 
patients. Of note, the EMA only recommends using the T25FW or MSWS to 
assess ambulation.
Assessment of ambulation
Ambulation was assessed at each visit with the T25FW and the MSWS. The 
T25FW was performed twice on both visits, as implemented in the Multiple 
Sclerosis Functional Composite (MSFC).(23) The shortest time to complete 
a trial was used in the analyses. The MSWS is a 12-item questionnaire with 
a five-point Likert-scale ranging from “not at all” to “extremely”. It assesses 
the perceived impact of MS-related walking impairment across a range of 
functional activities.(24) A total score ranging from 12 to 60 was calculated 
and transformed to a 0 to 100 scale, in which a higher score indicates worse 
perceived ambulatory function. In cases with one or two items missing, 
the mean of all other items was used as substitute score. Cases with more 
missing items were excluded from analysis. Patients were dichotomized into 
ambulatory responders and non-responders to fampridine based on T25FW 
and MSWS. A T25FW responder was defined as an improvement of ≥20% at 
follow-up visit.(17) A MSWS responder was defined as an improvement of ≥8 
points on the transformed scale at follow-up.(20)
Assessment of patients’ perspective on UEF
UEF was assessed on each visit with the Arm Function in Multiple Sclerosis 
Questionnaire (AMSQ). The AMSQ is a PRO that has been designed specifically 
for MS patients for assessment of activity limitations due to impaired UEF.
(25) The AMSQ consists of 31 items with a six-point Likert-scale ranging from 
“not at all” to “no longer able to.” The sum score ranges from 31 to 186, 
with a higher score indicating more impairment. In cases with one or two 
items missing, the mean of all other items was used as substitute score. If 
more than two items were missing, the questionnaire was excluded from 
further analysis. The responder criterion for the AMSQ was defined as an 




The proportion of responders on ambulation measures were compared 
between various subgroups. Clinical phenotype was dichotomized into 
relapsing-remitting and progressive types of MS. Disease duration was 
stratified into the following three subgroups: short (0 – 10 years), intermediate 
(10 – 20 years) and long (≥20 years). Disability severity was categorised into 
two subgroups according to EDSS score, as was defined as mild disability 
(EDSS 4.0 - 5.5) and severe disability (EDSS 6.0 - 7.0). Furthermore, the 
baseline T25FW performance in seconds was stratified into three clinically 
different ambulation subgroups: fully ambulatory (< 6 seconds), mild walking 
disability (6 – 8 seconds) and severe walking disability (≥ 8 seconds). The cut-
off values represents clinically meaningful performance benchmarks: a T25FW 
performance of 6 to 8 seconds was associated with a change in occupation 
due to MS, occupational disability, walking with a cane, and needing “some 
help” with instrumental ADL; while a T25FW of ≥8 seconds was associated 
with collecting Supplemental Security Income and government health care, 
walking with a walker, and inability to do instrumental ADL.(27) The effect on 
patients perspective on UEF was assessed in a subset of patients reporting 
impaired UEF at baseline visit, which was determined by the physician by 
asking the patient if they experienced any impairment of UEF (answers “yes” 
or “no”). Subgroup analyses in this subset of patients were performed for 
clinical phenotype, disease duration and EDSS.
Data analysis
All statistical data analyses were performed using the Statistical Package for 
Social Science (SPSS) version 22 (SPSS, Chicago, IL). All p-values were 2-tailed 
and statistical significance was assumed for p < 0.05 in all tests. Histograms 
and q-q plots were used to assess normality of distribution. Normally 
distributed data were analysed with the paired t-tests and were reported 
with mean values and standard deviation (SD). Non-normally distributed 
data were analysed using the Wilcoxon rank test for matched pairs and were 
reported with median values and the interquartile range (IQR). Subgroup 
analyses were performed and checked for statistical significance with chi-
square  tests. For disease duration and T25FW performance on baseline 
subgroups, a chi-square (Cochran-Armitage) test for trend was used.
3 RESULTS
In total 344 patients were assessed for eligibility. Sixty-nine patients were 
excluded from analyses because of various reasons as summarized in figure 
1. In total 275 patients were included for analyses.
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Figure 1, patient selection and schematic display of proportions of responders and continua-
tion of treatment in patients with ambulatory impairment and patients reporting upper extrem-
ity impairment. Abbreviations: EDSS = Expanded Disability Status Scale; T25FW= timed 25-foot 
walk; MSWS = multiple sclerosis walking scale; Arm Function in MS Questionnaire (AMSQ); NS: 
not statistically significantly different; T25FW responder defined as an improvement of ≥20% 
at follow-up; MSWS responder defined as an improvement of ≥8 points at follow-up; AMSQ re-
sponder defined as an improvement of ≥15 points at follow-up; *: p = 0.02; **: p = 0.04; ameas-
urements of 20 patients were missing; bmeasurement of 1 patient was missing; cmeasurements 
of 3 patients was missing; dmeasurement of 1 patient was missing.
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Total cohort of patients with ambulatory impairment
Demographic and MS characteristics of the total cohort are presented in 
table 1. The median follow-up was 21 days (IQR 17 – 25). The mean age was 
50.8 years (SD 10.6). The majority of patients were female (58.9%) and had 
a progressive MS phenotype (55.6%). The median disease duration was 
10.3 years (IQR 5.0 – 16.6). The median EDSS was 6.0 (IQR 4.5 - 6.5). Both 
ambulation measures showed statistically significant improvement at follow-
up (p <0.01). The proportion of responders was higher when defined by the 
MSWS (69.1%) than by the T25FW (44.2%). In total 207 (75.3%) of patients 
continued treatment (figure 1).
Table 1, baseline characteristics and ambulation measures at baseline and follow-up (n = 275). 
Demographic data & MS characteristics
Age (in years)a 50.8 (10.6)
Gender (female/ male) 162 / 113
Disease  phenotype (relapsing/ 
progressive)
122 / 153
Disease duration (in years)b 10.3 (5.0 – 16.6)
EDSSb 6.0 (4.5 – 6.5)
Ambulation measures
Baseline Follow-up P-value Responders, n 
(%)c
T25FW (in seconds)b 7.6 (5.9 – 10.6) 6.2 (5.2 – 8.1) <0.01 115 (44.2)d
MSWSb 81 (69 – 90) 56 (42 – 75) <0.01 181 (69.1)e
Abbreviations: Relapsing = relapsing-remitting multiple sclerosis; Progressive = secondary and 
primary progressive multiple sclerosis; EDSS = Expanded Disability Status Scale; T25FW= timed 
25-foot walk; MSWS = multiple sclerosis walking scale; aData are mean with standard deviation 
for normally distributed variables; bBecause of non-normal distribution, median and interquar-
tile range are provided; cT25FW responder defined as an improvement of ≥20% at follow-up, 
MSWS responder defined as an improvement of ≥8 points at follow-up; dmeasurements of 15 
patients were missing; emeasurements of 13 patients were missing; P-values in bold represent 
significant values.
The proportions of responders on the ambulation measures in subgroups 
are displayed in table 2. Only stratification by clinical phenotypes showed 
a significant difference between the proportion of patients continuing 
treatment: 83.6% of relapsing vs 68.6% of progressive patients. Stratification 
by disease duration or clinical phenotype did not show any statistically 
significant difference in proportion of responders. When stratified by EDSS 
subgroups, a higher proportion of T25FW responders was found in the 
subgroup with severe (EDSS 6.0 – 7.0) than mild (EDSS 4.0 – 5.5) disability 
(51.4 vs 36.4%, p = 0.02). Comparison of subgroups stratified by baseline 
T25FW performance revealed a positive linear trend (p <0.01) between 
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walking disability severity and T25FW response: there were 18.3, 42.7, and 
61.4% responders in the fully ambulatory, mild walking disability, and severe 
walking disability groups, respectively.  However, an inverse trend however, 
was found for proportion of MSWS responders (p = 0.03): 81.2%, 69.0%, and 
65.8% in the fully ambulatory, mild walking disability, and severe walking 
disability groups, respectively.
Table 2. proportion of responders on ambulation measures in subgroups (n = 275)a.
Disease duration
0 – 10 yrs. 
 (n = 137)
11 – 20 yrs.  
(n = 85 / 87)a
≥21 yrs.  
(n = 38)
P-value
T25FW responders, n (%)b 56 (40.9) 42 (49.4) 17 (44.7) 0.41
MSWS responders, n (%)c 99 (72.3) 52 (59.8) 30 (78.9) 0.91





(n = 144 / 146)a
P-value
T25FW responders, n (%)b 51 (44.0) 64 (44.4) 1.00
MSWS responders, n (%)c 82 (70.7) 99 (67.8) 0.71
Continued treatment, n (%) 102 (83.6) 105 (68.6) <0.01
Expanded Disability Status Scale
EDSS 4.0 – 5.5  
(n = 121 / 117)a
EDSS 6.0 – 7.0  
(n = 138 / 144)a
P-value
T25FW responders, n (%)b 44 (36.4) 71 (51.4) 0.02
MSWS responders, n (%)c 87 (74.4) 93 (64.6) 0.12
Continued treatment, n (%) 97 (80.2) 110 (71.9) 0.15
T25FW at baseline
<6 sec.  
(n = 71 / 69)a
6 – 7.99 sec.  
(n = 75 / 71)a
≥8 sec.  
(n = 114/ 111)a
P-value
T25FW responders, n (%)b 13 (18.3) 32 (42.7) 70 (61.4) <0.01
MSWS responders, n (%)c 56 (81.2) 49 (69.0) 73 (65.8) 0.03
Continued treatment, n (%) 56 (78.9) 56 (73.7) 88 (75.9) 0.70
Abbreviations: Relapsing = relapsing-remitting multiple sclerosis; Progressive = secondary and 
primary progressive multiple sclerosis; T25FW= timed 25-foot walk; MSWS = multiple sclerosis 
walking scale; EDSS = Expanded Disability Status Scale; a 15 T25FW and 13 MSWS measurements 
were missing; b T25FW responder defined as an improvement of ≥20% at follow-up; c MSWS 




Selection of patients reporting impairment of UEF
In total 183 (66.5%) patients reported impaired UEF at baseline visit (figure 
1). Demographic and MS characteristics of this subgroup are summarized in 
table 3.
Table 3, baseline characteristics and upper extremity function measures at baseline and fol-
low-up of patients reporting impairment of upper extremity function (n = 183). 
Demographic data & MS characteristics
Age (in years)a 50.1 (10.1)
Gender (female/ male) 107 / 76
Disease  phenotype (relapsing/ 
progressive)
79 / 104
Disease duration (in years)b 10.0 (5.2 – 15.9)
EDSSb 6.0 (4.5 – 6.5)
Upper extremity function measures
Baseline Follow-up P-value Responders,  
n (%)c
AMSQb 74 (49 – 99) 53 (39 – 81) <0.01 64 (39.3)d
Abbreviations: Relapsing = relapsing-remitting multiple sclerosis; Progressive = secondary and 
primary progressive multiple sclerosis; EDSS = Expanded Disability Status Scale; Arm Function 
in MS Questionnaire (AMSQ); aData are mean with standard deviation for normally distributed 
variables; bBecause of non-normal distribution, median and interquartile range are provided; c 
AMSQ responder defined as an improvement of ≥15 points at follow-up; dmeasurements of 20 
patients were missing; P-value in bold represent a significant value.
The median AMSQ improved significantly at follow up (p <0.01), and 64 
(39.3%) patients were classified as AMSQ responder. Stratification by disease 
duration, clinical phenotype or EDSS did not reveal any differences in 
proportion of AMSQ responders (table 4). However, similarly as in the total 
cohort, relatively more patients continued treatment with a relapsing than 
a progressive clinical phenotype (84.8 vs 68.3% of patients). More MSWS 
responders were found in the AMSQ responder group compared with the 
AMSQ non-responder group (82.8 vs 65.3%, p <0.02; figure 1), while the 
proportion of T25FW responders was similar. Furthermore, more AMSQ 
responders continued treatment than non-responders (85.9 vs 70.7%, p 
<0.04).
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Table 4, proportion of responders on AMSQ in subgroups of patients reporting impairment of 
upper extremity function (n = 183)a. 
Disease duration
0 – 10 yrs. 
(n = 86)
11 – 20 yrs.  
(n = 55)
≥21 yrs.  
(n = 22)
P-value
AMSQ responders, n (%)b 31 (36.0) 26 (47.3) 7 (31.8) 0.31
Continued treatment, n (%) 72 (75.8) 49 (77.8) 17 (68.0) 0.63
Clinical phenotype
Relapsing 




AMSQ responders, n (%)b 29 (43.3) 35 (36.5) 0.48
Continued treatment, n (%) 67 (84.8) 71 (68.3) 0.02
Expanded Disability Status Scale
EDSS 4.0 – 5.5  
(n = 76)
EDSS 6.0 – 7.0  
(n = 87)
P-value
AMSQ responders, n (%)b 31 (40.8) 33 (37.9) 0.83
Continued treatment, n (%) 66 (80.5) 72 (71.3) 0.21
Abbreviations: AMSQ = Arm function in Multiple Sclerosis Questionnaire, responder defined as 
an improvement of  ≥10 points at follow-up; UEF = upper extremity function; Relapsing = re-
lapsing-remitting multiple sclerosis; Progressive = secondary and primary progressive multiple 
sclerosis; EDSS = Expanded Disability Status Scale; Arm Function in MS Questionnaire (AMSQ); 
a AMSQ measurements of 20 patients were missing; b AMSQ responder defined as an improve-
ment of ≥15 points at follow-up.
4 DISCUSSION
In our cohort that was derived from a real-world setting, treatment with 
fampridine resulted in a statistically significant improvement of all measures 
of ambulation and UEF which led to continuation of treatment in the vast 
majority of patients, in a greater proportion of patients with a relapsing 
than progressive disease course. In patients with more severely impaired 
ambulation, a greater proportion showed improvement on walking speed 
than in patients with mild impairment. Conversely, the proportion of 
patients with MSWS improvement was larger in patients with less impaired 
ambulation. Furthermore, in the subset of patients with UEF impairment, 
the proportion of patients with improvement of AMSQ were more likely to 
show improvement on MSWS and continue treatment, than patients without 
improvement of AMSQ.
Responder rates and clinical subgroups
The proportion of T25FW responders in our study (defined as a ≥20% 
improvement) is in line with findings from a pooled data analyses of the 
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phase 3 trials of fampridine,(5) and two real-world studies.(12, 15) Another 
real-world study reported only 11% of patients improving ≥20% on T25FW. 
Since only 39 of 221 records were selected for inclusion in that study, there 
is a high chance of selection bias.(16) Considering response on MSWS, these 
studies all reported improvement on fampridine.(5, 12, 14-16) However, none 
used responder criteria as we used in our study which hampers comparison.
Our findings suggest that the T25FW might be a more appropriate measure 
for assessing response to fampridine in patients with worse ambulatory 
impairment, and, conversely, the MSWS for patients with less impaired 
ambulation. This may be explained by measurement properties of T25FW, 
since it is not sensitive enough to detect abnormalities in patients with mild 
ambulation impairment, i.e. a ceiling effect.(19) In these patients PROs, 
such as the MSWS, are more suitable to assess change of ambulation as is 
experienced in daily life. Alternatively, fampridine may just be not effective 
to improve walking speed in patients with relatively preserved ambulation. A 
similar finding concerning T25FW improvement was presented in a real-world 
study.(12) However, no difference of MSWS was found between subgroups 
of T25FW, which may be a result of  using a single cut-off value for baseline 
T25FW performance (i.e. 8 seconds), or a more stringent definition of MSWS 
improvement (i.e. ≥15%).
Comparison of the subgroups of disease duration and clinical phenotype in 
our study did not reveal different treatment response on ambulation, and 
this is in line with pooled analyses of the phase 3 trials.(5) Three out of four 
real-world studies did not perform analyses of subgroups.(14-16)
In the subset of patients reporting impaired UEF as well, approximately 40% 
of patients were classified as AMSQ responders. To our knowledge, only one 
study assessed PRO on UEF with the ABILHAND questionnaire in a cohort 
that was selected on impairment in UEF.(6) The ABILHAND improved by 
16% after one month, and 31% after three months of treatment. In contrast, 
in another study no response on ABILHAND was found.(27) This might be 
due not selecting patients on impaired UEF, which probably attenuated the 
impact on ABILHAND. Also, the ABILHAND may be less suitable to detect 
change of UEF in MS patients, because it was not specifically designed for MS 
patients. Small sample sizes (i.e. 25 and 26 patients) are other limitations of 
these studies.
Treatment decision making
In our total cohort, 75% of patients continued treatment based on the 
physicians’ judgment, which concurs with other real-world data (ranging from 
70 – 87%).(12, 14-16) In one study, fampridine response was assessed in 
120 patients and 74% were classified as responders when defined as a 15% 
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improvement of at least one of the three walking tests (i.e. T25FW, 2-min walk 
test or MSWS).(12) This is a more liberate definition of response than used 
in pre-marketing studies, and possibly better reflects the physician’s overall 
judgement in clinical practice. However, no data were presented on factors 
that influenced treatment decision making.
We found two studies in which treatment decision making was analysed. 
The first study included 189 patients in which the EMA recommendations for 
continuing treatment were compared with the physicians’ overall judgement 
of improvement, similarly to our study.(14) They found that 70% of patients 
continued treatment, and that a combination of T25FW and MSWS offered 
the best sensitivity and specificity for determining response, based on a 
receiver operating characteristic (ROC) curve analyses. The other study found 
that baseline performance of the 6-miute walk test and T25FW predicted 
responder status (defined as ≥15% improvement in at least one clinical 
walking test) with an accuracy of 85.5%.(28) The MSWS did not contribute 
significantly as a predictor for response.
In our impaired UEF cohort, 39.3% of patients showed improvement of 
AMSQ, and in this subgroup 82.8% also reported improvement of MSWS 
and continued treatment in 85.9% of patients, which is a larger proportion 
(70.7%) than in the subgroup without AMSQ improvement. Therefore, 
it is likely that patient reported benefits of treatment contributed to the 
physicians’ decision to continue treatment. Obviously, physician-based 
factors (such as experience, training, influenceability) and local factors (such 
as reimbursement policies) influence treatment decision making as well. It 
nevertheless illustrates the gap between clinical trials and practice, and the 
challenges physicians are being faced with the real-world.
The inclusion of specific PRO measures in clinical trials are valuable for 
enhancing information on the functional impact of various aspects of 
impairment.(29) In clinical practice, standardized measurement of PRO 
provides valuable insight into the patient perspective.  For example, 
treatment success for a patient might be more influenced by adverse events 
than a physician perceives or deduces from other outcome measures. All in 
all, assessment of PRO is indispensable for accurate understanding of clinical 
aspects of a disease or treatment.
Limitations
A strength of our study is the large cohort size of patients derived from a real-
world setting. Although randomized controlled trials are the gold standard, 
they inherently have a limited degree of external validity.(13) Another strength 
is that our study is the first study in which the patient’s self-perceived effects 
of fampridine on UEF was assessed with a PRO measure specifically designed 
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for MS patients (i.e. the AMSQ). Also, the use of responder definitions that 
are based on established clinically relevant changes, gives a more robust 
insight into clinically meaningful treatment effects than merely statistical 
differences of the crude scores of the outcome measures. Our study also has 
some limitations. Firstly, a placebo or learning effect of the measures used 
cannot be ruled out without comparison with a placebo group. Secondly, we 
do not have long-term follow-up data to assess the persistence of efficacy, 
particularly on PRO measures. Thirdly, fampridine response on UEF might 
be underestimated due to patient selection based on the presence of 
ambulatory impairment. Analysis of a cohort primarily selected on impaired 
UEF may give different results.
5 CONCLUSIONS
We conclude that responder rates, and treatment continuation of fampridine 
differed between clinical subgroups of MS. PROs influenced treatment 
decision making of fampridine in clinical practice, particularly in patients with 
mild ambulatory impairment or those reporting UEF impairment. To some 
extent, these findings explain discrepancies found between clinical trials 
and clinical practice, and support the importance of subgroup analyses and 
incorporation of PROs in clinical trials. For clinical practice, using PROs to 
assess patients experience in conjunction to performance measures helps 
in treatment decision making.
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Motor dysfunction, particularly ataxia, is one of the predominant clinical 
manifestations in patients with multiple sclerosis (MS). Assessment of motor 
dysfunction suffers from a high variability. We investigated whether the 
clinical rating of ataxia can be improved through the use of reference videos, 
covering the spectrum of severity degrees as defined in the Neurostatus-
Expanded Disability Status Scale. Twenty-five neurologists participated. 
The variability of their assessments was significantly lower when reference 
videos were used (SD = 0.12; range = 0.40 vs SD = 0.26; range = 0.88 without 
reference videos; p = 0.013). Reference videos reduced the variability of 
clinical assessments and may be useful tools to improve the precision and 
consistency in the clinical assessment of motor functions in MS. 




In multiple sclerosis (MS) clinical assessment scales—mainly the Expanded 
Disability Status Scale (EDSS)—are used to quantify impairment and disability. 
The EDSS is known for a low inter- and intrarater reliability and suffers from 
a high variability, especially at lower EDSS scores.(1) Motor dysfunction 
and particularly ataxia is one of the predominant clinical manifestations in 
patients with MS and a major contributor to disability progression.(2) Thus, 
reliable and consistent rating of ataxia is crucial for the follow up of patients 
with MS. 
2 OBJECTIVE
The objective of this report is to investigate whether reference videos (RVs) 
exemplifying degrees of ataxia severity can reduce the variability of motor 
dysfunction assessment in MS.
3 METHODS 
Study design and participants
This study was a subproject of “Assess MS,” a study approved by the local 
ethics committees.(3) All patients gave their written informed consent to 
the video recordings. Twenty-five raters (neurologists) from the university 
hospitals in Bern and Basel rated 60 videos based on 43 MS patients 
performing the finger-to-nose test (FNT). The videos were recorded with 
a Microsoft Kinect® 1 camera and chosen out of >2000 videos recorded 
for the Assess MS study, with the constraint to have coverage for all limb 
ataxia grades of the Neurostatus- EDSS definitions.(4,5) According to these 
definitions there  are  five  grades  of  limb  ataxia:  0 = no ataxia, 1 = signs 
only, 2 = tremor or clumsy movements easily seen, minor interference with 
function, 3 = tremor or clumsy movements interfere with function in all 
spheres and 4 = most functions are very difficult. The ratings were performed 
at baseline and six weeks later (“retest”), to assess the long-term intrarater 
agreement. In both rating sessions 10% of the videos were presented twice 
for short-term intrarater agreement.
Forty-one RVs, different from the videos used for rating, were chosen by 
experienced neurologists of the Assess MS study. They also showed MS 
patients performing the FNT, with different degrees of limb- ataxia severity, 
based on the Neurostatus-EDSS definitions.(4,5) The raters were randomized 
into two groups: one group assessing videos based only on the written 
Neurostatus-EDSS definitions,(5) without simultaneous access to the RVs 
(Setting 1), and the other, with simultaneous  access  to  the  RVs (Setting 2). 
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The characteristics of the raters are summarized in Table 1. There was no 
difference in experience with MS patients between the groups (Setting 1 vs 
Setting 2).
Table 1, characteristics of patients and neurologists participating in this study. 
Patients
Mean Age, y [range] 42.79 ± 12.09 [23-77]
Gender (female), f/m 29/14
Disease duration (y), mean ± SD [range] 13.25 ± 8.38 [0.5-40]
Median EDSS [range] 3.5 [1-6.5] 








Neurologists Group Setting 1 Group Setting 2
Gender (female), f/m 7/6 5/7
Years of experience with MS, mean [range] 5.5 [0.5-12] 5.8 [0.2-12]
EDSS: Expanded Disability Status Scale; MS: multiple sclerosis; PPMS: primary progressive mul-
tiple sclerosis; RRMS: relapsing–remitting multiple sclerosis; SPMS: secondary progressive mul-
tiple sclerosis.
Patient-performance
For FNT videos, MS patients were instructed by the recording neurologists of 
the Assess MS study to close their eyes and abduct their arms to 90 degrees 
at the shoulder in full extension, before touching the nose with the tip of 
their  index  finger,  first  with the dominant, then with the nondominant side 
(Figure 1).
Video rating
Videos were presented for rating on a touchscreen. Setting 2 allowed for 
simultaneous presentation of RVs on the right part of the screen (Figure 1). 
Horizontal swipe allowed for viewing RVs of different limb-ataxia severity 
degrees; vertical swipe for viewing alternative RVs of the same severity degree. 
In Setting 1 this part of the screen remained black. Raters were allowed to 
view each video as often as required for scoring.
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Figure 1, reference videos on the right, videos to be rated on the left, below fields for scoring 
the appropriate severity of the performance using ataxia grades of the Neurostatus-Expanded 
Disability Status Scale definitions. According to these definitions there are five grades of limb 
ataxia: 0 = no ataxia, 1 = signs only, 2 = tremor or clumsy movements easily seen, minor interfer-
ence with function, 3 = tremor or clumsy movements interfere with function in all spheres and 
4 = most functions are very difficult. People shown are not patients and gave written consent 
to be shown.
Statistics
The analysis was conducted using Matlab R2014b (MathWorks, Natick, MA, 
USA). F test was used to compare the variability of the ratings between the two 
rater groups (Setting 1 vs Setting 2). Interrater agreement was calculated as 
intraclass correlation coefficient (ICC) for single measurements and absolute 
agreement.(6) Intrarater agreement was calculated as the percentage of 
identical ratings.
4 RESULTS
The variability of ratings was significantly lower in Setting 2 (standard deviation 
(SD) = 0.12; range = 0.40) than in Setting 1 (SD = 0.26; range = 0.88, F test; 
p = 0.013), as illustrated in Figure 2. The ICC for interrater agreement was 
numerically slightly higher in Setting 2 (0.816 (95% confidence interval (CI): 
0.756–0.871) vs 0.756 (95% CI: 0.674–0.829) in Setting 1) but this difference 
was not significant. Short-term and long-term intrarater agreement were 
similar across settings (Setting 1: 79 ± 18% and 69 ± 11%; Setting 2: 75 ± 22% 
and 68 ± 9%, not significant).
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Figure 2, on the left the ratings of Setting 1, i.e. the group without reference videos are shown 
without ((w/o) ref) and on the right, those from Setting 2, i.e. the group with reference videos 
(“with ref”). Mean and standard deviation (SD) are shown in green, median in magenta. The varia-
bility of ratings was significantly lower in Setting 2 (SD = 0.12; range = 0.40) than in Setting 1, w/o) 
reference videos (SD = 0.26; range = 0.88, F test; p = 0.013). Each dot represents the average of 
all ratings of one neurologist (blue at baseline and red six weeks later). 
The average score of limb ataxia (according to the Neurostatus-EDSS 
definitions) was slightly higher in Setting 2, with RVs (mean score (test and 
retest after six weeks): 1.4 ± 0.1 in Setting 2, vs 1 ± 0.3 in Setting 1, p < 0.0001), 
as illustrated in Figure 2. No significant interaction was found between 
intrarater agreement, raters’ experience with MS or EDSS assessments, or 
the centers (data not shown). 
5 DISCUSSION
As pars pro toto,” the results of this study show that using preselected RVs 
can reduce the rating variability in the assessment of limb ataxia of MS 
patients. The use of such videos can be easily implemented and does not 
require an additional/new scale, since we used the already well-established 
Neurostatus- EDSS definitions.(4) Whether this approach can also be used 
for assessments other than limb ataxia remains to be shown.
We found a small but statistically significant difference of the average 
severity level obtained in the two settings with higher ratings in the setting 
with RVs. As the ataxia degrees were assigned to the RVs by neurologists 
with special expertise in clinical ratings, this may have contributed to stricter 
interpretation of the grade definitions. A further limitation in our study was 
the low number of severely affected patients (ataxia grades 3 and 4). In daily 
routine, however, rating of lower-severity grades is more challenging than 
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higher grades. Our RV approach may also have a role in training machine-
learning algorithms (MLAs). Such an example is the Assess MS system, a 
potentially finer-grained tool to measure motor dysfunction in MS.(3) This 
system uses advanced MLAs to analyze three-dimensional-depth-sensor 
recordings of MS patients performing standard tests of motor function, like 
the FNT. Reducing the variability of clinical assessments that are used to train 
MLAs should also contribute to improved algorithms that are derived from 
machine learning.
6 CONCLUSIONS
The use of RVs may represent a simple method to reduce variability in the 
assessment of motor dysfunction in MS. This method could be particularly 
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Assessing motor function is important to monitor the disease course of 
multiple sclerosis (MS). Video-capturing and -rating of the performance of 
classical neurological tests and tasks of activities of daily living (ADL) may 
improve the detection of change in motor function. We investigated the 
additional value of video-assisted composite measures for the detection of 
change in mobility and upper extremity function (UEF). 
Methods  
Data were collected from 43 MS patients who started fampridine treatment 
and performed video-recorded composites of tests prior to and after at 
least two weeks of treatment. Patients were classified as improved and not 
improved on mobility (MOB-COM) and UEF (UEF-COM) composites based on 
neurologists’ video-ratings of the tests. The proportional agreement between 
the composites and the Timed 25-Foot Walk test (T25FW) and Nine-Hole Peg 
Test (NHPT) was determined and compared to clinically relevant improvement 
with Venn diagrams. Clinically relevant improvement was determined using 
patient-reported ratings of change in mobility and UEF.
Results  
Agreement between MOB-COM and T25FW was 79.5% and 82.1% for UEF-
COM and NHPT. 26 patients had perceived clinical improvement on mobility, 
in which MOB-COM identified two (7.7%) patients with improvement that was 
not detected with T25FW. In 13 patients with perceived UEF improvement, 
three (23.1%) patients improved on UEF-COM without improving on NHPT. 
Conclusion  
The video-assisted composites of ADL tasks and classical neurological tests 
detected motor improvement in patients with perceived improvement 
who were missed with conventional measures only. This may improve the 
detection of treatment effects in clinical practice and trials in MS.




Clinical assessment of patients with multiple sclerosis (MS) is notoriously 
difficult largely due to the multifaceted aspect of disability caused by the 
disease.(1) With increasing numbers of effective disease modifying therapies 
and expanding treatment windows, selection of outcome measures 
that adequately detect clinical change is increasingly important.(2) This 
was demonstrated by two large MS trials in which no effect on disease 
progression was found based on the primary endpoint that was heavily 
weighted on ambulation, while positive effects were found on upper extremity 
function (UEF).(3, 4)  The accurate assessment of disability is also relevant 
in the evaluation of symptomatic treatment options such as fampridine.(5) 
Fampridine improves walking speed and UEF in a subset of MS patients, albeit 
patient-perceived improvement does not fully correspond with improvement 
measured with clinical instruments.(6-8) 
The Expanded Disability Status Scale (EDSS) is the most widely used outcome 
measure in MS trials, despite having a high inter- and intra-rater variability 
and a disproportional impact of ambulation on the total score.(9, 10) To 
improve the assessment of commonly affected functional domains in MS, 
the Multiple Sclerosis Functional Composite (MSFC) was introduced to assess 
ambulation (timed 25-foot walk test, T25FW), UEF (nine-hole peg test, NHPT), 
and cognition.(11, 12) Despite generally good psychometric properties, the 
individual components have several shortcomings.(13, 14) For instance, 
the T25FW may not be sensitive enough to detect abnormalities in patients 
with mild ambulatory impairment.(15) Furthermore, the T25FW and NHPT 
measure only a certain aspect of ambulation and UEF: respectively walking 
speed and manual dexterity, which do not fully capture the broader aspects 
of functioning. Because of these shortcomings possible clinically relevant 
treatment effects might be missed.
By recording movements of patients on video, multiple standardised 
functional tests can be assessed at different time points and still be rated 
simultaneously. This video-assisted approach allows the assessment of tests 
of the neurological examination with less intra-rater variability as there is no 
recall bias.(16, 17) Moreover, standardised tasks of activities of daily living 
(ADL) can be added to the assessment, which is valuable in measuring the 
patients’ functioning.(18) All in all, such video-assisted composite measure 
taking into account multiple aspects of motor function, may achieve a more 
complete assessment of (change in) motor performance. In this study we 
investigated the additional value of a multidimensional video-assisted 
composite measure compared to conventional measures and aim to enhance 
the detection of change in mobility and UEF in patients with MS.
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2 PATIENTS AND METHODS
Data used in this study were part of a multicentre project to develop the 
Assess MS system, performed in four large European MS centres located 
in Amsterdam, Basel, Bern and Lucerne.(19, 20) The aim was to develop a 
consistent and fine-grained system that automatically quantifies motor 
function in MS patients. Standardised movements of MS patients were 
recorded using a 3D depth sensing and colour camera (i.e. the Microsoft 
Kinect®) with the aim of training machine learning algorithms to automatically 
quantify motor function. Written informed consent was obtained from all 
subjects prior to study participation and the study was approved by the 
respective ethics committee. 
Subject recruitment
Patients were recruited at Amsterdam UMC, location VU Medical Center 
between August 2017 and April 2018. Patients initiating treatment with 
fampridine were eligible for study participation, as fampridine can have 
positive treatment effects on ambulatory function and UEF.(6-8) Inclusion 
criteria were, conforming to the official treatment label of fampridine, 
diagnosis of MS according to the revised 2010 McDonald’s criteria,(21) age 
above 18 years, and ambulatory impairment defined as an estimated EDSS 
score between 4.0 and 7.0 without additional diseases that contributed to 
disability. Contraindications as stated in the fampridine product label were 
handled as exclusion criteria.(22) Patients were assessed at baseline prior to 
fampridine treatment and at follow-up after at least two weeks of fampridine 
treatment. Patient and disease characteristics were collected during the 
baseline visit: age, sex, EDSS,(9) disease type, and disease duration.
Conventional measures
As conventional measure for mobility the T25FW was used, and for UEF the 
NHPT. The T25FW was performed twice on both visits, as implemented in the 
MSFC.(11) For each visit two trials were averaged for each patient. A decrease 
of at least 20% of baseline walking time was used to indicate significant 
improvement in mobility function.(14, 23, 24) The NHPT was performed 
twice for both hands on both visits, as implemented in the MSFC.(11) The 
trials from the dominant and non-dominant hand were averaged into one 
value. Similarly to the T25FW, a decrease in completion time of at least 20% 
between visits was used as cut-off for significant improvement of UEF.(23) 
Video-assisted composite measures
In addition to the conventional measures, patients performed a set of 
standardised movements consisting of ADL tasks and tests from the 
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neurological examination, see fi gure 1A. Three classical neurological tests 
and four ADL tasks assessed mobility and comprised the mobility composite 
(MOB-COM). UEF was assessed with three classical neurological tests and 
two ADL tasks and were combined into the UEF composite (UEF-COM). The 
movements comprising MOB-COM and UEF-COM were recorded using the 
Microsoft Kinect® camera, as shown in fi gure 1B. Each colour video was 
rated by two neurologists, who were blinded for the visit type (baseline or 
follow up) and the patients’ performance on the conventional measures. 
The classical neurological tests were quantifi ed according to predetermined 
rating scales based on the Neurostatus-EDSS functional system scoring 
defi nitions.(25) For the ADL tasks, a fi ve-point Likert scale was created ranging 
from 0 (‘normal’) to 4 (‘unable to perform due to disability’). Video rating was 
performed by using reference videos.(17) Using an algorithm that takes into 
account individual rater bias, the videos were then assigned a consensus 
score.(26) This consensus score was subsequently used in the statistical 
analyses. Videos of insuffi  cient quality or inaccurately performed movements 
were excluded from the analysis. A more comprehensive description of the 
standardised movements, video rating, and score calculation can be found 
elsewhere.(17, 18) Signifi cant improvement on MOB-COM and UEF-COM was 
defi ned as two or more tests improving (i.e. ≥1 point decrease) and no more 
than one test worsening (i.e. ≥1 point increase) during follow-up compared 
to baseline.
Figure 1, schematic overview of the video-assisted composite measures (A). Setup of the vid-
eo-assisted composite measure (B). Consent was given by the people in the fi gure. aFrom the 
classical neurological examination, scored according to the Neurostatus EDSS. bNormal walking 
gait over 25 foot, sc oring: 0 (normal), 1 (mild), 2 (moderate), 3 (severe), 4 (not possible). cTurning 
360 degrees while standing, scoring: 0 (normal), 1 (mild), 2 (moderate), 3 (severe), 4 (not possi-
ble). dGetting up from a chair without using the arms, scoring: 0 (normal), 1 (mild), 2 (moderate), 
3 (severe), 4 (not possible). eTaking a sip from a cup, scoring: 0 (normal), 1 (mild), 2 (moderate), 3 
(severe), 4 (not possible)Abbreviations: UEF = Upper Extremity Function; ADL = Activities of Daily 
Living; t1 = Baseline visit; t2 = Follow-up visit; MOB-COM = Video-assisted Mobility Composite; 




Clinically relevant improvement was externally anchored by using Global 
rating of change (GRC) scales.(27) At the follow-up visit, patients rated 
their perceived change on mobility and UEF at compared to baseline. GRC 
mobility was rated on a 7-point Likert scale ranging from -3 (i.e. very much 
deteriorated) to +3 (i.e. very much improved) and GRC UEF was rated on 
a 5-point scale ranging from -2 (i.e. much deteriorated) to +2 (i.e. much 
improved). Patients with positive GRC scores were classified as having 
clinically relevant improvement, whereas GRC of 0 or negative scores were 
classified as no clinically relevant improvement.
Statistical analysis
All statistical analyses were performed using IBM SPSS Statistics version 24. 
Categorical variables were summarised as frequencies with percentages. The 
mean and standard deviation were used to summarise continuous variables 
that were normally distributed, otherwise the median and interquartile 
range were used. The proportional agreement between the video-assisted 
composite and conventional measures was determined using 2 by 2 
contingency tables for ambulation (T25FW and MOB-COM) and UEF (NHPT 
and UEF-COM). To determine and visualise the added value of the composite 
measures, Venn diagrams were drafted showing the overlap in patients who 
improved on the various outcomes for mobility and UEF. 
3 RESULTS
A total of 43 MS patients initiating fampridine treatment were included 
and completed baseline measurements. After baseline measurements, 
2 patients discontinued treatment prematurely due to side-effects, and 2 
patients refused follow-up assessment due to time constraints. The baseline 
characteristics of the 39 patients that completed the study are summarised 
in table 1.
Table 1, baseline patient characteristics (n = 39). 
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Age, y, mean (SD) 54.0 (10.4)
Disease duration, y, mean (SD) 13.8 (8.1)
EDSS, median (IQR) 5.5 (4.0 – 6.0)
Fampridine treatment duration, d, mean (SD) 24.5 (8.5)
T25FW, s, median (IQR) 6.9 (5.8 – 9.3)
MSWS, mean (SD) 73.2 (17.5)
NHPT, s, median (IQR) 27.3 (23.7 – 42.2)
AMSQ, median (IQR) 63.0 (45.0 – 94.0)
Abbreviations: RRMS = Relapsing Remitting Multiple Sclerosis; SPMS = Secondary Progressive 
Multiple Sclerosis; PPMS = Primary Progressive Multiple Sclerosis; EDSS = Expanded Disability 
Status Scale; T25FW = Timed-25 Foot Walk test; MSWS = Multiple Sclerosis Walking Scale; NHPT 
= Nine-Hole Peg Test; AMSQ = Arm function in Multiple Sclerosis Questionnaire.
Based on the conventional measures and the video-assisted composite 
measures, the number and percentage of patients with signifi cant 
improvement of mobility and UEF are shown in fi gure 2.
Figure 2, bar graphs depicting the counts and percentages of patients with signifi cant improve-
ment at follow-up for mobility (A) and upper extremity (B) function. Abbreviations: GRC = Glob-
al Rating of Change; T25FW = Timed 25-Foot Walk test; MOB-COM = Video-assisted Mobility 
Composite; NHPT = Nine-Hole Peg Test; UEF-COM = Video-assisted Upper Extremity Function 
Composite.
Of the patients improving on MOB-COM, the proportion of improvement 
on ADL tasks and classical neurological tests was equal. This was similar for 
UEF, only slightly favouring neurological tests (54.5%) compared to ADL tasks 
(45.5%). See fi gure 3.
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Figure 3, stacked bar graphs depicting the number of tests contributing to MOB-COM and 
UEF-COM improvement split between ADL tasks and Classical neurological tests. Abbreviations: 
MOB-COM = Video-assisted Mobility Composite; UEF-COM = Video-assisted Upper Extremity 
Function Composite; ADL = Activities of Daily Living.
Comparison of conventional and video-assisted composite measures
Table 2 shows the proportion of patients who improved as stratifi ed by 
the conventional measures and video-assisted composite measures for 
ambulatory function. Three (7.7%) patients improved on the MOB-COM 
without improvement on T25FW. Conversely, fi ve (12.8%) patients improved 
on T25FW without improvement on MOB-COM. The remaining patients 
(79.5%) were stratifi ed similarly by both measures. 
Table 2, cross tabs between T25FW and MOB-COM.
MOB-COM Improveda Not improved
T25FW
  Improvedb 6 (15.4) 5 (12.8)
  Not improved 3 (7.7) 25 (64.1)
Data are expressed as n (%). a≥ 2 improvement and ≤ 1 worsening of movements on the mobility 
composite, b≥ 20% increase of walking speed at follow-up compared to baseline. Abbreviations: 
MOB-COM = Video-assisted Mobility Composite; T25FW = Timed 25-Foot Walk test
For UEF, 32 (82.1%) patients were stratifi ed similarly by NHPT and UEF-COM. 
Four (10.3%) patients improved on the UEF-COM with no improvement on 
the NHPT. Conversely, three (7.7%) patients did not improve on UEF-COM, 
and improved on NHPT. See table 3.
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Table 3, cross tabs between NHPT and UEF-COM. 
UEF-COM Improveda Not improved
NHPT
  Improvedb 0 (0.0) 3 (7.7)
  Not improved 4 (10.3) 32 (82.1)
Data are expressed as n (%). a≥ 2 improvement and ≤ 1 worsening of movements of the upper 
extremity function composite, b≥ 20% decrease of time to complete the Nine-Hole Peg Test 
at follow-up compared to baseline. Abbreviations: UEF-COM = Video-assisted Upper Extremity 
Function Composite; NHPT = Nine-Hole Peg Test.
Detection of clinically relevant improvement
Of the 26 patients who reported improvement on ambulatory function on 
the GRC, 10 also showed signifi cant improvement on T25FW compared 
to 8 on MOB-COM. One patient signifi cantly improved on T25FW without 
reporting improvement on GRC. Two of three patients that improved on 
MOB-COM and not on the T25FW, also reported improvement of GRC. The 
overlap between improvement on GRC, T25FW and MOB-COM is depicted in 
fi gure 4. There was no overlap of patients reporting improvement on GRC (n 
= 13) and showing improvement on 9HPT (n = 3). Three of four patients that 
improved on UEF-COM and not on the 9HPT, also reported improvement 
of GRC. The overlap between improvement on GRC, 9HPT and UEF-COM is 
depicted in fi gure 5.
Figure 4, Venn diagrams depicting the overlap between patient-perceived improvement (GRC) 
and improvement on the conventional (T25FW and NHPT) and video-assisted composite (MOB- 
and UEF-COM) measures for mobility (A) and upper extremity function (B). Abbreviations: GRC = 
Global Rating of Change; T25FW = Timed 25-Foot Walk test; MOB-COM = Video-assisted Mobility 





In this study we investigated the additional value of two multidimensional 
video-assisted composites in relation to conventional measures to detect 
change in motor function. The composites used here cover various aspects 
of motor function: ADL tasks and classical neurological tests. In patients 
who reported perceived improvement, the composites for mobility function 
detected two (7.7%) and UEF three (23.1%) patients with improvement which 
were not found using the conventional measures.
With single modality measures alone, improvement of motor function may be 
missed. For instance, a patient might walk more coordinated despite needing 
the same amount of time to walk 25 feet compared to a patient who is able to 
walk faster, but walks more impaired. In addition, for the T25FW both ceiling 
and floor effects have been pointed out in patients with EDSS >6.5 and 
patients in the lower EDSS ranges, respectively.(14, 15). With the highest EDSS 
of 6.5 in our cohort, only floor effects of the T25FW are likely to have incurred 
in the patients who had close to ‘normal’ short distance walking speed. These 
patients are unlikely to achieve an even faster walking speed to satisfy the 
clinically meaningful improvement criterion of 20%, but may improve in other 
domains than walking speed. This is supported by a larger cohort of patients 
treated with fampridine where lower baseline walking speed was matched 
with lower rates of 20% improvement on T25FW.(28) Similarly, floor effects 
have also been reported for the NHPT together with the suggestion of the 
use of multiple clinical tests to overcome the deficiency.(29) 
The composite measures also incorporated tasks of ADL, which we found 
to be equally important, proportionally wise, as neurological examination 
tests when assessing improvement of ambulation and UEF. A previous study 
with similar methodology in a cross-sectional setting suggests ADL tasks to 
be important, perhaps even more valuable than neurological tests, for the 
assessment of motor function in MS.(18) This study confirms the role of ADL 
functioning in assessment of change in a longitudinal setting. Strikingly, there 
was no overlap between NHPT improvement and patient-perceived UEF 
improvement. Whereas 75% of the patients with improvement on the UEF 
composite also had perceived UEF improvement, further supporting the role 
of ADL functioning.
Several advantages may be pointed out regarding the use of video-
assistance in the assessment of motor function. This includes the ability to 
directly compare motor performance across patients and within patients in 
a longitudinal setting, which may reduce intra- and interobserver variability. 
Which can be potentially further reduced when aided by the use of reference 
videos or machine-learning algorithms in the rating of movements. In addition, 
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video-assisted assessment of motor function allows disease monitoring from 
physical distance. The importance of assessment from physical distance is 
emphasized in the current COVID-19 pandemic, especially in patients with 
MS who may be at higher risk due to immunomodulatory therapies. On 
the other hand, limitations of this study include the small sample size. The 
studied composite measures were based on consensus scores derived from 
ratings of only two neurologists. For the assessment of clinically relevant 
change potential placebo effects are not accounted for. Our findings also 
provide limited insight in patients in the lower and upper ranges of EDSS 
scores as disability in our cohort of patients ranged from EDSS of 3.5 to 6.5. 
Lastly, potential learning effects in performing the video-assisted composite 
at follow-up were not studied, although we assume this is not a major bias 
since the composites were assessed once each visit with an interval of at 
least 2 weeks. 
CONCLUSIONS
The composite measures allow assessment of multiple domains of physical 
functioning, including ADL which is not conventionally measured. The video-
based rating method also enables direct comparison of motor function 
across patients and within patients in a longitudinal setting. Through the 
video-assisted composites, previously undetected objective improvement 
can be found in patients with self-perceived improvement. This video-
assisted method, enabling assessment from physical distance, enhances the 




1. Scalfari A, Neuhaus A, Daumer M, Deluca GC, Muraro PA, Ebers GC. Early relapses, onset 
of progression, and late outcome in multiple sclerosis. JAMA neurology. 2013;70(2):214-
22.
2. Faissner S, Plemel JR, Gold R, Yong VW. Progressive multiple sclerosis: from 
pathophysiology to therapeutic strategies. Nature reviews Drug discovery. 
2019;18(12):905-22.
3. Kapoor R, Ho PR, Campbell N, Chang I, Deykin A, Forrestal F, et al. Effect of natalizumab 
on disease progression in secondary progressive multiple sclerosis (ASCEND): a phase 
3, randomised, double-blind, placebo-controlled trial with an open-label extension. The 
Lancet Neurology. 2018;17(5):405-15.
4. Montalban X, Hauser SL, Kappos L, Arnold DL, Bar-Or A, Comi G, et al. Ocrelizumab versus 
Placebo in Primary Progressive Multiple Sclerosis. The New England journal of medicine. 
2017;376(3):209-20.
5. Hayes KC. Impact of extended-release dalfampridine on walking ability in patients with 
multiple sclerosis. Neuropsychiatric disease and treatment. 2011;7:229-39.
6. Goodman AD, Brown TR, Schapiro RT, Klingler M, Cohen R, Blight AR. A pooled analysis of 
two phase 3 clinical trials of dalfampridine in patients with multiple sclerosis. International 
journal of MS care. 2014;16(3):153-60.
7. Savin Z, Lejbkowicz I, Glass-Marmor L, Lavi I, Rosenblum S, Miller A. Effect of Fampridine-
PR (prolonged released 4-aminopyridine) on the manual functions of patients with 
Multiple Sclerosis. Journal of the neurological sciences. 2016;360:102-9.
8. Klineova S, Farber R, Friedman J, Farrell C, Lublin FD, Krieger S. Objective and subjective 
measures of dalfampridine efficacy in clinical practice. Multiple sclerosis journal - 
experimental, translational and clinical. 2018;4(3):2055217318786742-.
9. Kurtzke JF. Rating neurologic impairment in multiple sclerosis: an expanded disability 
status scale (EDSS). Neurology. 1983;33(11):1444-52.
10. van Munster CE, Uitdehaag BM. Outcome Measures in Clinical Trials for Multiple Sclerosis. 
CNS drugs. 2017;31(3):217-36.
11. Cutter GR, Baier ML, Rudick RA, Cookfair DL, Fischer JS, Petkau J, et al. Development of 
a multiple sclerosis functional composite as a clinical trial outcome measure. Brain : a 
journal of neurology. 1999;122 ( Pt 5):871-82.
12. Meyer-Moock S, Feng YS, Maeurer M, Dippel FW, Kohlmann T. Systematic literature review 
and validity evaluation of the Expanded Disability Status Scale (EDSS) and the Multiple 
Sclerosis Functional Composite (MSFC) in patients with multiple sclerosis. BMC neurology. 
2014;14:58.
13. Feys P, Lamers I, Francis G, Benedict R, Phillips G, LaRocca N, et al. The Nine-Hole Peg 
Test as a manual dexterity performance measure for multiple sclerosis. Multiple sclerosis 
(Houndmills, Basingstoke, England). 2017;23(5):711-20.
14. Motl RW, Cohen JA, Benedict R, Phillips G, LaRocca N, Hudson LD, et al. Validity of the 
timed 25-foot walk as an ambulatory performance outcome measure for multiple 
sclerosis. Multiple sclerosis (Houndmills, Basingstoke, England). 2017;23(5):704-10.
15. Goldman MD, Motl RW, Scagnelli J, Pula JH, Sosnoff JJ, Cadavid D. Clinically meaningful 
performance benchmarks in MS: timed 25-foot walk and the real world. Neurology. 
2013;81(21):1856-63.
Video-assisted rating for detection of change in motor function
155 
8
16. Steinheimer S, Dorn JF, Morrison C, Sarkar A, D’Souza M, Boisvert J, et al. Setwise 
comparison: efficient fine-grained rating of movement videos using algorithmic support - 
a proof of concept study. Disability and rehabilitation. 2019:1-7.
17. D’Souza M, Steinheimer S, Dorn J, Morrison C, Boisvert J, Kravalis K, et al. Reference 
videos reduce variability of motor dysfunction assessments in multiple sclerosis. Multiple 
sclerosis journal - experimental, translational and clinical. 2018;4(3):2055217318792399.
18. van Munster CE, D’Souza M, Steinheimer S, Kamm CP, Burggraaff J, Diederich M, et al. 
Tasks of activities of daily living (ADL) are more valuable than the classical neurological 
examination to assess upper extremity function and mobility in multiple sclerosis. Multiple 
sclerosis (Houndmills, Basingstoke, England). 2018:1352458518796690.
19. Morrison C, D’Souza M, Huckvale K, Dorn JF, Burggraaff J, Kamm CP, et al. Usability and 
Acceptability of ASSESS MS: Assessment of Motor Dysfunction in Multiple Sclerosis Using 
Depth-Sensing Computer Vision. JMIR human factors. 2015;2(1):e11.
20. Kontschieder P, Dorn JF, Morrison C, Corish R, Zikic D, Sellen A, et al. Quantifying 
progression of multiple sclerosis via classification of depth videos. Medical image 
computing and computer-assisted intervention : MICCAI  International Conference on 
Medical Image Computing and Computer-Assisted Intervention. 2014;17(Pt 2):429-37.
21. Polman CH, Reingold SC, Banwell B, Clanet M, Cohen JA, Filippi M, et al. Diagnostic criteria 
for multiple sclerosis: 2010 revisions to the McDonald criteria. Annals of neurology. 
2011;69(2):292-302.
22. European Medicines Agency. Fampyra: EPAR - Summary for the public [Internet]. 2011 
[updated 2017 August 4; cited 2019 July 24]. Available from: https://www.ema.europa.eu/
en/medicines/human/EPAR/fampyra.
23. van Winsen LM, Kragt JJ, Hoogervorst EL, Polman CH, Uitdehaag BM. Outcome 
measurement in multiple sclerosis: detection of clinically relevant improvement. Multiple 
Sclerosis Journal. 2010;16(5):604-10.
24. Hobart J, Blight AR, Goodman A, Lynn F, Putzki N. Timed 25-foot walk: direct evidence that 
improving 20% or greater is clinically meaningful in MS. Neurology. 2013;80(16):1509-17.
25. Kappos L. Neurostatus scoring definitions (Version 04/10.2) 2011 [Available from: https://
www.neurostatus.net.
26. Sarkar A, Morrison C, Dorn JF, Bedi R, Steinheimer S, Boisvert J, et al. Setwise Comparison: 
Consistent, Scalable, Continuum Labels for Computer Vision.  Proceedings of the 2016 
CHI Conference on Human Factors in Computing Systems; San Jose, California, USA: 
Association for Computing Machinery; 2016. p. 261–71.
27. Jaeschke R, Singer J, Guyatt GH. Measurement of health status. Ascertaining the minimal 
clinically important difference. Controlled clinical trials. 1989;10(4):407-15.
28. van Munster CEP, Kaya L, Lam KH, Kalkers NF, Killestein J, Uitdehaag BMJ. Responder 
rates to fampridine differ between clinical subgroups of MS patients and patient reported 
outcome influences treatment decision making. Multiple sclerosis and related disorders. 
2020;38:101489.
29. Solaro C, Cattaneo D, Brichetto G, Castelli L, Tacchino A, Gervasoni E, et al. Clinical 
correlates of 9-hole peg test in a large population of people with multiple sclerosis. 
Multiple sclerosis and related disorders. 2019;30:1-8.

CHAPTER 9
Autoencoder: a new method 
for keeping data privacy when 
analysing videos of patients 
with motor dysfunction - 
a proof of concept study
 
Caspar E.P. van Munster, Marcus d’Souza, J. Dorn, A. Dorier, C.P. Kamm, S. 
Steinheimer, F. Dahlke, B.M.J. Uitdehaag, L. Kappos, M. Johnson. 





In chronic neurological diseases, especially in multiple sclerosis (MS), 
clinical assessment of motor dysfunction is crucial to monitor the disease in 
patients. Traditional scales are not sensitive enough to detect slight changes. 
Video recordings of patient performance are more accurate and increase 
the reliability of severity ratings. When these recordings are automated, 
quantitative disability assessments by machine learning algorithms can be 
created. Creation of these algorithms involves non–health care professionals, 
which is a challenge for maintaining data privacy. However, autoencoders 
can address this issue. 
Objective  
The aim of this proof-of-concept study was to test whether coded frame 
vectors of autoencoders contain relevant information for analyzing videos of 
the motor performance of patients with MS.
Methods  
In this study, 20 pre-rated videos of patients performing the finger-to-nose 
test were recorded. An autoencoder created encoded frame vectors from 
the original videos and decoded the videos again. The original and decoded 
videos were shown to 10 neurologists at an academic MS center in Basel, 
Switzerland. The neurologists tested whether the 200 videos were human-
readable after decoding and rated the severity grade of each original and 
decoded video according to the Neurostatus-Expanded Disability Status 
Scale definitions of limb ataxia. Furthermore, the neurologists tested whether 
ratings were equivalent between the original and decoded videos.
Results  
In total, 172 of 200 (86.0%) videos were of sufficient quality to be ratable. The 
intrarater agreement between the original and decoded videos was 0.317 
(Cohen weighted kappa). The average difference in the ratings between the 
original and decoded videos was 0.26, in which the original videos were rated 
as more severe. The interrater agreement between the original videos was 
0.459 and that between the decoded videos was 0.302. The agreement was 
higher when no deficits or very severe deficits were present. 
Conclusions  
The vast majority of videos (172/200, 86.0%) decoded by the autoencoder 
contained clinically relevant information and had fair intrarater agreement 
with the original video. Autoencoders are a potential method for enabling 
the use of patient videos while preserving data privacy, especially when non–
health-care professionals are involved. 




In chronic neurological diseases, especially multiple sclerosis (MS), clinical 
assessment of motor dysfunction is crucial to monitor the disease in patients.
(1) Traditional scales used to assess MS, such as the Expanded Disability 
Status Scale (EDSS), are not sensitive enough to detect slight changes in 
motor performance.(2) Video recordings of patient performance are more 
accurate and increase the reliability of severity ratings.(3,4) Moreover, 
when these recordings are automated, quantitative disability assessments 
by machine learning algorithms (MLA) can be created.(5) Machine learning 
algorithms are potentially more sensitive in detecting small changes between 
images; however, they require high-resolution images because of the high 
dimensionality of the data.(6,7) Creation of these algorithms usually involves 
non–health care professionals, which is a potential challenge for maintaining 
data privacy. Autoencoders can address this issue. They embed visual 
information into a lower-dimensional latent space that preserves information 
needed for algorithm development but is not visually interpretable by 
humans.(6) An autoencoder consists of an encoder that creates encoded 
videos by creating a sequence of coded frame vectors and a paired decoder 
that transforms the coded frame vectors back into the original video. Videos 
encoded in this way can be shared with non–health care professionals, while 
the decoder can be used to verify if the essential information from the video 
has been captured. However, it is unknown whether the condensed data in 
the coded frame vectors contain clinically relevant data. Therefore, the aim 
of this proof-of-concept study was to test whether coded frame vectors of 
autoencoders contain relevant information for analyzing videos of the motor 
performance of patients with MS.
2 METHODS
Study design and participants
This study was a subproject of the ASSESS MS study and was approved by 
the local ethics committees.(6) All participants gave their written informed 
consent prior to inclusion. In the ASSESS MS study, 9 standardized movements 
were recorded on video; these movements covered overall motor function, 
including upper extremity function, truncal stability, and mobility. A detailed 
description of the movements can be found elsewhere.(8) For this study, we 
used recordings of the finger-to-nose test. The execution of the finger-to-
nose test was standardized using a detailed protocol: Each participant was 
instructed to close their eyes and abduct their arms to 90° at the shoulder 
in full extension before touching their nose with the tip of their index finger. 
Both sides were tested. Original and decoded videos of 20 participants were 
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shown to 10 neurologists at an academic MS center in Basel, Switzerland. 
The neurologists tested whether these 200 videos in total were human-
readable after decoding and rated the severity grade of each original and 
decoded video according to the Neurostatus-EDSS definitions of limb ataxia 
(subscore grade 0=no ataxia; grade 1=signs only; grade 2=tremor or clumsy 
movements easily seen, minor interference with function; grade 3=tremor 
or clumsy movements that interfere with function in all spheres; and grade 
4=most functions are very difficult).(9) The decoded videos were shown firstly, 
and after an interval of 2-3 weeks, the original videos were shown in the 
same order to minimize recall bias. The neurologists tested whether these 
videos were human-readable after decoding. 
Autoencoder
A variational autoencoder was trained on 2230 videos comprising the 9 
standardized motor performances included in the ASSESS MS study. The 
autoencoder was structured so that the frames of each video were encoded 
into a lower-dimensional space and then decoded into their original form. 
The key property of interest to us was that when a frame is in its coded form, 
it is computationally prohibited to decipher it without access to the decoder.
(6) An autoencoder as described above reduces the dimensionality of the 
input data (in our case, videos) by passing the data through an “information 
bottleneck”.(14) The resulting coded, or latent, space sufficiently describes 
the data in a way that allows an accurate partial reconstruction. The shared 
latent embedding is optimized to represent the salient information that is 
similar across frames of multiple videos (in our case,: the movement), whereas 
dissimilar aspects (eg,. background aspects, details of physical features) 
are less well conserved. Neural networks are a machine learning approach 
that is inspired by biological neuronal computation; these networks have 
demonstrated exceptional performance in complex image-related tasks in 
recent years.(15-17) Given this success, in this study, we used a neural net 
approach called a variational autoencoder [18]. A variational autoencoder 
has at its center a coded vector of vastly reduced dimensionality. This is 
because the decoder requires millions of floating-point values to be set 
precisely before the coded vector can be successfully decoded into an image. 
At the same time, the coded vector contains all the information necessary 
to reconstruct that frame; interestingly, due to the variational constraints 
during training, the frame has semantically meaningful cosine distances to 
other visually similar frames. This property is very useful for machine learning 
tasks that operate upon these coded vectors because the coded frames can 
be used in place of the original video frames without the possibility that a 
human could use it to recognize the depicted participant. 
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Figure 1, depicts the structure of the autoencoder.(10) An encoder network was presented with 
a single frame from the video without further context. The frame passed through 5 encoding 
blocks. In each block, the input was processed in a block inspired by a densely connected con-
volutional network,(11) wherein a skip connection was provided between the input and output 
layers in addition to a convolutional layer/batch normalization sequence. Each block halved the 
resolution of the image and doubled the feature depth. This network predicted the mean and 
variance of a normal distribution, which was then sampled to produce a code. The code was 
presented to a second network that consisted of 5 decoding blocks. Each decoding block con-
sisted of a skip connection (which performed a simple upsampling process) and a transposed 
convolutional block like that used in a deep convolutional generative adversarial network.(12) 
Each block doubled the resolution and halved the feature depth. The network was trained using 
a multi-scale structural similarity–based perceptual loss function with Kullback-Leibler regulari-
zation as per Kingma and Welling.(10,13) The input images were 256×256 RGB-D images with a 
code length of 256. The training hyperparameters were as follows: the learning rate was 0.001, 
the convolutional kernel size was 5, and the number of initial fi lters was 8. The model was trained 
for 400 epochs. 
Statistics
Intrarater agreement between the ratings of the original and the decoded 
videos was assessed using the Cohen weighted kappa with linear weights 
(ie, disagreements of 1, 2, and 3 were weighted by factors of 1, 2, and 3, 
respectively). A Cohen kappa of 0 corresponds to chance agreement; 0-0.2, to 
slight agreement; 0.21-0.4, fair agreement; 0.41-0.6, to moderate agreement; 
0.61-0.8, to substantial agreement; and 0.81-1, to almost perfect agreement.




The characteristics of the study population and the participating neurologists 
are summarized in Table 1. In total, 172/200 (86.0%) videos were of sufficient 
quality to be ratable. 
Table 1, characteristics of patients and neurologists. 
Patients
Mean Age, years (95% CI) 44.4 [27-74]
Gender female/ male 12/7
Mean disease duration, years (95% CI) 13.2 [1-40]







Gender (female), f/m 5/5 
Years of experience in Neurology, mean [range] 8.8 [3->30] 
CI = confidence interval; EDSS = Expanded Disability Status Scale; MS = Multiple Sclerosis; RRMS 
= Relapsing Remitting MS; SPMS = Secondary Progressive MS.
In total, 172/200 (86.0%) videos were of sufficient quality to be ratable. 
The Cohen weighted kappa indicating intra-rater agreement between the 
original and decoded videos was 0.317. The average difference in the ratings 
between the original and decoded videos was 0.26, in which the original 
videos were rated as more severe. The inter-rater agreements of the original 
and decoded videos were 0.459 and 0.302, respectively. As depicted in 
Figure 2, agreement was higher when no deficits (grade 0) or very severe 
deficits (grade 4) were present. Note that most videos that were not ratable 
were judged so by neurologists 2 and 5. 
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Figure 2, ratings by 10 neurologists of the original and decoded videos. The colored squares 
represent the diff erent grades for limb ataxia of the fi nger-to-nose-test according to the Neu-
rostatus-Expanded Disability Status Scale subscores: black=0, dark grey=1, grey=2, bright 




In this proof-of-concept study, 172/200 (86.0%) of the decoded videos were 
of suffi  cient quality to be ratable. We found fair intrarater agreement between 
the original and decoded videos. The agreement was better for minor and 
severe defi cits in motor function.
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Data security and privacy are increasingly requested by health care 
professionals for data capture, analysis, and storage.(20) At the same 
time, the use of machine learning algorithms and deep neuronal network 
techniques as subdomains of artificial intelligence is increasingly infiltrating 
all areas of health care.(21,22) The use of new technologies and electronic 
tools for capture and automated analysis of clinical data generally requires 
the involvement of non–health care professionals, which creates challenges 
regarding data privacy. To our knowledge, this is the first study to use an 
autoencoder to allow the analysis of patient videos while preserving data 
privacy. 
Patients with MS may present with slight changes in motor performances 
over their disease course. Clinical assessment of these changes is notoriously 
difficult. Video analysis of motor performances allows automated analyses 
and quantification of disability by using machine learning algorithm–based 
analysis systems such as those used in the ASSESS MS study; however, 
it requires a huge data set.(5) Since the creation of machine learning 
algorithms usually involves non-medical collaborators, encoding of these 
videos is essential. The intra-rater agreement of original and decoded videos 
in this study was fair. It is unclear whether this is due to accordance of the 
video quality or the test-retest reliability of the finger-to-nose test. To our 
knowledge, no data are available regarding this psychometric property of the 
finger-to-nose test. 
Limitations
A limitation of this proof-of-concept study is the class imbalance of the 
patient videos according to the four grades of limb ataxia for the finger-to-
nose test.(9,21) Further iterations of the deep neural network are necessary 
to increase the intrarater reliability. 
Conclusions
In this proof-of-concept study, we have shown that the vast majority (172/200, 
86.0%) of videos decoded by an autoencoder contained clinically relevant 
information regarding upper extremity motor performance represented by 
the finger-to-nose test and had fair intrarater agreement. Autoencoders are 
a potential method for enabling the use of patient videos while preserving 
data privacy, especially when non–health care professionals are involved. 
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The clinical assessment of disability in patients with Multiple Sclerosis (MS) 
is not straightforward. This is largely due to the heterogeneous nature of 
the disease, the variable contribution of symptoms and signs to disability, 
the slow accumulation of disability and confounding factors. Although many 
clinical measurements exist to aid disability assessment, each measurement 
has specific limitations and caveats, which are described in chapter 2.
The traditional and most widely used outcome measure to assess disability 
in MS trials is the Expanded Disability Status Scale (EDSS), which is regularly 
used in daily practice as well (schematic representation in figure 1). The 
EDSS intends to capture the disability of MS patients based on neurological 
examination, ambulation and ability to carry out activities of daily living 
(ADL). An overall score is given on an ordinal scale ranging from 0 (normal 
neurological examination) to 10 (death due to MS). Despite many limitations 
and caveats, the EDSS is still the most widely used measure. Chapter 2 
describes the attempts that have been made to (i) improve (the practical use 
of) the EDSS, and (ii) develop other measures to enhance the ability to assess 
disability in MS.
Figure 1, schematic representation of the Expanded Disability Status Scale (reproduced from 
van Munster et al. with permission from Springer Nature).(1)
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Clearly, good clinical assessment is pivotal for (i) early and adequate diagnosis 
of MS, (ii) assessment of disease activity and progression to evaluate treatment 
indication and response, and (iii) choosing the right treatment for the right 
clinical phenotype. As the range of treatment options continues to expand, 
treatment goals are becoming more ambitious (with the ultimate objective 
in future being no evidence of disease activity (NEDA)). Consequently, clinical 
assessment in adjunct to paraclinical measures such as MRI, has become 
increasingly relevant. In this thesis, novel insights into the clinical assessment 
of disability in patients with MS are presented.
Main findings
Part II – Clinical assessment of upper extremity function and mobility
The studies described in this part of the thesis aimed to improve the 
assessment of disability in the functional domains of upper extremity 
function (UEF) and mobility. It has been demonstrated that assessment of 
disability in MS can be improved when (i) UEF and ambulation are assessed 
independently (chapter 3), and (ii) tasks of ADL are used in conjunction 
to other measures (chapter 4). In addition, a minimal clinically important 
difference (MCID) of improvement was calculated for the Arm Function 
in Multiple Sclerosis Questionnaire (AMSQ), which is a patient-reported 
outcome measure (PROM) of UEF that was specifically developed for MS 
patients (chapter 5). Lastly, improved evaluation of treatment effects was 
demonstrated using multimodal assessment of UEF and mobility, and 
subgroup analyses (chapter 6). 
Independent assessment of UEF and ambulation
Historically, the focus of clinical assessment of disability in MS patients 
has been on ambulatory impairment. However, although many patients 
experience impaired ambulation, often already early in the disease course, 
other functional domains such as UEF, cognition and vision are frequently 
affected as well.(2-4) Fortunately, the importance of assessing these initially 
under-recognized domains is now generally acknowledged. Identifying 
deficits in these functional domains, and characterizing their magnitude and 
impact is important in MS management. However, the ways in which UEF 
and ambulation are exhibited and interact during the disease course are 
largely unknown. To develop the understanding of this, various aspects of 
UEF across different levels of ambulation were cross-sectionally examined 
in 247 patients. These results are presented in detail in chapter 3, and key 
findings are summarized as follows.
Over 80% of patients showed some impairment of UEF, even when 
ambulation was still unaffected. Patients with worse ambulation displayed 
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worse performance on all UEF measures, including ADL tests and a PROM. 
Remarkably, most patients showed only mild UEF impairment, even when 
ambulation was severely impaired (EDSS 6.0 – 7.0). To conclude, UEF and 
ambulation show distinct patterns of impairment, affecting multiple aspects 
of UEF. These findings underscore the importance of adopting multimodal 
measurement of UEF in the assessment of disability in MS, independent 
from ambulation. A previous study supports this by showing a concurrent 
deterioration of various aspects of UEF with disability accrual.(5)
Although these data are derived cross-sectionally, the high prevalence of mild 
UEF impairment in all EDSS groups may suggest that UEF is affected early on 
in the disease course, and deteriorates more slowly than ambulation. This 
mirrors findings from an earlier study which describes the high prevalence 
of UEF impairment in patients with low EDSS scores is described in one 
earlier study.(3) Another study revealed that patients frequently report 
some level of UEF impairment within the first year of onset.(6) Findings from 
this longitudinal study suggest an early, and more gradual deterioration of 
UEF relative to ambulatory impairment, which deteriorated more rapidly.(7) 
Although the methodology of this study differed from the study in chapter 
3, the data are indicative of a similar trend.
What aspects of UEF are affected, and when these effects occur during the 
disease course, is important because it potentially widens the treatment 
window and the opportunity for rehabilitation strategies targeted towards 
impairment. This is clearly illustrated by several studies that evidence 
treatment efficacy on UEF, including in SPMS patient with natalizumab,(8) in 
PPMS patient with ocrelizumab,(9) and in rehabilitation studies with various 
training programmes.(10)
Assessment of UEF and mobility with ADL tasks
In the study presented in chapter 3, patients were asked to perform 
several movements to evaluate UEF and mobility, including a task of ADL 
and several classical neurological tests. Patients were selected from an 
international multicentre study, which developed the Assess MS system with 
the aim to automatically quantify motor functioning using Machine Learning 
Algorithms (MLA). Chapter 4 outlines a study that evaluated to what extent 
a combination of movements can contribute to the assessment of UEF and 
mobility.
Multivariate linear regression models were used to determine to what extent 
the (combinations of) movements explained the variance in the Nine-Hole 
Peg Test (9HPT) and AMSQ for UEF, and the Timed 25-foot Walk Test (T25FW) 
for mobility. The variances in 9HPT and T25WT scores were largely explained 
by the combinations of movements, and, importantly, ADL tasks contributed 
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most to the variances. This finding indicates that including ADL tasks (such as 
drinking from a cup, or standing up from a chair) in daily practice or clinical 
trials may be more valuable than classical neurological test (such as placing a 
fingertip on one’s nose) in terms of assessing MS. This result also highlights a 
caveat of the EDSS. Whilst classical neurological examination plays a central 
role in the lower EDSS range (0 – 4.0), and ADL in the higher range (7.0 – 
9.5), clinically relevant impairment of UEF and mobility remains probably 
undetected. This reasoning favours the use of multiple measures, rather 
than one-size-fits-all approaches to assess disability.
At present, the 9HPT and T25FW are often used in clinical practice and in 
trials as secondary outcome measures. Both correlate with the ability to 
perform ADL tasks.(11, 12) However, the ADL movements used in the study 
presented here can be administrated more quickly, and more easily. Further, 
the neurologists who rated the movements found the scales used for the 
ADL tasks much easier to apply than those of the classical neurological 
examination (personal communication). Nevertheless, the psychometric 
properties of the ADL tasks should be examined before implementing them 
in clinical practice or trials. This will require further testing in a more disabled 
population than was included in this study.
MCID for AMSQ
Performance measurements such as those described in chapter 3 and 4, are 
valuable tools in disability assessment, however they do not give any insight 
into the patient’s perspective of impairment. Therefore, complementary 
PROMs can be used to fulfil this purpose. Many PROMs are being used in 
the MS field, with some being developed specifically for use with MS patients 
(chapter 2). The AMSQ, for example, was designed to assess the impact 
of MS on patient-perceived UEF. The questionnaire covers a variety of ADL 
tasks, ranging from gross to fine movements, and has valuable psychometric 
properties.(13, 14) Notably, PROMs generally detect clinically meaningful 
change, discarding changes with no clinical relevance.
As described in chapter 5, the MCID was determined to be 15 points. A cohort 
of patients that were treated with fampridine was used in a sensitivity and 
specificity anchor-based approach. We acknowledge that future studies will 
have to confirm our findings and dispel remaining uncertainties, preferably 
with other statistical methods.(15, 16) Nonetheless, this MCID value was used 
in the study presented in chapter 6.
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Multimodal assessment of UEF and ambulation, and subgroup analyses
Building on the findings in chapters 3 through 5, the treatment response 
to fampridine was examined in a cohort of MS patients, who were selected 
from a real-world setting using a process described in chapter 6. It is 
particularly interesting to assess UEF and mobility independently, using 
multiple measures, including a PROM for UEF, in a cohort such as this. 
Firstly, it may give insight into the discrepancy between a physicians’ overall 
judgement of improvement of motor functioning in cases where, re-
imbursement policies dictate insufficient efficacy. Secondly, subgroups of 
patients may be identified that have the largest treatment effects on specific 
motor functions. Clinically relevant benchmarks and MCID values were used 
as cut-off points to determine such subgroups. Using this method, it may be 
possible to discriminate between patients with and without clinically relevant 
improvement. Lastly, scrutinizing a real-world cohort with such methods may 
give insight into treatment decision-making in clinical practice.
In total, 275 patients reporting ambulatory impairment were analysed. At a 
group level, patients treated with fampridine showed statistically significant 
improvements on the T25FW and MS walking scale ([MSWS] which is a 
PROM to assess perceived difficulties on several ambulation tasks in daily 
life). This result justified the continuation of fampridine treatment in the vast 
majority of patients. Notably, response rates in terms of improved T25FW 
score were higher amongst patients who were more severely disabled 
(EDSS 6.0-7.0) or exhibited more impaired ambulation. This might suggest 
a higher efficacy in more severely affected patients. Alternatively, it may also 
merely reflect a floor effect of the T25FW.(17) In contrast, the proportion 
of patients with MSWS improvement was larger amongst patients with less 
impaired ambulation. This may reflect a certain placebo effect, likely to have 
also influenced treatment decision-making, because no further proportional 
difference between subgroups was found amongst patients continuing 
treatment. Nonetheless, the MSWS may still be useful in complement with 
the T25FW to evaluate ambulation in less impaired patients.
A subgroup of 183 patients who also reported UEF impairment were 
subsequently examined. On average, a statistically significant improvement 
was found in AMSQ while on treatment, and approximately 40% of cases 
were classified as an AMSQ responders. In this subset of the cohort, patients 
with AMSQ improvement were more likely to show improvement on MSWS 
and continue treatment, than patients without improvement of AMSQ. This 
finding suggests that there is an influence of patient-reported outcome 
on treatment decision making in daily practice. Obviously, physician-based 
factors (such as experience, training, influenceability) and local factors (such 
as reimbursement policies) influence treatment decision making as well. It 
nevertheless illustrates the gap between clinical trials and practice, and the 
challenges physicians are being faced with in the real-world.
Discussion and future perspectives
10
177 
These observations, together with other data, contributed to the revision 
of the initially negative decision on reimbursement for fampridine made 
by regulatory authorities in the Netherlands. Reimbursement is now being 
granted for patients with more severely impaired ambulation, meaning a 
T25FW performance of 6 seconds or worse, and an EDSS of 4.0 – 7.0. A strict 
improvement of at least 20% on the T25FW is a condition for reimbursement. 
Before these revisions, reimbursement criteria were less strict with the 
main selection criterion being an EDSS between 4.0 and 7.0, which included 
patients with less severe ambulatory impairment. As described in the study 
described in chapter 6, efficacy on ambulation in this subgroup of patients 
is less clear, and patient-reported outcome probably influenced the decision 
to continue treatment. Consequently, treatment was continued for a certain 
proportion of patients who likely only had a placebo-effect, leading to cost-
inefficacy. The study in chapter 6 therefore exemplifies the practical and 
policy-relevance, as well as the challenges of good clinical assessment of UEF 
and mobility in MS patients.
Part III – Video-assisted assessment of motor functioning
Part III describes three studies in which several aspects of video-assisted 
assessment of motor functioning are evaluated. Video-assisted assessment 
has the potential to improve evaluation of disability in several ways. It may 
improve certain psychometric properties, such as intra- and interobserver 
variability, of performance-based measures (e.g. finger-to-nose test (FNT)), 
and promotes data quality by allowing a visual check on compliance relative 
to the standardization of performance. Furthermore, digital video-data can 
be used for building MLA that automatically quantify motor performance. 
Ultimately, automated video-assisted assessment of disability can be 
performed by patients themselves, at their preferred location and time, 
without needing to be physically present in a hospital or research clinic. 
The COVID-19 pandemic, which imposed strict protocols on 1.5-meter 
social distancing to safely assess patients, combined with a preference for 
home-based assessments, particularly for vulnerable patients with chronic 
diseases or immunosuppression, emphasises the relevance this flexibility. 
video-assisted assessment can also contribute to shorter administration 
times and associated administrative burdens, relative to other assessments, 
particularly the EDSS, which takes at least 15 – 20 min to obtain.
In this part, it is established that the use of reference videos can reduce 
the variability of motor functioning assessment (chapter 7). Furthermore, 
it is determined the detection of change in UEF and mobility can be 
improved when video-assisted composite measures are used in conjunction 
with conventional measures (chapter 8). Lastly, a proof of concept study 
demonstrates that autoencoders are a potentially valuable method for the 




The EDSS is known for its high intra- and interrater variability, especially in 
the lower ranges if the score.(18) This is partly a consequence of variability 
in performing a neurological examination, including the FNT. The study 
presented in chapter 7 investigated whether the rater variability of such a 
test can be reduced by using reference videos. These are videos of patients 
performing a movement according to specific test instructions, where the 
movements have been rated according to a predefined rating scale. In the 
case of the FNT, for example, a patient is instructed to perform the test 
with eyes closed and holding the arm 90 degrees abducted in the shoulder, 
and subsequently putting the tip of the index finger on the top of the nose. 
The movement is rated according to the Neurostatus-EDSS definitions.
(19) Collectively, a set of reference videos showcases all possible degrees 
of performance on the test., from high to low. As such, a set can be used 
as a benchmark to assist the rater in accurately rating the clinical videos 
presented.
As expected, the use of reference videos substantially reduced the intra- 
and interrater variability of video-assessment of FNT, as compared with the 
sole use of the textual rating scale. These findings confirm the common 
impression of participating rating neurologists, including the author of this 
thesis, that rating of videos was much easier to do when using reference 
videos (personal communication). Further, the software used to display the 
reference videos was user-friendly and easily integrated into practice. To 
conclude, reference videos improve clinical assessment of motor functioning, 
and could be present a valuable addition if integrated in daily practice and 
clinical trials.
Video-assisted composite measures to detect change in UEF and mobility
Building on the finding that using reference videos facilitated video-assisted 
rating of motor performance, it is likely that multidimensional assessment 
(including multiple tests) can more broadly be facilitated using videos. 
Combining multiple tests into a composite measure allows a more complete 
assessment of change in motor performance. The difficulties of documenting 
clinical change in MS has been repeatedly illustrated throughout this thesis. 
Therefore, the study presented in chapter 8 investigated the value of 
multidimensional video-assisted composite measures to enhance detection 
of change in UEF and mobility. For this purpose, a cohort of 43 patients treated 
with fampridine was analysed. Fampridine can quickly improve several motor 
functions (within two weeks of treatment), and thus offers the possibility to 
observe change in the scope of a short follow up. By contrast, performing 
such a study in a natural disease course cohort would take several years.
Composite measures were determined for UEF and one for mobility, and 
compared the detection of improvement with the conventional measures of 
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9HPT and T25FW. The composite measures consisted of tasks of ADL and 
classical neurological tests, which were performed by patients performed 
who were recorded on video. These videos were subsequently rated by 
a neurologist, using reference videos such as described in chapter 7. To 
confirm whether the improvement in composite measures that was not 
detected with the conventional measures was clinically relevant, a global 
rating of change scales was used to assess if patients perceived the change.
When used in conjunction with conventional measures (9HPT and T25FW 
in this study), the video-assisted composite measures identified additional 
patients who exhibited clinically relevant change. This implies that the use 
of a series of videos of patients performing movements can be useful to 
monitor disease course and evaluate treatment outcome. Novel methods that 
improve clinical disease monitoring in progressive phenotypes are particularly 
welcome, considering the recent introduction of disease modifying therapies 
(DMT) for these patients. Further, these results indicate that assessing motor 
functioning on video is feasible, and might even have the potential to replace 
conventional measures. As such, clinical assessment would no longer have to 
be confined to specific time slots or locations that primarily suit the physician 
or researcher. However, these conclusions to date are based on findings in 
a small cohort with no control, and thus future studies will have to replicate 
and re-investigate the hypothesis before video-based composites can be 
justifiably integrated in daily practice or clinical trials.
Autoencoders for preserving data privacy
Video-assisted assessment has the potential to improve the assessment of 
motor functioning in MS by several ways, such as increased accuracy,(20) 
reliability (chapter 7) and sensitivity to change (chapter 8). Moreover, the 
video data can be used for building MLA which can be used for example to 
automatically assess motor functioning. In the current digital age, MLA and 
artificial intelligence (AI) are increasingly used in various areas of healthcare 
research.(21) However, if implemented, this implies the need for collaboration 
with IT specialists and other non-healthcare workers, which may pose a 
threat to data privacy. The issue of data security and privacy remains pivotal 
in modern society, as reflected by contemporary public debates. The use of 
autoencoders may help to overcome this barrier.
Autoencoders are a digital technique that embed visual information into a 
latent space, which essentially means that the visual data are compressed 
into a form in which similar data points are closer together in space. The 
compressed data preserve information needed for MLA development, but 
is not visually interpretable by humans. Simply put, an autoencoder contains 
an encoder that compresses the data, coupled with a paired decoder that 
transforms the compressed data back into the original video. A schematic 
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representation is depicted in figure 2. However, the question remains as 
to whether the compressed data, which can be used for MLA building, still 
retains the clinically relevant data when decompressed.
Figure 2, schematic representation of an autoencoder.(22)
In the “proof of concept” study presented in chapter 9, this issue has 
been assessed. Videos of patients performing the FNT were rated by 10 
neurologists before encoding and after decoding, and these ratings were 
subsequently compared to see how closely they agreed. The vast majority of 
videos decoded by the autoencoder contained clinically relevant information 
and had a fair intra-rater agreement with the original video. To conclude, 
autoencoders are a potentially valuable method in healthcare research to 
preserve data privacy, although iterative testing is required to confirm this 
conclusion prior to implementation.
Future perspectives
What determines the appropriateness of clinical outcome measurements for 
daily practice and clinical trials in MS? The right choice of measurements is 
central to clinical decision making in both diagnosis and treatment, and as 
well as for assessing the efficacy of novel DMT. Consequently, the measures 
chosen will influence patient prognosis in daily practice, and determine if a 
drug can proceed to the next step of the development process and obtain 
regulatory approval.
Many of the outcome measures used in clinical trials are also implemented 
in daily practice. However, the levels of standardization and quality control 
of assessments, both of which are mandatory in trials, are rarely met in 
daily practice.(23) Efforts have been made in trials to implement outcome 
measures that are commonly used in daily practice, particularly to monitor 
treatment response.(24, 25) The well-known EDSS, which is traditionally used 
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in trials, is also widely used in daily practice, although it is more challenging 
to apply consistently than might be assumed at first encounter. EDSS also 
has the advantage that it is immediately understood by clinicians, which 
is not always the case for novel measures. Nevertheless, novel measures 
are generally superior in detecting more subtle changes in disability. Other 
important considerations for measures to be implemented in daily practice 
include ease of use (e.g. administration time of EDSS is inconveniently long, 
requiring at least 15 – 20 minutes), the clinical utility and ease of interpretation 
of the data collected (e.g. what is the clinical relevance of a given change 
score?).
The findings of this thesis contribute to the resolution of these clinical 
challenges, specifically:
• Clinical assessment of disability can be improved when (i) UEF and ambu-
lation are assessed independently (chapter 3), (ii) tasks of ADL are used 
in conjunction to other measures (chapter 4), and (iii) a value for MCID of 
improvement for AMSQ is determined (chapter 5)
• Multimodal assessment of UEF and mobility, and subgroup analyses im-
prove evaluation of treatment effects (chapter 6)
• Reference videos reduce the variability of motor functioning assessment 
(chapter 7)
• Detection of change in UEF and mobility can be improved when video-as-
sisted composite measures are used in conjunction with conventional 
measures (chapter 8)
• Autoencoders are a valuable method to preserve data privacy in analyses 
of patient videos (chapter 9).
In the last part of this chapter possible future perspectives of the clinical 
assessment of MS patients in daily practice and clinical trials of MS will be 
elaborated on. A special emphasis is placed on the potential of biosensor-
based technology. Finally, the benefits of collecting data in multidisciplinary 
data infrastructures will be highlighted.
Clinical assessment in daily practice and clinical trials of MS
As elaborated previously, the complexity of clinical assessment in MS is 
largely a consequence of its heterogeneous symptomatology. A logical 
consequence is that patients cannot be fully evaluated with a single, universal 
and all-encompassing measure. Therefore, multiple measures are needed 
to cover all relevant clinical aspects of MS. Combining multiple measures to 
better capture (multidimensional) change is the core concept of composite 
measures. A composite measure can be tailored to a specific domain of 
interest or broadened to cover multiple functional areas. Therewith, detection 
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of infrequent events such as relapses, or small changes such as disease 
progression, can be improved. This is particularly relevant for patients under 
(highly effective) treatment and with progressive MS phenotypes, in which 
small and gradual treatment effects can be expected. Furthermore, trial 
duration and size may be reduced through the use of composite measures. 
Notably, it is important to differentiate composite measures from composite 
scores. A composite score is a statistical method to combine the results 
of several tests into a single score. The resulting score can be difficult to 
interpret and is not always widely accepted. Other limitations and caveats of 
composite measures are summarized in table 6 of chapter 2.
What are the minimum functional clinical domains that should be assessed 
to monitor MS? The most commonly affected domains in MS are ambulation, 
UEF, cognition and vision. Problems in these domains can be found in 
approximately three-quarter of patients.(2-4) It would therefore make 
sense to include these domains in a basic set of tests. Measures with good 
psychometric properties and are already well-established in the MS field 
should also be considered for inclusion in this basic set. The inclusion of 
a PROM is particularly important because it gives healthcare professionals 
insight into the patient’s perspective of a certain aspect of the disease or 
matter of interest. This aspect should not be underestimated, because the 
physicians’ view does not necessarily agree with the patients’ view. Patient 
and physician perspectives may diverge on, inter alia, what symptoms are 
fundamental for perception of health,(26, 27) and preference for specific 
attributes of DMT.(28) Some PROMs that focus on a specific functional 
domain, such as UEF (AMSQ) or ambulation (MSWS), assess perceived 
difficulties on performing several ADLs in that domain. The aspect of ADL 
may be valuable, because the ability to perform (instrumental) ADL tasks 
can discriminate between different levels of disability and predict disability 
progression.(29) To reduce the patient burden of filling in multiple PROMs, 
computer adaptive testing should be further developed for all PROMs.(30) 
However, disadvantages and caveats of PROMs should be taken into account 
(summarized in table 3 of chapter 2) when including them into the basic set.
With these considerations in mind, a set of valuable measurements is 
proposed in table 1 that may be considered as a basic clinical composite 
to monitor disease course and treatment efficacy. This set can be extended 
based on the individual characteristics of a patient, preferably with measures 
that are designed or well established for MS patients (see chapter 2). In the 
end, the measurements chosen for application in daily practice should be 
tailored to the individual situation to achieve a holistic view of a patient. For 
example, the AMSQ might me more important to use in patients with severely 
impaired ambulation, since UEF becomes more important to maintain self-
dependence when ambulatory function deteriorates. On the other hand, 
one could argue that a yearly assessment of quality of life should be applied 
to all patients.
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Table 1, proposition of a basic set of measurement to monitor disease course and treatment 
efficacy
Functional domain Measure
Ambulation Timed 25-Foot Walk test, to assess walking speed for patients 
with more severe ambulatory impairment, or the 6 Minute 
Walking Test to assess walking speed in patients with relatively 
mild ambulatory impairment.(31-33)
PROM: MS walking scale.(34)
Upper extremity function Nine-Hole Peg Test (NHPT) to assess manual dexterity.(11)
PROM: Arm Function in Multiple Sclerosis Questionnaire,.(13)
Cognition Symbol Digit Modalities Test to assess information processing 
speed.(35)
Vision Low-contrast letter acuity test to assess visual acuity.(36)
PROM = patient-reported outcome measure.
In addition to the clinical assessment, complementary paraclinical methods 
should be used to produce a holistic assessment of MS patients. In addition 
to basic MRI measures such as (gadolinium enhancing) lesion load, other 
valuable measures that are broadly implemented in clinical trials as a 
secondary endpoint are slowly infiltrating daily practice. Examples are optical 
coherence tomography and biomarkers in body fluids such as neurofilament 
light chain. Grey matter pathology and volumetric assessment of the brain 
and spinal cord are also potentially valuable, as they are associated with 
physical and cognitive functioning.(37) The exact value of these measures in 
daily practice have yet to be determined. If they are clinically meaningful, they 
may be particularly useful in disease monitoring of progressive MS, because 
the identification of progression or neurodegenerative changes remains very 
challenging. Further elaboration about paraclinical measures is beyond the 
scope of this thesis.
Clinical monitoring of the progressive disease course in SPMS and PPMS 
cases is particularly challenging. This is increasingly important because 
the treatment window is opening up for these phenotypes.(38) The main 
reason that the assessment of clinical progression is so difficult is that it 
generally accumulates slowly. The duration of MS trials is commonly limited 
to 2-3 years, which is insufficient time to effectively assess progression (and 
certainly improvement), particularly in progressive phenotypes. Further, the 
development trajectories of impairment differ across functional domains, as 
does the clinical relevance of certain functional changes over the disease 
course (chapter 3). For example, UEF might deteriorate in the early stages 
of the disease, but it becomes most relevant when ambulation becomes 
impaired, since the ability of wheelchair-bound patients to perform ADL tasks 
is more dependent on UEF. This means that the clinical relevance of different 
functional domains differs throughout the disease course. If these facets are 
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not taken into account, possible positive treatment effects may be missed.
(8, 9) On this note, the choice of inadequate clinical outcome measures has 
been cited as a possible explanation for negative trails in the MS field.(39)
What we deem necessary to include in the clinical assessment of patients with 
MS also depends on how much we want to raise the bar. For example, the 
concept of NEDA as the ultimate treatment goal of a disease-activity-free status 
can be handled as the ultimate treatment goal. The term was been originally 
described as the absence of relapses, EDSS progression and disease activity 
on MRI.(40) One important argument for setting this as the objective is its 
high predictive value for achieving the absence of disability progression in 
the long run. Specifically, the predictive value was greater for NEDA than for 
any of its individual components.(41) Notably, the timing of assessing NEDA 
after the initiation of treatment is crucial to its interpretation.(1) Raising the 
bar higher by adding more components to NEDA (e.g. with a PROM or brain 
volume measures) will give a more sensitive composite to detect change. A 
downside is that this will also reduce the number of patients fulfilling NEDA, 
which may lead to the rejection of highly effective DMT, as well as possibly 
more severe side-effects.
In order to achieve more holistic clinical assessment, a paradigm shift 
from physician/centre-based care to patient-based care is necessary. In 
centre-based care, the healthcare professional is put at the centre of the 
management process. Via various clinical tests, usually performed within 
a hospital, information is conveyed to the healthcare professional, and 
choices concerning periodical assessment, pharmacological treatment and 
rehabilitation strategies are made. In a patient-based care system, the patient 
is actively involved in this process. In addition to clinical tests performed at the 
centre, the patient can report about certain aspects of the disease via PROMs, 
and modern methods such as biosensor-based technology (described in the 
next paragraph) deliver personalised, on-demand data to the team, which 
supports treatment decision making based on specific needs of a patient. 
Importantly, in this system of care a patient should never feel alone. Instead, 
there is a need for more education and supervision to support the patient.
(42) As we have recently experienced in the COVID-19 pandemic, e-health 
(tele-health) consulting is acceptable to many patients and can be more 
easily used than was previously perceived. It also has several advantages 
over classical physical contacts in the hospital, such as clinical sorting of care 
and more frequent contacts.(43)
Biosensor-based technology 
The clinical measurement of MS patients discussed so far is largely based on 
the classical neurological examination, which can be seen as the ground truth 
for diagnosis and assessment of the disease course. This elegant examination 
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dates back as far as the end of the 19th century. However, modern 21st century 
technologies potentially offer new ways to capture more subtle clinical signs 
and changes over time. Biosensors are used in these techniques to monitor 
and convert biological human signs into electrical signals and digital data, to 
be subsequently analysed using different methods (such as MLA for AI) for a 
specified goal.
Biosensors can be broadly categorized into (i) small molecular sensors that 
are used inside tissue or externally, and (ii) wearable/ wireless sensors.(44) 
In the MS field the first category has not yet emerged fully. On the contrary, 
wearable/wireless biosensors are increasingly becoming the subject of 
research, with some already being used in daily practice. The most extensively 
evaluated – and perhaps most promising - wearable biosensors in MS are 
accelerometers, either with or without gyroscopes. Other less well examined 
biosensors are grip sensors, electrodermal sensors and surface/ portable 
electromyography.(42)
Accelerometers can track various motor functions. Continuous step counts 
and measurements of physical activity are already widely used in normal 
daily life, as an integral part of smartphones and -watches. The addition of 
gyroscopes to accelerometers improves their accuracy to detect falls and 
movement to stand up from a chair, as well as quantify gait, balance and 
tremor.(42, 44) Various devices have been tested in MS patients.(42) Examples 
are the Floodlight Open,(45) and Multiple Sclerosis Performance Test.(46) A 
strong trait of accelerometers is that they allow continuous assessment of 
motor functioning during a person’s daily life. Thus, an enormous amount 
of data can be collected for analyses. More extensive longitudinal studies of 
accelerometers are needed to assess predictive value of long-term disability 
and accuracy to detect small changes, which is particularly important for 
progressive MS phenotypes.
A more high-tech biosensor technique that was recently introduced is based 
on wireless radio reflection signals.(47) No wearable sensor is needed. This 
method uses a device that emits low-power radio frequency signals, which 
is placed at home or any other location. The waveforms are changed when 
they come into contact with a body moving in space. These changes are 
detected by the device and subsequently analysed using MLA and AI. In this 
way a person’s motion, sleep pattern and falls can be analysed. This futuristic 
biosensor technique sounds appealing, although it may raise substantive 
privacy issues, which will have to be resolved before it can be implemented 
in daily practice or clinical trials.
Video-recording of movements is another sensor-based technique. Several 
chapters of this thesis use data from the multinational project Assess MS, 
which aimed to develop a system to assess motor functioning in MS by 
using a colour and 3D-depth camera (Kinect from Microsoft).(20, 48-52) 
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The hardware and software used in Assess MS was usable and acceptable 
to both patients and healthcare professionals, and generated high quality 
data suitable for clinical analysis.(51) This technique has the potential to 
provide a more nuanced measure for motor functioning. The Assess MS study 
aimed to develop a system that could automatically assess motor functioning 
by developing MLA for AI. A major advantage is that the assessment could 
be performed by patients themselves, at a preferred location and time, 
without the need to be physically present in a hospital or research clinic. 
Unfortunately, the study has not yet succeeded to develop a MLA that was 
able to assess motor functioning sufficiently. The amount of data in colour- 
and 3D-depth videos was too large for the MLA to quantify movements at the 
level required in daily practice and clinical trials. In this case, the human brain 
still seems to prevail over AI.
The implementation of biosensor-based technology for the automatic 
measurement of physical signs will improve the ability to assess disability in MS. 
Biosensors can provide additional information to complement conventional 
clinical measurements, which will give a finer-grained and richer presentation 
of disability. During the coming decades, these techniques are likely to 
penetrate daily practice and clinical trials. However, the clinical significance, 
reliability, sensitivity to change and other psychometric properties first have 
to be established. Other factors such as data privacy, disruption to daily life, 
costs and user-friendly software will also have to be clarified.
Using real-world data for clinical research: multidisciplinary data 
infrastructures
The clinical data obtained from MS patients in daily practice and clinical trials 
are complemented by various paraclinical techniques, and primarily serves 
to improve patient healthcare and answer scientific questions. However, 
looking beyond these primary objectives, these hard-earned data may 
contribute to other goals too.(53) (i) Regulatory authorities can use these data 
for making reimbursement policies, and to check effectiveness and safety in 
the real-world. (ii) Pharmaceutical or health-care technology organisations 
may use data for development of new DMT or health-care improving 
techniques. (iii) Researchers can increase their knowledge about the disease. 
(iiii) Neurologists can improve the diagnostic accuracy, prognostication 
and personalization of treatment. To achieve these, and other, goals, the 
multidimensional measurements of MS patients will have to be merged into 
large multidisciplinary data infrastructures.
It is important in MS to pursue multidisciplinary data infrastructures for several 
key reasons.(53) Firstly, MS is a complex disease for which no universal all-
encompassing description exists or will ever be sufficient. Secondly, several 
aspects of MS symptomatology, treatment and rehabilitation effects are 
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interdependent, and should therefore be interpreted together. Thirdly, to truly 
reach personalized healthcare in MS, a measure of that person’s fundamental 
biology is needed, as reflected by a dynamic cluster of technological markers 
such as body fluid biomarkers and genomics. Lastly, the inclusion of PROMs 
in the multivariable dataset facilitates the understanding of the patient 
perspective, putting the patient at the heart of healthcare. These arguments 
are elaborated in more detail elsewhere.(53)
The number of MS data initiatives in the form of MS databases and 
(national) registries is growing. In the Netherlands the MS kwaliteitsregister 
started in 2017, and currently more than 60 centres participate which 
led to the inclusion of data from more than 800 MS patients. Other well-
known real-world registries are the international MSBase consortium, 
North American Research Committee on MS Registry (NARCOMS), German 
MS Register (GMSR), and United Kingdom MS (UK-MS) Register. Various 
technological improvements have contributed to facilitate data collection, 
input and communication with MS patients.(54-56) Looking to the future, 
multidisciplinary data infrastructures  could be linked to establish a foundation 
for (big) data-analyses. In a recent topical review, three joint actions were 
proposed to increase the chance of getting to that point.(53) In short, these 
are the inclusion of multidisciplinary staff for data collection, agreement on a 
minimal set of relevant measurements, and the implementation of protocols 
for measurements and common data models (CDM) in data collection 
procedures. The principle of CDM is that standard data-formats are used 
across different applications or systems (e.g. opening or reading a word 
file with a PDF viewer). Recent evidence shows that harmonization across 
different MS registries is feasible.(57)
Final conclusion
The clinical assessment of MS patients is an exciting field grounded on illustrious 
historical foundations and deepened through contemporary technological 
innovation. Further improvement and integration into multidisciplinary data 
infrastructures will eventually lead to a better understanding and control of 
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Invaliditeit bij multiple sclerosis
“Verbeteren van de klinische beoordeling”
Achtergrond
Multiple Sclerose (MS) is een ernstige neurologische ziekte waarbij zowel 
ontstekingsprocessen (i.e. neuro-inflammatie) als progressieve zenuwschade 
(i.e. neuro-degeneratie) een rol spelen, en een gevolg is van een interactie 
tussen verschillende oorzakelijke (ofwel etiologische) factoren in de omgeving 
en genetica. Het is een relatief zeldzame ziekte die zich meestal openbaart 
bij jonge mensen, wat meer bij vrouwen dan bij mannen. Het klinisch beeld 
is heterogeen en gekarakteriseerd door het optreden van neurologische 
uitvalsverschijnselen (zoals verlammingsverschijnselen en blindheid van 
een oog) die ontstaan in dagen tot enkele weken, om vervolgens na enige 
tijd weer af te nemen, al dan niet met permanente restverschijnselen. Een 
periode met neurologische symptomen wordt een schub genoemd. Er is een 
grote variatie in wanneer en hoe vaak een schub optreedt, en hoe ernstig 
deze is. Een aanzienlijk deel van de patiënten ontwikkeld in de loop der 
jaren een meer geleidelijk verslechterend klinisch beeld met toenemende 
uitvalsverschijnselen, al dan niet in combinatie met optreden van schubs.
In dit klinisch beeld ligt ook een voorname uitdaging in de dagelijkse 
klinische praktijk en het wetenschappelijk onderzoek. Het maakt het 
stellen van de diagnose en opvolgen van het klinisch verloop niet rechttoe 
rechtaan, en vergt een zekere mate van opleiding en expertise. Omdat de 
behandelmogelijkheden de laatste drie decennia enorme sprongen vooruit 
hebben gemaakt, zijn juist deze facetten belangrijker geworden. Wanneer kan 
de diagnose met voldoende zekerheid gesteld worden om zo vroeg mogelijk 
te starten met behandeling? Is de ziekte voldoende onder controle, of moet 
er gestart worden met een meer effectieve (maar vaak ook risicovollere) 
behandeling? Alhoewel de aanvullende technieken, zoals Magnetic Resonance 
Imaging (MRI) en het meten van eiwitten in het bloed (genaamd biomarkers), 
zeer waardevol (kunnen) zijn, is hun plaats in de dagelijkse klinische praktijk 
soms nog onzeker, kostbaarder en tijdrovender dan klinische beoordeling 
van patiënten.
Doel van dit proefschrift
In dit proefschrift worden enkele studies gepresenteerd met als doel de 
klinische beoordeling van MS patiënten te verbeteren. Hoofdstuk 2 in Deel 
I creëert daarvoor eerst het raamwerk door een overzicht te presenteren 




Deel II presenteert vier studies die betrekking hebben op het beoordelen 
van arm-handfunctie (AHF) en mobiliteit. Van oudsher lag de focus van het 
beoordelen van invaliditeit op loopstoornissen. Gelukkig wordt nu erkent 
dat ook andere functionele domeinen, zoals AHF en cognitie, vaak zijn 
aangedaan en wordt het belang ingezien van medebeoordeling hiervan 
om een volledig beeld te krijgen van de impact van MS op patiënten. Het is 
echter niet duidelijk wanneer stoornissen in deze domeinen zich voordoen, 
en hoe hun interactie is. Om hier meer duidelijkheid in te krijgen worden in 
hoofdstuk 3 verschillende aspecten van AHF onderzocht bij 247 patiënten 
met verschillende mate van loopfunctiestoornissen. Bij meer dan 80% werd 
een zekere mate van AHF stoornis gevonden, zelfs als de loopfunctie nog 
normaal was. Alle maten voor AHF waren meer gestoord indien de loopfunctie 
ook meer gestoord was. Opmerkelijk was dat de meeste mensen nog 
slechts een geringe AHF stoornis hadden, ook bij diegenen met een ernstige 
loopstoornis. Samengevat laten deze bevindingen zien dat de beoordeling 
van invaliditeit van MS patiënten kan worden verbeterd wanneer AHF en 
loopfunctie onafhankelijk van elkaar worden beoordeeld.
Vervolgens wordt in hoofdstuk 4 onderzocht wat de relatieve waarde is 
van verschillende klinische maten voor AHF en mobiliteit ten opzichte van 
elkaar. In het statistisch model kon het grootste deel van AHF en mobiliteit 
beoordeeld worden met deze klinische maten. De maten die algemene 
dagelijkse levensverrichtingen (ADL) weerspiegelen, zoals drinken uit een 
beker of opstaan uit een stoel, droegen het meeste bij in deze modellen. Het 
beoordelen van ADL functies kan dus het meten van invaliditeit verbeteren. 
De ADL maten kunnen tevens snel en gemakkelijk worden afgenomen.
De maten die in hoofdstuk 3 en 4 zijn gebruikt meten de fysieke prestatie 
van bewegingen. Het geeft echter geen inzicht in het perspectief van de 
patiënt op de onderzochte functie. Een patient-reported outcome measure 
(PROM) kan hier uitkomst bieden. Dit zijn vragenlijsten over een bepaald 
functioneel domein, klacht of andere specifiek facet. In hoofdstuk 5 werd 
een waarde voor minimaal klinisch relevant verschil bepaald van de Arm 
Function in Multiple Sclerosis Questionnaire (AMSQ). Dit is een vragenlijst voor 
een verscheidenheid aan ADL taken voor arm-handfunctie.
De bevindingen die in hoofdstuk 3 tot en met 5 werden gedaan, zijn gebruikt 
in de studie in hoofdstuk 6 waarin de effectiviteit van fampridine getest is in 
een cohort MS patiënten uit de dagelijkse klinische praktijk. Fampridine is een 
middel dat gebruikt wordt om de loopfunctie te verbeteren van MS patiënten, 
maar heeft ook gunstige effecten op andere motorische functies. Onderzoek 
in een cohort zoals deze heeft een aantal voordelen. Ten eerste geeft het 
inzicht in het verschil tussen de beoordeling door de clinicus van het effect 
op motorisch functioneren enerzijds, en de formele vergoedingsregels om 
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effectiviteit te beoordelen anderzijds. Ten tweede laat subgroep analyse zien 
welke patiënten het meeste voordeel laten zien. Tenslotte geef het inzicht in 
het behandelkeuze proces in de klinische praktijk.  
De overgrote meerderheid continueerde de behandeling. Het grootste effect 
op loopsnelheid was te zien bij patiënten met een relatief slechte loopfunctie. 
Bij patiënten met een relatief gespaarde loopfunctie werd het grootste effect 
gevonden op een PROM voor loopfunctie, en continueerde ook hier de 
meeste patiënten. Bij een subgroep van patiënten met tevens een gestoorde 
arm-handfunctie, werd bij 40% een klinisch relevante verbetering gevonden 
met de AMSQ. In deze groep werd ook vaker een verbetering op de PROM 
voor loopfunctie gezien, en werd de behandeling vaker gecontinueerd. Dit 
kan betekenen dat een mogelijk placebo effect invloed had op het besluit 
van de clinicus om door te gaan met de behandeling.  Ook wordt hiermee 
het verschil geïllustreerd tussen wetenschappelijk onderzoek en klinische 
praktijk, en de uitdagingen waarvoor clinici komen te staan. Deze bevindingen 
hebben bijgedragen aan de aanpassing van de vergoedingsregels van 
fampridine in Nederland.
Deel III presenteert drie studies waarin de toegevoegde waarde van video-
ondersteunde beoordeling van motorisch functioneren is onderzocht. Het 
gebruik hiervan kan de klinische evaluatie van patiënten op verschillende 
manieren verbeteren. Ten eerste kunnen bepaalde (psychomotore) 
eigenschappen van uitkomstmaten worden verbeterd, zoals de inter- en 
intra-beoordelaar variabiliteit. Ten tweede kunnen de digitale data gebruikt 
worden voor het maken van Machine Learning Algorithms (MLA). Dit kan 
bijdragen aan de ontwikkelingen van technieken voor bijvoorbeeld het 
automatisch beoordeling van bewegingen. Tenslotte, kan het motorisch 
functioneren van patiënten op een voor de patiënt geschikt locatie en 
tijd worden beoordeeld, en naar de behandelaar of onderzoeker worden 
verzonden. Zeker in tijden van een wereldwijde crisis zoals de COVID-19 
pandemie, kan dit soort technieken waardevol zijn.
Hoofdstuk 7 toont aan dat de variabiliteit van beoordeling van motorische 
functies verbetert als er gebruik wordt gemaakt van referentie video’s. Dit zijn 
voorbeeld video’s van patiënten die een beweging uitvoeren, waaraan een 
beoordeling volgens het scoringssysteem is gegeven (bijvoorbeeld normaal, 
geringe stoornis, matig ernstige stoornis, ernstige stoornis, niet mogelijk).  
De detectie van verandering in AHF en mobiliteit kan verbeterd worden met 
video-ondersteunde beoordeling, als meerdere bewegingen (inclusief ADL 
taken) worden beoordeeld en gecombineerd. Hoofdstuk 8 laat dit zien in 
een groep patiënten die behandeld zijn met fampridine. Er werden enkele 
aanvullende patiënten gevonden met een klinisch relevante verbetering, die 
geen verbetering toonden op twee standaard maten voor AHF en mobiliteit. 
Deze studie laat het belang zien van het gebruik van meerdere maten om 
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ziektebeloop en behandeleffect te meten.
De data van de video-ondersteunde beoordeling van motorisch functioneren 
kunnen voor verschillende doelen gebruikt worden. Echter zal dan moeten 
worden samengewerkt met IT specialisten en niet-medisch personeel, wat 
een potentieel risico is voor behoud van dataprivacy. Het gebruik van auto-
encoders kan hiervoor een oplossing zijn. Auto-encoders zijn een digitale 
techniek die visuele informatie kunnen comprimeren tot informatie die wel 
gebruikt kan worden voor ontwikkeling van MLA, maar niet te interpreteren 
is door het menselijk brein. Vervolgens kan de data weer gedecomprimeerd 
worden tot een begrijpelijk beeld. Hoofdstuk 9 laat zien dat de 
gedecomprimeerde data klinisch relevante videobeelden bevat, en daarmee 
het gebruik van auto-encoders een potentieel waardevolle methode is om 
dataprivacy te waarborgen.
Toekomstperspectieven
In deel IV worden bovenstaande studies uitgebreid bediscussieerd en 
toekomstperspectieven geschetst. Wat bepaald de geschiktheid van een 
klinische uitkomstmaat voor de klinische praktijk en wetenschappelijk 
onderzoek in MS? Het maken van de juiste keus is uiterst belangrijk voor het 
maken van klinische beslissingen en bepalen van effectiviteit in onderzoek 
naar nieuwe medicatie. Deze keuze heeft dus invloed op de prognose van 
een patiënt en welk medicijn uiteindelijk wordt toegelaten op de markt.
Een voorstel wordt gedaan voor een minimale set van klinische uitkomstmaten, 
waarmee de meest relevante functionele neurologische gebieden bij MS 
worden beoordeeld, namelijk: loopfunctie, AHF, cognitief functioneren en 
de visus. Medebeoordeling van het perspectief van de MS patiënten met 
betrekking tot de invloed die de ziekte heeft op deze gebieden is relevant 
in aanvulling op prestatiegerichte uitkomstmaten (zoals zo snel mogelijk 
een afstand van 25 foot afleggen). Deze meetmethode kan in combinatie 
met gangbare (bijvoorbeeld MRI) en toekomstige (bijvoorbeeld biomarkers 
in bloed) technieken gedaan worden. De beschikbaarheid en het juist 
gebruiken van klinische en paraklinische maten wordt steeds belangrijker, 
omdat het behandelspectrum van MS patiënten groter wordt en de lat van 
de behandeldoelen steeds hoger wordt gelegd.
Om een holistisch beeld van een patiënt te krijgen, zou er een 
paradigmaverandering moeten komen van een systeem waarin niet de 
dokter, maar de patiënt centraal staat. In zo een systeem participeert de 
patiënt zelf actief aan het proces door gebruik te maken van vragenlijsten 
(PROM), moderne technieken zoals biosensor technieken en andere on-
demand data levering aan het team. Hiermee kan naast de informatie 
uit reguliere ziekenhuisbezoeken de behandeling gericht worden op de 
specifieke behoeften van de patiënt.
 Appendices
198
Biosensor technieken kunnen het meten van MS patiënten verbeteren, en 
hebben de potentie om MLA en artificial intelligence (AI) te ontwikkelen. Er 
worden verschillende innovatieve biosensor technieken besproken, zoals 
accelerometers met of zonder gyroscopen, wireless radio reflection signals 
en video-opnames van bewegingen. De komende decennia zullen deze 
technieken in toenemende mate de klinische praktijk en wetenschappelijk 
onderzoek doordringen.
Al deze klinisch en paraklinische data van MS patiënten uit de dagelijkse 
praktijk en het wetenschappelijk onderzoek worden primair gebruikt voor 
patiëntenzorg en het beantwoorden van wetenschappelijke vragen. Echter 
zouden deze welverdiende data ook voor andere doelen gebruikt kunnen 
worden als het wordt samengevoegd in grote multidisciplinaire data-
infrastructuren. Een belangrijk argument voor de ontwikkeling van deze 
data-infrastructuren is de complexiteit van MS waarbij geen universele maat 
bestaat die de ziekte volledig in beeld brengt. Er zijn reeds verschillende 
initiatieven die dit doel nastreven, zoals het Nederlands MS kwaliteitsregister.
De klinische beoordeling van MS patiënten is een boeiend veld dat gebaseerd 
is op historische grondslagen en gegroeid door hedendaagse technologische 
innovatie. Verdere verbetering en integratie in multidisciplinaire data-
infrastructuren zal uiteindelijk leiden tot een beter begrip van en controle 
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Begin met het einde voor ogen en doe de belangrijke dingen eerst. Deze 
eigenschappen hebben mij geholpen bij het maken van dit boekje. Wat 
dit betreft zou ik het dankwoord eigenlijk al vóór het eerste hoofdstuk 
moeten plaatsen. Dankzij velen heb ik mijn focus op het einddoel en de echt 
relevante aspecten kunnen vasthouden. Dat was mij alleen nooit gelukt. In 
dit belangrijke laatste deel van mijn boekje wil ik deze personen bedanken en 
benoemen wat zij voor mij hebben betekend.
First of all, prof. dr. B.M.J. Uitdehaag. Beste Bernard, jij staat aan de basis 
van mijn neurologische loopbaan en loopt er als een rode draad doorheen. 
We spraken elkaar voor het eerst samen met Chris Polman in 2009 op een 
door mijn vader gearrangeerde bijeenkomst. Daarna heb je meerdere keren 
een belangrijke rol gespeeld op voor mij cruciale momenten. Je hielp mij 
kiezen tussen een promotieplek of starten met de opleiding, faciliteerde een 
wetenschappelijke stage, en als belangrijkste creëerde je voor mij een functie 
als fellow in het MS centrum. Ik wilde graag promoveren, maar dit raadde 
je mij af. Je legde uit dat een jonge neuroloog die eerst 4 jaar uit kliniek zou 
treden voor onderzoek, waarschijnlijk uiteindelijk een minder grote kans heeft 
op een mooie klinische neurologenplek. Je hielp mij daarmee het einde voor 
ogen te zien. Desalniettemin heb je volgens mij altijd in de gaten gehouden of 
het niet toch op een promotie zou kunnen uitkomen. Je creëerde kansen en 
gaf mij keuzes die achteraf gezien de broodkruimels waren die leidden naar 
dit boekje. Deze stijl, de rust die je kan geven als het even niet lukt (er is altijd 
een oplossing) en de onvoorwaardelijke vriendelijkheid bewonder ik enorm 
en zijn voor mij een voorbeeld. Bernard, ik wil je bedanken voor wat je voor 
mij betekent hebt de afgelopen 10 jaar.
Prof. dr. J. Killestein, beste Joep, alleen jij had mijn copromotor kunnen zijn. 
Zonder dat je het misschien wist ben jij doorslaggevend geweest om het 
onderzoek door te zetten tot een promotie. Op een gewone donderdag in 
de bunker, die zich polikliniek laat noemen, vroeg je mij of ik al dat onderzoek 
niet zou moeten bundelen. Ik vertelde je dat ik me er eigenlijk al bij had 
neergelegd dat dit niet meer zou lukken. In plaats dit gewoon als persoonlijke 
tegenslag voor mij te laten, baalde je zelf juist dat je dit niet had voorzien. 
Op één op andere manier bleef dit in mijn hoofd zitten, en hielp het mij het 
doel weer te zien. De afgelopen jaren zijn er meer van dit soort momenten 
geweest waarbij je op een totaal onverwachte, originele manier reageerde 
en mij op weg hielp. Ik wil je hiervoor bedanken, en voor al die keren dat ik 
even bij je binnen kon hobbelen met een vraag of één of andere flauwe grap.
Prof. dr. H.C. Weinstein, beste Henry, als opleider heb je natuurlijk veel voor 
mij betekend. Je hebt voor een groot deel bijgedragen aan hoe ik nu ben als 
neuroloog, maar het is meer dan dat alleen. Sinds mijn komst in Amsterdam 
had ik altijd het gevoel dat je achter me stond. Je leerde mij dingen van een 
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andere kant te zien en wat echt belangrijk was voor mijn opleiding. Ook meer 
recent stond je voor me klaar en hielp je me weer op weg. Wat je me leerde 
heeft mij als persoon verbeterd, zowel op professioneel als persoonlijk vlak. 
Ooit wilden we samen onderzoek doen naar het neurologisch onderzoek. 
Alhoewel dat niet helemaal gelukt is, ligt er hier nu wel een boekje over 
klinisch onderzoek en zit je in de leescommissie. De cirkel is rond. Dank je 
voor alles.
De andere leden van de leescommissie, prof. dr. V. de Groot, prof. dr. L.H. 
Visser, Dr. N.F. Kalkers en Dr. M.M. Schoonheim, wil ik hartelijk danken het 
zitting nemen in de leescommissie en de kritische beoordeling van mijn 
proefschrift. Beste Nynke, jij ook veel dank voor de fijne samenwerking als 
co-auteur en mede-clinicus.
Uiteraard wil ik ook de patiënten bedanken die hebben deelgenomen in de 
Assess MS studie en de Fampyra-poli. Dankzij jullie bereidheid langer in het 
ziekenhuis te blijven en gekke bewegingen voor een camera te doen, heb ik 
dit boekje kunnen schrijven. We zijn samen een stapje verder gekomen in het 
doorgronden van de ziekte MS.
The Assess MS project gave me the opportunity to do scientific research in 
an international multi-center study. I would like to thank the Assess MS team 
for this fantastic experience. The clinicians: Christian Kamm, Kristina Kravalis, 
Ludwig Kappos, Manuela Diederich, Marcus D’Souza and Saskia Steinheimer. 
The Novartis team: Frank Dahlke, Jacques Boisvert, Jonas Dorn and Lorcan 
Walsh. The Microsoft team: Abigail Sellen, Cecily Morrison, Matthew Johnson 
and Yordan Zaykov. Jessica Burggraaff, jou wil ik hier speciaal noemen. Het 
is ons allebei gelukt! Ik weet nog goed toen we allebei aan de wetenschap 
begonnen te ploeteren in 2013. We hebben elkaar denk ik goed bij onze 
frustraties kunnen helpen door er vooral ook de grap van in te zien. Dank je 
wel daarvoor.
Beste Brigit de Jong en Bob van Oosten, uiteraard wil ik ook jullie bedanken. 
Hoewel jullie niet direct hebben bijgedragen aan dit boekje, hebben jullie 
mij geleerd “hoe MS werkt”, voor zover we dat natuurlijk werkelijk weten. 
Bob, ik vond het fantastisch dat ik altijd even bij je langs kon komen voor 
een ingewikkeld neurologisch probleem. Bizar hoe in een paar minuten iets 
ingewikkelds opeens overzichtelijk en hanteerbaar kan worden. Daar pluk 
ik nog de vruchten van. Brigit, dank voor alle hulp die je me gegeven hebt. 
Hiermee bedoel ik niet alleen op het gebied van MS, maar ook de dingen van 
alle dag. Ik bewonder jouw balans tussen werk en privé; dat is voor mij een 
voorbeeld.
Ook wil ik de onderzoekers van het MS Centrum Amsterdam bedanken voor 
de fijne samenwerking: Cyra Leurs, Danko Coric, Djoeke Doesburg, Floor 
Loonstra, Ilse Nauta, Iris Dekker, Jenny Nij Bijvank, Lisanne Balk, Marloes 
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Hagens en Martijn Wijburg. Dank voor jullie enorme inzet als Fampyra-ridders. 
Ka-Hoo Lam, jou wil ik in het bijzonder danken voor de fijne samenwerking 
als co-auteur. Ik bewonder je integere houding en doorzettingsvermogen, 
en kijk uit naar de resultaten van jouw onderzoek. Levent Kaya en Morgan 
Obura, jullie ook veel dank voor de soepele samenwerking als co-auteur.
Dan mijn kamergenoten Luuk van Rooij en Floris de Kleermaeker. Jullie zijn 
fantastische kerels en ik heb enorm geluk gehad om met jullie samen te 
werken. Vooral ook heel erg bedankt voor het weglachen van alle frustraties 
en ellende die we tegen kwamen. Ik vind het mooi dat we elkaar blijven 
tegenkomen in de MS wereld. En dan…. Zoé van Kempen, ouwe dikzak, wat 
een geschenk dat we na onze opleiding nog 2,5 jaar roomies konden zijn! We 
hebben elkaar beter leren kennen en hebben elkaar verder kunnen helpen. 
Maar ik wil je natuurlijk vooral bedanken voor de mafkees die je bent om wie 
ik zo ontzettend veel heb moeten gelachen.
De dames van het secretariaat neurologie van het VUmc mogen niet 
ontbreken in mijn dankwoord. Beste Brenda, Claudia, Elles, Karin en Lianne, 
dank jullie voor de ondersteuning en gezellige praatjes die we hadden. Het 
voelde altijd een beetje als thuiskomen bij jullie.
Verder wil ik Gianina Eissens en Danielle Savelkoel van het clinical trial 
bureau bedanken voor de robuuste ondersteuning en vriendelijkheid die 
jullie gegeven hebben. Ook Jana, Laura, Loek en Sara van de data unit wil ik 
danken voor het harde werk aan de eentjes en nulletjes.
Alle neurologen van VUmc wil ik bedanken voor de fijne samenwerking in 
de kliniek en polikliniek. Dank voor de back-up die ik soms nodig had als 
beginnend neuroloog.
De periode voor mijn fellowship tijdens mijn opleiding heeft in zekere zin 
ook bijgedragen aan dit boekje. Ik wil alle neurologen van het SLAZ hiervoor 
bedanken. Ik heb van jullie geleerd goed klinische te redenen. Dat is de 
basis van neurologie. Hiermee is een klinisch proefschrift als de mijne beter 
geworden. Minstens zo belangrijk uit deze periode zijn de arts-assistenten. 
Dank jullie allemaal voor het team dat we waren en vooral voor de lol die we 
hebben gehad. Juerd Wijntjes, jou in het bijzonder wil ik bedanken voor de 
vriendschap die in deze periode is ontstaan. Dank hiervoor, en dank je dat je 
met Marieke dicht bij ons bent komen wonen in de Provence.
Ook wil ik mijn collega neurologen, assistenten, verpleegkundigen en de 
medewerkers van onze afdelingen van Amphia bedanken voor de fijne 
werkplek die ik nu heb.
Ik vraag me altijd af waarom een jaarclub in een dankwoord van een 
proefschrift wordt genoemd. Die hebben daar toch niets aan bijgedragen? 
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Echter begon het me bij het schrijven van dit boekje te dagen: zonder goed 
ontspannen kan je niet hard werken. Voor dat eerste betekenen jullie veel 
voor me en brengen jullie de zaak in balans.
Bij de genoemde balans hoort ook mijn familie, de van Munsters en de 
Wijnens. Dank jullie voor onze sterke familieband waar ik steun en lol kan 
vinden. Nina, jou zou ik hier in het bijzonder willen bedanken voor je kritische 
blik op de inhoud en het Engels van de introductie en discussie van dit boekje. 
Het is er veel beter van geworden.
Tim van Veen, je bent mijn oudste vriend, en alleen daarom al wil ik je te 
bedanken. Onze vriendschap is goud. Hoewel we elkaar minder zien dan 
25 jaar geleden, is het mooie van dit soort vriendschappen dat je bij elke 
ontmoeting gewoon weer verder gaat met het gesprek. Daarmee ben je 
een rode draad door mijn leven die vast ook ergens door dit boekje heen 
getrokken is. Dank je voor je vriendschap.
Wendy Koster, mijn lieve paranimf. Het cirkeltje is weer rond. Ik dank je voor 
de oude vriendschap die wij hebben, al bijna 20 jaar. Sinds onze avonturen bij 
Sensation Black in 2001 ben jij mijn studiemaatje. Niet om te studeren, maar 
om te borrelen en te ouwehoeren. Ik was in een andere tijd jouw paranimf, jij 
nu de mijne. Veel logischer dan dat had het niet kunnen zijn.
Lieve Eduard, Valérie, Rik en Freek. Dank jullie voor de goede zorgen voor 
mijn zussen en broer. Jullie liefde voor hun stelt mij als broer gerust.
Lieve Daphne, Harmen, Edith, Iris en Dominique. Ik ben trots op jullie en het 
unieke gezin dat wij samen vormen. Met elk van jullie heb ik een speciale 
band. We hebben geleerd onvoorwaardelijk er voor elkaar te zijn, niet alleen 
in moeilijke tijden, maar vooral ook om er een feestje van te maken. Lieve 
Daph, fantastisch dat je mijn paranimf bent. Met mijn grote zus naast me 
moe(s)t het wel goed komen. Dank je wel daarvoor.
Het is gelukt pap! Dat heb ik niet in de laatste plaats aan jou te danken. Jij 
hebt altijd gelooft dat dit eens zou gaan lukken, terwijl ik de moed meerdere 
keren had opgegeven. Hierbij heb je me steeds weer gesteund en gezegd 
dat ik moest volhouden. Dank je wel daarvoor. De laatste jaren ben ik je 
steeds beter gaan begrijpen, misschien ook omdat onze wegen steeds meer 
op elkaar zijn gaan lijken. Daarin ben je een voorbeeld voor mij hoe ik als 
neuroloog, maar ook als mens wil zijn. Dank voor al je liefde en steun.
Eigenlijk zou ik je in één adem willen noemen met papa, maar je weet hoe 
graag hij het zo wilt hebben ;-) Lieve mam, door jou ben ik geworden wie 
ik ben. De fijne tijd thuis met al mijn zussen en broer is de basis hiervan. Jij 
hebt mij de belangrijkste kernwaarden geleerd. Dit heeft mij geholpen bij het 
maken van dit boekje, en helpt mij elke dag. Ik wil je bedanken voor alles.
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Lieve Pépé en Mémé, ik geloof niet in sprookjes, maar ben ervan overtuigd 
dat jullie ergens mee kijken naar wat we hier uitspoken. Deze gedachte geeft 
mij een gerust gevoel. Pépé, dit boekje draag ik op aan u. Ik heb veel aan u 
gedacht toen ik ermee bezig was. Hoe zou Pépé dit doen? Wat zij hij ervan 
vinden? Kan ik dit niet doen? Mijn herinneringen aan u hebben mij geholpen 
dit boekje te schrijven. U had het beremooi gevonden om erbij te zijn. We 
zien elkaar ooit weer.
Lieve Inca, Nola en Aura. Mijn dametjes die van elke dag een feest maken. 
Nu dit boekje af is ga ik niet opeens meer tijd aan jullie besteden. Dat hoeft 
namelijk helemaal niet: jullie hebben altijd al mijn hoogste prioriteit. Ik ben 
enorm trots op jullie. Niet te snel groot worden hè?
Allerliefste liefde van me, lieve Maya. Aan jou heb ik alles te danken, zo simpel 
is dat. Jij maakt het voor mij mogelijk dat ik kan doen wat ik doe. Je creëert 
daarmee een balans in mijn leven die ik alleen niet vinden kan. De afgelopen 
10 jaar waren de beste tot nu toe, laten we hetzelfde doen voor de rest van 
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